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ABSTRACT

ABSTRACT

This study investigated the role of NMDARs in the differentiation of MEG-01 cells and in 
the activation of human platelets. This investigation demonstrated that the NR1, NR2D 
and NR3 subunit proteins are expressed in human platelets, with the NR1 subunit also 
expressed in MEG-01 cells. The NR2A subunit protein was not detectable in either 
MEG-01 cells or human platelets. PMA-induced differentiation of MEG-01 cells did not 
appear to stimulate changes in expression of any of the subunit proteins tested. Using 
2+
assays to measure the changes in [Ca ]i and ATP secretion, it was determined that donors 
could be separated into those who responded to the agonists applied and those who did not; 
responses also decreased over time in both assays. Human platelets from responding 
2+
donors demonstrate an increase in [Ca ]i in response to extracellular glutamate, and that 
increases in ATP secretion are detected at a 10-fold lower concentration. The same is also 
2+
true with extracellular glycine. Increases in [Ca ]i were elicited on the addition of 
extracellular NMDA; extracellular D-serine had no effect. NMDAR inhibitors, MK-801 
and D-AP5, inhibited ATP secretion evoked by either glutamate alone or in combination 
with glycine. D-serine inhibited responses elicited by extracellular glycine. NMDARs 
play a role in MK differentiation, with the adhesion of MEG-01 cells cultured on a 
fibrinogen-surface and differentiated with PMA reduced by both inhibitors. PMA-treated 
MEG-01 cells increased both in size and irregularity, with the addition of NMDAR-
specific inhibitors having no effect. S­nitrosylation also inhibits activation of NMDAR, 
and a new molecule has been developed which can detect S-nitrosylated proteins through a 
single step process in live cells. Overall, this study has shown that both human platelets 
and MEG-01 cells express NMDAR subunits, which have been demonstrated to form 
functional receptors in human platelets. 
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CHAPTER 1: INTRODUCTION

CHAPTER 1

INTRODUCTION

Studies from two separate groups have highlighted an important role for glutamate and 
glutamate binding receptors in the function of both megakaryocytes (MKs) and circulating 
blood platelets (Genever et al, 1999; Hitchcock et al, 2003; Franconi et al, 1996 and 1998). 
Extracellular glutamate has been implicated in the differentiation of bone marrow derived 
MKs through to the production of platelets and platelet function in the blood. In this study, 
I have investigated the expression of a specific subtype of glutamate receptor, the 
N-methyl-D-aspartate (aspartate analogue; NMDA) activated receptor (NMDAR), in both 
human platelets and MKs. 
1.1. Megakaryocytes 
MKs are highly specialized precursor cells that differentiate to generate blood borne 
platelets. Platelets were first identified as “extremely minute…granules” in 1841 by 
Addison, and were subsequently termed platelets in 1882 (Bizzozero). Bone marrow 
derived MKs were identified as the source of platelets in 1906 (Wright). MKs are 
produced via megakaryopoiesis from pluripotent haematopoietic stem cells (HSCs), and 
are found primarily in the bone marrow, where they constitute less than 1 % of myeloid 
cells, as well as in the lungs and peripheral blood (Patel et al, 2005). Thrombopoietin 
(TPO) has been identified as the primary cytokine required for HSC differentiation and the 
eventual production of platelets (Bartley et al, de Sauvage et al, Lok et al, and Kaushansky 
et al; 1994). HSCs are maintained in the G0 phase of the cell cycle in the bone marrow, 
re-entering the cell cycle upon stimulation with TPO alone or in combination with 
interleukin-3 (IL-3), IL-6, stem cell factor (SCF) or granulocyte colony-stimulating factor 
(G-CSF) (Ku et al, 1996; Sitnicka et al, 1996). Various combinations of factors are 
required at each stage of megakaryopoiesis, however TPO alone has been found to be 
sufficient to stimulate the entire process from HSCs to platelets (table 1) (Kaushansky et 
al, 1995). 
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Table 1. Table illustrating the stages of haematopoiesis when surface integrins, transcription 
factors and cytokines are expressed (Szalai et al, 2006; Pang et al, 1995; Kaushansky et al, 1995; 
Lambert et al, 2007). CLP, common lymphoid progenitor; MEP, MK/ erythrocyte progenitor; HPP-
CFU-MK, high proliferative potential colony forming unit megakaryocyte; BFU-MK, burst 
forming unit- megakaryocyte; CFU-MK, colony forming unit-megakaryocyte; IL, interleukin; 
G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony 
stimulating factor; PF4, platelet factor 4. 
1.1.1. Cytokines and chemokines 
TPO is a cytokine constitutively expressed by the liver and has been demonstrated to be 
the main regulator of megakaryopoiesis (Szalai et al, 2006). It was identified in 1994 by 
4 different groups, Bartley et al, de Sauvage et al, Lok et al, and Kaushansky et al, and 
consists of 332 amino acids with a molecular mass of approximately 70 kDa (Muto et al, 
2000). The TPO receptor was originally identified from the oncogene v­mpl of the mutant 
murine myeloproliferative leukaemia virus, which is capable of transforming 
haematopoietic progenitor cells, and by its homology to other members of the cytokine 
receptor superfamily (Vigon et al, 1992). The proto-oncogene, c-mpl, was identified as the 
cellular counterpart of v­mpl with the genes encoding human and mouse c-mpl isolated in 
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1992-3, and identified as the TPO receptor (Vigon et al, 1992; Vigon et al, 1993). The 
N-terminal domain of TPO binds to the high affinity c-mpl receptor expressed on the 
surface of haematopoietic cells leading to receptor activation (Linden et al, 2000; Muto et 
al, 2000). 
The c-mpl protein is constitutively expressed and contains both extracellular and 
intracellular domains, with TPO binding to the extracellular domain and the intracellular 
containing 2 conserved membrane-proximal boxes (box 1 and 2) constitutively bound to 
Janus kinase 2 (JAK2). Binding of TPO to c-mpl induces the formation of c-mpl dimers, 
which moves the 2 JAK2 kinases closer together, leading to their mutual activation which 
stimulates phosphorylation of c-mpl tyrosine residues (amino acids 112 and 117) (Gedis et 
al, 2002; Drachman and Kaushansky, 1997). Phosphorylation of other proteins is then 
triggered through activation of Src homology 2 (SH2) domain-containing tyrosine 
phosphatase (SHP2), which binds the complex formed of growth factor-receptor-bound 
protein-2 (Grb2) and Son of Sevenless (SOS). This activates Ras, a GTPase, which then 
activates the mitogen activated protein kinase (MAPK) pathway. Phosphorylated 
extracellular related kinase (ERK) translocates to the nucleus where it has been shown to 
phosphorylate GATA-1 and Friend leukaemia integration-1 (Fli-1) stimulating 
megakaryopoiesis. ERK is also hypothesised to regulate Bad, a proapoptotic factor 
(Scheid et al, 1999). Phosphoinositol-3-kinase (PI3K) is activated by TPO binding, 
stimulating protein kinase B (PKB/ Akt) (Pasquet et al, 2000). STATs (signal transducers 
and activators of transcription) 3 and 5 are phosphorylated, then translocate to the nucleus 
and stimulate transcription of genes including cyclin D and Bcl-xL (Miyakawa et al, 1996; 
de Groot, 2000). Other factors activated by TPO binding are known to have an inhibitory 
role, such as SHIP1 (SH2 containing inositol phosphatase), a negative regulator of the 
PI3K pathway, and SOCs (suppressor of cytokine signalling proteins) (Drachman and 
Kaushansky, 1997). SOCs also act as a negative regulator, inhibiting further activation of 
GP130 through IL-6 mediation by binding to the phosphorylated activation loop of the 
JAK kinase domain via its SH2 domain (Schmitz et al, 2000). Activation of these 
pathways regulates the transcription of genes (e.g. SOCS and c-fos) determining the fate of 
the cells (figure 1). 
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Figure 1. JAK/ STAT pathway. Illustrating some of the intracellular pathways triggered by 
binding of thrombopoietin (TPO) to its receptor, c-mpl. JAK, Janus kinase; 1/ 2, box 1/ 2; STAT, 
signal transducers and activators of transcription; SOCS, suppressor of cytokine signalling proteins; 
SHP2, Src homology 2 domain-containing tyrosine phosphatase; SOS, son-of-sevenless; Grb2, 
growth factor-receptor-bound protein-2; MEK, mitogen-activated/ extracellular-regulated kinase; 
ERK, extracellular-regulated kinase; CREB, cAMP response element-binding protein; FOG, friend 
of GATA; PIP3, phosphotidylinositol (3, 4, 5)-triphosphate; GSK-3β, glycogen synthase kinase-3β; 
mito, mitochondria; P, phosphorylation. 
Levels of free circulating TPO within the bloodstream are regulated by platelets, which 
have been found to express 25-100 copies of the c-mpl receptor per platelet (Broudy et al, 
1997; Li et al, 1999). TPO binds to the c-mpl receptor forming a complex, which is then 
internalised and degraded, reducing the amount of free TPO (Li et al, 1999). If platelet 
numbers in the blood become too high, levels of unbound TPO decrease, leading to a 
reduction in the number of maturing MKs and therefore a decrease in platelet production. 
Equally, when the platelet number decreases, the level of free TPO is higher, stimulating a 
higher level of platelet production to return platelet levels to normal. 
20 
C.M. HOBBS

CHAPTER 1: INTRODUCTION

While TPO is able to direct megakaryopoiesis alone, under normal physiological 
conditions other factors are also involved at specific stages of differentiation. For 
example, IL-3 is involved during the early stages of differentiation around the colony 
forming unit MK (CFU MK) stage (table 1) (Quesenbury et al, 1985; Robinson et al, 
1987). G-CSF is implicated in stimulating HSCs back into the cell cycle; however it is 
postulated to have another, inhibitory role in the latter stages of differentiation, controlling 
the levels of platelet release (Ku et al, 1996; Saito et al, 1996). Granulocyte-macrophage 
colony stimulating factor (GM-CSF) has also been implicated in the early stages of 
megakaryopoiesis, with IL-11 shown to be required during the intermediate stages 
(Robinson et al, 1987; Neben et al, 1993). 
Platelet factor 4 (PF4 or CXCL4) has been shown to have 2 different roles, assisting in 
stimulation of megakaryopoiesis from approximately the BFU-MK until the mature MK 
stage, then switching to an inhibitory role negatively regulating platelet production. PF4 is 
produced by MKs and is present in α-granules (Briquet-Laugier et al, 2004). The PF4 
content of platelets has been shown to be inversely proportional to platelet number and 
knocking down PF4 in mice has been demonstrated to increase the number of mature MKs 
in comparison to the wild-type (WT) (Lambert et al, 2007). It is hypothesised that PF4 is 
released from mature MKs and platelets inhibiting further differentiation of immature 
MKs. 
1.1.2. TPO­independent differentiation 
Both TPO
-/-
and c-mpl
-/-
mice are viable with normal clotting behaviour, but have only 
10 % of the normal level of platelets present in WT mice (Bunting et al, 1997). This 
indicates that other pathways and regulators are present which are able to maintain a level 
of haematopoiesis in the absence of TPO or TPO binding, for example IL-6/ GP130. 
1.1.2.1. IL­6/ GP130 
IL-6 acts via the membrane-bound glycoprotein GP130, stimulating the JAK/ STAT and 
the Ras/ Raf/ MAPK pathways, and has been shown to stimulate MK differentiation and 
platelet production in the presence and absence of TPO. GP130 conditional knockout mice 
have shown that when IL-6 is unable to bind the glycoprotein, the number of immature 
MKs and white blood cells (WBCs) increases as the cells are unable to differentiate to 
form more mature MKs (Jenkins et al, 2002). GP130, like TPO, has been shown to be 
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constitutively bound to JAK2, as well as to JAK1, which are able to phosphorylate SHP2 
and STAT 1 and 3 (Stahl et al, 1994). As with TPO, a range of pathways are stimulated, 
leading to activation of CREB binding protein (CBP) and the MAPK pathway for example 
(figure 1), and eventually to regulation of gene transcription (Schmitz et al, 2000; Scheid et 
al, 1999). 
The loss of GP130 causes embryonic lethality due to severe thrombocytopenia. A 
postnatal conditional knockout however leads to only a mild decrease in platelet numbers 
(Yoshida et al, 1996; Betz et al, 1998). The number of MKs in the bone marrow is not 
affected by the loss of GP130, suggesting that its role is in maintaining platelet production 
rather than in the early stages of differentiation (Jenkins et al, 2002). 
1.1.3. HSC differentiation 
The differentiation of HSCs to platelets can be tracked by following the changes in 
expression of transcription factors (TFs) and surface integrins together with changes in 
morphology (table 1). 
1.1.3.1. Transcription factors 
Several different TFs have been demonstrated to be involved with megakaryopoiesis, 
including RUNX1, GATA-1 and -2 and Friend-of-GATA-1 (FOG-1), and are detailed in 
table 2. 
1.1.3.2. Surface integrins 
Differentiation of bone marrow stem cells can be tracked through the expression of the CD 
integrins on the surface of the cells. Different combinations of CD integrins are expressed 
at each stage of megakaryopoiesis, for example HSCs in humans are CD34
+ 
CD38
-/lo 
while 
human platelets are CD41
+ 
CD42
+ 
CD61
+ 
(Chang et al, 2007) (table 1). CD integrin 
expression can be used to determine the maturity of MKs with methods such as flow 
cytometry. These markers also combine to form receptor complexes such as the GPIIb/IIIa 
(CD41/CD61; αIIbβ3) that binds von Willebrand factor (vWF), vitronectin, fibronectin and 
fibrinogen (Szalai et al, 2007). CD42 (GPIb) has also been shown to bind vWF and has 
been linked to increasing expression of c-mpl, and two collagen receptors, GPVI and the 
α2β1 integrin (Chang et al, 2007; Atkinson et al, 2003). A collagen binding complex 
formed of the glycoproteins GPIb, GPIX and GPV is expressed on the surface of platelets. 
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TRANSCRIPTION 
FACTOR 
DESCRIPTION EXPRESSION INTERACTIONS 
GATA-1 and 
GATA-2 
DNA-binding proteins 
expressed in cis-
regulatory sequences 
N-terminus binds 
FOG-1, C-terminus 
binds DNA directly at 
(A/T)GATA(A/G) 
From MEP to 
mature MK 
(GATA-1) and 
from HSC to 
CFU-MK 
(GATA-2) 
FOG-1 
FOG-1 9-fingered 
haematopoietic-specific 
TF 
HSC to mature 
MK 
4 of the zinc-fingers 
interact with either 
GATA-1 or 
GATA-2 
Fli-1 Contains winged helix-
loop-helix DNA 
binding (Ets) domain, 
binds GGA(A/T) (Ets 
binding sequence) 
HSC to mature 
MK 
Transcriptionally 
activates genes with 
Ets binding 
sequence in 
promoter region 
GATA-1, PF4, 
c-mpl 
NF-E2 (nuclear 
factor erythroid-2) 
Basic leucine zipper 
protein p45 subunit 
with either MafK or 
MafG 
CFU-MK to 
platelet 
Regulates β-tubulin 
expression 
Tal-1 Basic helix-loop-helix HSC to mature 
MK 
Required for 
commitment to 
initiate 
haematopoiesis 
Implicated in 
NF-E2 regulation 
Table 2. Main transcription factors involved in haematopoiesis. Szalai et al, 2006; Chang et al, 
2007; Elagib et al, 2003. 
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1.1.3.3. Morphology and cell structure 
Once MKs are fully mature, they cease to proliferate and instead increase in size to 
approximately 50 to 100 µm in diameter (Italiano et al, 2005). They undergo mitosis, but 
do not pass through anaphase B or cytokinesis in a process called endomitosis. This results 
in the nucleus increasing in size and becoming multi-lobed, with the number of single sets 
of chromosomes (ploidy) increasing from 2N up to 128N (Italiano et al, 1999) (figure 2). 
Demarcation membranes form and increase within the MK together with the number of 
organelles present in the cells and the synthesis of proteins such as vWF. There is an 
increase in the number of mitochondria and electron dense granules that contain serotonin, 
2+
adenosine nucleotides and calcium (Ca ) (Italiano Jr et al, 2003). These changes form the 
preparatory step prior to the production of proplatelets. 
Figure 2. Changes in MK morphology during proplatelet production. The MK enlarges as it 
matures, increasing the number of granules and developing a multilobed nucleus. Proplatelets then 
start to form once the cell has stopped increasing in size. They branch and granules move along 
microtubules, becoming trapped in the developing platelets. The platelets eventually separate from 
the parent cell to enter the bloodstream either singularly or in a ‘bar-bell’ where 2 platelets are 
joined by a fragment of proplatelet, eventually separating. 
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1.1.3.3.1. Proplatelet formation 
It has been demonstrated that proplatelet formation starts from one point on the MK 
surface, with 5-10 proplatelets forming per cell each of which can reach 50-100 µm in 
length (Italiano Jr et al, 2003). Proplatelets have been shown to form at a rate of 
-1
0.85 µm min , taking between 4 and 10 h for the whole MK to be formed into platelets 
(Patel et al, 2005). The remaining nucleus, membrane and cytoplasmic material are then 
degraded by apoptosis. 
The main driving force for proplatelet formation is the reorganisation of microtubules 
within the MK. These are formed of αβ-tubulin dimers, and have been shown to form in 
immature MKs coupled to the centrosome, growing towards, then parallel to the cell cortex 
(Patel et al, 2005). Microtubule production at the centrosome halts immediately prior to 
proplatelet formation, and the microtubules converge at the cell cortex. As the proplatelets 
form, microtubules extend in both directions, aided by the presence of the minus-end 
microtubule motor protein, dyenin (Patel et al, 2005). Platelets are formed at the end of 
each proplatelet by microtubules looping around themselves 8-12 times before re-entering 
the proplatelet shaft (Freson et al, 2005). Actin is also present throughout proplatelets and 
is implicated in the branching process, which is thought to be driven by the actin-based 
molecular motor, myosin; higher concentrations of actin are found at these points (Italiano 
et al, 1999; Italiano and Shivdasani, 2003). Organelles and granules are trafficked from the 
parent MK bidirectionally along the microtubules contained within the proplatelet 
eventually becoming trapped within developing platelets. This transport occurs through a 
combination of microtubule sliding and movement of the positive-end microtubule motor 
protein, kinesin (Richardson et al, 2005) 
1.1.3.3.2. Platelet release 
The mechanism of platelet release from proplatelets is not yet fully understood. Platelets 
are released into the blood stream through the blood sinusoids that link the bone marrow to 
the blood stream. Immature MKs have been shown to express CXCR4, the receptor for 
stromal-derived factor-1 (SDF-1) which has been demonstrated to form a gradient guiding 
the cells along the sinusoids from the osteoblastic niche to the vascular niche as they 
differentiate (Avecilla et al, 2004). The adhesion of the cells to the bone marrow 
endothelium is enhanced by fibroblast growth factor-4 (FGF-4), with SDF-1 assisting MK 
migration between the cells forming the endothelium barrier (Avecilla et al, 2004). The 
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junctions are too small for whole MKs to move into the sinusoids; however proplatelets are 
able to pass through. They separate from the remnants of the parent MK through retraction 
of the membranes such that platelets are released individually or more commonly as a ‘bar-
bell’ where 2 platelets are joined by a proplatelet branch and then finally separate in the 
bloodstream (Italiano et al, 1999). MK fragments are able to pass into the sinusoids, and 
have been found in the bloodstream following platelet release (Junt et al, 2007). 
The remnants of the parent cell are then degraded by apoptosis (Radley and Haller, 1983), 
and it has been demonstrated that pro-apoptotic factors are expressed during later stages of 
megakaryopoiesis, with anti-apoptotic factors expressed earlier during the process. 
Pro-apoptotic factors located within MKs include caspases-3 and -9 and nitric oxide (NO). 
Both procaspase-3 and procaspase-9 are compartmentalised in the cytoplasm of MKs, and 
have been shown to be present in mature platelets (de Botton et al, 2002). Both are 
activated prior to proplatelet production, with caspase-3 playing the major role. Previous 
work has shown that the inhibition of caspases induces thrombocytopenia (low platelet 
8 -1
number, < 1 x 10 platelets ml ), and it has been hypothesised that caspases-3 and -9 are 
implicated in the formation of proplatelets (de Botton et al, 2002). Caspase-12 is also 
present in mature MKs and has been demonstrated to link G-protein coupled receptors to 
αIIbβ3 activation. While it has been hypothesised to play a role in platelet aggregation, the 
mechanism by which this occurs has not been determined (Kerrigan et al 2004). NO has 
also been implicated in MK apoptosis using 2 cell lines, MEG-01 and HEL (Battinelli and 
Loscalzo, 2000), and there is also evidence to suggest its involvement in platelet 
production, where treatment of MEG-01 cells with NO assisted in the induction of platelet-
like particle production (Battinelli et al, 2001). Several anti-apoptotic factors have been 
identified, including Bcl-2, whose overexpression leads to reduced platelet counts (Ogilvy 
et al, 1999). The expression of Bcl-2 has been shown to be regulated by a proapoptotic 
factor Bim, the loss of which has been shown to approximately halve the number of 
platelets produced (Bouillet et al, 1999). Another factor is Bcl-xL, overexpression of 
which has also been shown to inhibit proplatelet formation (Kaluzhny et al, 2002). Both 
Bcl-2 and Bcl-xL have been potentially implicated in platelet survival (Zhang et al, 2007). 
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1.2. Platelets 
Platelets are small, anucleate cell fragments which circulate freely in the bloodstream, until 
they become activated and form a platelet aggregate. The average platelet count in an 
8 -1 
adult human is between 1.5 and 4.0 x 10 platelets ml with approximately 
11 
1 x 10 platelets produced each day; this can increase by more than 10 fold when required 
(Kaushansky, 2005). Platelets have been shown to contain 3 different types of granules 
each with specific contents- α, dense and lysosomal granules, which are released upon 
activation for example in thrombus formation (table 3). 
α­GRANULES DENSE GRANULES LYSOSOMES 
P-selectin ATP Acid phosphatase

vWF
 ADP Arylsuphatase

von Willebrand antigen II
 Calcium Carboxypeptidase A

Fibrinogen
 Serotonin Carboxypeptidase B

Fibronectin
 Pyrophosphate Proline carboxypeptidase

PF4
 Glutamate Cathepsin D

Protein S
 Cathepsin E

Factor V

Factor VIII

Albumin

Platelet-derived collagenase

inhibitor

Vitronectin

Osteonectin

IgG, IgA, IgM

Plasminogen

Neutrophil-activating protein II

Table 3. The contents of platelet secretary granules. PF4, platelet factor 4; vWF, von 
Willebrand factor; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; 
ATP, adenosine triphosphate; ADP, adenosine diphosphate (Nicol et al, 1999). 
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1.2.1. Coagulation cascade 
The coagulation cascade contains two pathways through which platelets can be activated, 
the extrinsic which is triggered by vascular injury and subsequent exposure of tissue factor, 
and the intrinsic, which is triggered by the activation of factor XII, in turn stimulating the 
activation of factor XI (Davie et al, 1991) (figure 3). The pathways lead to activation of 
factors X and V, which combine to form the prothombinase complex that cleaves 
prothrombin, leading to the release of thrombin, a serine protease (Orkutt and 
Krishnaswamy, 2004; Tracey and Mann, 1983). Thrombin then stimulates the conversion 
of fibrin from fibrinogen in addition to activating factor XIII, which triggers the formation 
of crosslinks between the fibrin monomers, strengthening the clot (Davies et al, 1991). 
The site of clot formation is regulated by the location of the exposed tissue factor, an 
integral membrane glycoprotein, preventing formation where it is not required. Clot 
formation is limited by the activity of thrombomodulin located on the viable endothelial 
membranes. Thrombomodulin binds active thrombin removing it from the blood stream 
and leading to the activation of Protein C. Active Protein C subsequently inhibits FVa 
and FVIIIa resulting in attenuation of the clotting cascade (Esmon and Owen, 1981; 
Fulcher et al, 1984). 
1.2.2. Thrombin 
In addition to a role in the coagulation cascade thrombin has been demonstrated to activate 
the 7-transmembrane G-protein coupled protease activated receptors (PAR) 1 and 4 
expressed on the surface of human platelets, by cleaving the extracellular N-terminus 
between residues Arg-42 and Ser-43 (Vu et al, 1991). The new N-terminus acts as a 
tethered ligand, binding to the body of the receptor and activating intracellular signalling 
(Vu et al, 1991). Each PAR can only be activated once before desensitising and 
uncoupling from the induced signalling pathway. The receptor is internalised by 
endosomes within the first 60 s of activation (Hoxie et al, 1993). The internalised 
receptors are then targeted to the lysosomes for degradation (Trijo et al, 1998). PAR-1 has 
been localised to both the cell surface and the demarcation membrane of platelets (Molino 
et al, 1997), and in megakaryocytic cells, it has been demonstrated that new receptors can 
be synthesised and transported to the cell surface. However, due to an apparent lack of 
machinery to synthesise new proteins this is not possible within platelets, and no further 
reserve of receptors other than those at the demarcation membrane has been determined 
(Molino et al, 1997). 
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Figure 3. Intrinsic and extrinsic pathways of the coagulation cascade which end in the 
formation of a cross­linked fibrin clot. Initiation of the coagulation cascade occurs following 
vascular injury, triggering the extrinsic pathway (right hand side; ). The intrinsic pathway is 
triggered by FXII binding to exposed collagen (left hand side; ) The pathways converge 
) to trigger activation of FX which leads to the generation of thrombin from prothrombin 
and the conversion of fibrin from fibrinogen, from which an insoluble clot forms. 
PL, phospholipid; F, factor; a, activated; numbers are in Roman numerals where I= 1, V= 5, X= 10. 
( 
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The sensitivity of the receptors to thrombin has been shown to vary, with the EC50 for 
PAR-4 shifting from 20 (platelets- endogenous receptors) to 100 fold (oocytes- transfected 
receptors) greater than for PAR-1 (Kahn et al, 1998; Xu et al 1998; Covic et al, 2000), 
indicating that while PAR-1 is the main mediator of platelet stimulation, PAR-4 is able to 
participate in platelet activation at high concentrations. There is evidence that the response 
to thrombin is biphasic with the more rapid initial phase due to PAR-1 activation, and the 
second, slower, sustained response mediated by PAR-4 (Kahn et al, 1999). Also in 
comparison to the rapid desensitisation of PAR-1, the desensitisation of PAR-4 is slower, 
indicating a role in sustaining a response to thrombin (Shapiro et al, 2000). 
PAR-1 and -4 have also been demonstrated to stimulate different intracellular pathways. 
PAR-1 has been shown to trigger Gαi which inhibits the production of adenylyl cyclase, 
and thus the production of cAMP, Gq/ 11 which activates phospholipase C (PLC), and 
G12/ 13 which have both been shown to stimulate RhoA kinase. In comparison, PAR-4 has 
been shown to activate only the Gαq pathway, but potentially also the G12 pathway (Farugi 
et al, 2000) (figure 4). 
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Figure 4. Pathways linked to activation of protease activated receptor 1 (PAR1) by thrombin. 
The N-terminus is cleaved by thrombin exposing a new N-terminus, which binds to the receptor 
leading to activation. PLC, phospholipase C; DAG, diacylglycerol; IP3, inositol triphosphate; 
PKC, protein kinase C; *, activated receptor. 
1.2.3 Platelet activation 
Inactive platelets are discoid in shape, but upon activation they swell, becoming spherical 
and extend pseudopods (figure 5). The peripheral microtubule rings contract and break 
down, and the granules become centralised (Klages et al, 1999). The granules then fuse 
with the membrane invaginations of the open canalicular system, and release their contents 
into the surrounding environment (Lemons et al, 1997). 
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Figure 5. Changes in platelet structure upon activation. A, B, Transmission electron 
micrograph of platelets following 5 min incubation at 37 
o
C in nominally Ca
2+
-free saline, prior to 
fixation. C, D, The effects of stimulation in the presence of 1mM extracellular calcium, followed 
by immediate fixation (MacKenzie, 1996). 
Platelets become activated upon exposure to collagen, P-selectin or tissue factor revealed 
by injury to the vascular wall, production of thrombin or factors released from previously 
activated cells. Initial binding, or tethering, of platelets is rapidly reversible, for example 
when platelet GPIbα binds to endothelial P-selectin, the platelet then rolls and binds more 
securely to exposed collagen via GPVI (Frennete et al, 1995). This process activates the 
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platelet causing the granules to migrate to the open canalicular system to release their 
contents into the surrounding environment, and adhesion proteins are exposed. This 
stimulates the activation of other platelets in the immediate environment, that bind to the 
platelets already present through surface αIIbβ3, using fibrinogen as a bridge, and through 
expressed vWF which binds GPIb/IX/V (Szalai et al, 2006). The formation of fibrin 
through the extrinsic coagulation cascade (figure 3) occurs alongside platelet activation, 
which acts to strengthen and stabilise the forming thrombus (Furie and Furie, 2005). This 
process continues in an autocrine and paracrine manner, as contents released from 
activated platelets further stimulates the original platelets together with those around them. 
It has been determined that the gap between platelets ranges between 0-50 nm (Skaer et al, 
1979), enabling the connection of platelets for example by αIIbβ3 receptors linked by 
fibrinogen. It also limits the distances factors released from activated platelets have to 
diffuse, for example ATP which is rapidly broken down to ADP and AMP by 
ecto-ATPases following release, and is able to activate the ionotropic P2X1 receptor which 
is involved in the initiation of platelet aggregation (Toth-Zsamboki et al, 2003). The 
integrin αIIbβ3 is present in an inactive state on the surface of resting platelets. Upon 
platelet stimulation, more integrins translocate to the cell membrane, enabling the platelet 
to bind to both stimulated and unstimulated platelets through binding to vWF or fibrinogen 
(Niiya et al, 1987). vWF is a multimeric protein synthesised in both endothelial cells and 
MKs, which binds GPIbα and collagen as well as the β3 integrin, giving it a multifaceted 
role in platelet activation and aggregation (Muira et al, 2000; Romikjn et al, 2001; 
Ruggeri, 2007). Talin, a cytoskeletal protein has also been shown to bind to the β3 
cytoplasmic domain, leading to activation of the integrin through inside-out signalling 
(Calderwood et al, 1999). 
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1.2.4. Storage and secretion of glutamate 
1.2.4.1. Bone marrow 
The MEG-01 cell line has been demonstrated to express the glutamate/ aspartate 
transporter, GLAST (also called excitatory amino acid transporter 1 (EAAT1)) together 
with the vesicular glutamate transporter, VGLUT1, suggesting that glutamate is taken up 
by MKs and stored (Genever et al, 1999; Thompson et al, 2010). MKs are located within 
the bone marrow in close proximity to osteoblasts and osteoclasts, which are responsible 
for maintaining the bone marrow matrix. Both osteoclasts and osteoblasts have been 
shown to express EAAT1 (Mason et al, 1997), with osteoclasts found to take up glutamate 
into the vesicles through the VGLUT1 transporter (Morimoto et al, 2006). The cells have 
been demonstrated to secrete the contents of these vesicles through transcytosis (Morimoto 
et al, 2006). This process is stimulated by depolarisation of the cells causing the vesicles 
to move across the cell and release their contents (glutamate and other bone degradation 
products) into the extracellular surroundings (Morimoto et al, 2006). Osteoblasts are also 
thought to express a vesicular glutamate transporter (Hinoi et al, 2002), and have been 
shown to release glutamate through a vesicular pathway, which mimics release from 
presynaptic glutamatergic neurones involving Rab, synaptosomal-associated protein-25 
(SNAP-25) and syntaxin (Bhangu et al, 2001). The glutamate transporter GLT-1 (EAAT2) 
usually expressed on glia cells is also expressed on marrow cells, indicating that levels of 
glutamate in the bone marrow are tightly regulated (Mason et al, 1997). 
1.2.4.2. Platelets 
Glutamate is stored within the dense granules of platelets, which express EAAT1, 2 and 3 
at both protein and mRNA levels (Zoia et al, 2004). EAATs are sodium-dependent 
transporters, and it has been suggested that activation of platelets by thrombin stimulates 
the translocation of EAAT2 from α-granules to the dense granules and the cell surface, 
enabling the influx of glutamate into the cells (Hoogland et al, 2005). EAAT1 is found in 
platelet membranes, with EAAT3 also located at the membranes as well as within the 
cytoplasm, suggesting that it is also able to translocate to the membranes when required 
(Zoia et al, 2004). Uptake can be affected detrimentally by changes in EAAT expression, 
for example in amyotrophic lateral sclerosis (ALS) where a decrease in expression of 
EAAT2 occurs in the brain, spinal cord and in platelets (Ferrarese et al, 2001). EAAT1 
has been shown to decrease in expression with age, but has been demonstrated to decrease 
further in patients with Alzheimer’s disease (AD) (Zoia et al, 2004). Platelets have also 
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been found to express the transporters, VGLUT1 and 2, with the latter only found 
previously on glutamatergic axon terminals (Tremolizzo et al, 2006). VGLUTs transport 
glutamate from the cytoplasm of cells into vesicles, using an H
+
-ATPase-driven H
+ 
electrochemical gradient to drive the process (Ikemoto et al, 2003). 
1.2.4.2.1. Role of glutamate in platelet function 
Glutamate is released by platelets upon activation for example by collagen, with the 
vesicles and dense granules fusing with the open canalicular system and plasma membrane 
(Tremolizzo et al, 2006). This increases the level of extracellular glutamate which can be 
taken up by neighbouring platelets. Glutamate levels in the blood can increase rapidly, for 
example during an ischemic event, and removal of glutamate from the area is important as 
part of limiting the damage caused, for example by platelets as well as neurones and glia 
(Káradóttir et al, 2005). Moreover, the increased circulating glutamate associated with 
ischemic events such as stroke may be associated with the increased pro-thrombotic state. 
There is conflicting evidence in the literature for the role of glutamate in platelet 
activation. Earlier studies report an anti-aggregatory action of the NMDA-activated 
glutamate receptor leading to an inhibition of thromboxane A2 (TbA2) synthesis from 
exogenous arachidonic acid (AA), but did not alter TbA2-mediated platelet aggregation 
(Franconi et al, 1996). However, despite the reported anti-aggregatory action, extracellular 
2+ 
NMDA was demonstrated to elicit an increase in intracellular Ca (Franconi et al, 1998). 
Platelet sensitivity to glutamate has been demonstrated to increase in both schizophrenia 
and depression, with increases in intracellular calcium higher in platelets from patients 
with these disorders than in control patients (Berk et al, 2000). Overall this demonstrates 
that the role of glutamate in platelet activation has only started to be understood and 
requires further investigation. 
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1.3. Glutamate receptors 
Glutamate is a non-essential amino acid which was originally known for its role in the 
Krebs and urea cycles in addition to the production of γ-butyric acid (GABA) (Watkins 
and Jane, 2006). It has more recently been demonstrated to play a major signalling role in 
both the central nervous system (CNS) and in non-excitable cells (table 6). 
Glutamate was identified as having an excitatory role in 1954 by Hayashi, where 
L-glutamate triggered convulsions following injection into the brain, leading to its proposal 
as a central synaptic transmitter. Further studies by Curtis et al (1960 and 1961) 
demonstrated that the application of glutamate to neurones elicited a rapid response that 
quickly returned to baseline. In addition, aspartate had been demonstrated to elicit 
responses from cells which also responded to glutamate, and subsequent work determined 
that glutamate receptors could be divided into those receptors that responded to NMDA, an 
aspartate analogue, and those which did not (Watkins and Evans, 1981). The latter group 
responded to both quisqualate and kainate; however they could be divided into those which 
were activated preferentially by quisqualate (later refined as those which responded to the 
more specific agonist (S)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid 
(AMPA)) and those preferentially activated by kainate. The discovery of the glutamate-
like compounds L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) and 
(9)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD) that induced excitatory 
responses which were not inhibited by known glutamate antagonists led to the cloning of 
the first metabotropic receptor (mGluR) subunit, mGluR1 (Masu et al, 1991; Houamed et 
al, 1991). This in turn led to the discovery of other members of the mGluR family, found 
to be G-protein coupled receptors, demonstrating that glutamate signalling is not limited to 
only ionotropic receptors (Tanabe et al, 1992). The mGluR family has been divided into 2 
based on their coupled G-protein, either Gαi (group I) or Gαq. Those acting via Gαq are 
further subdivided into groups II and III, depending on the effects of L-AP4 (group III) or 
trans-ACPD (group II) (Hollman and Heinemann, 1994; Hall et al, 1979; Nicoletti et al, 
1986) (figure 6). At the time of commencing my studies, there was no evidence in the 
literature indicating the presence of functional AMPA or kainate receptors (AMPARs or 
KARs) in human MKs or platelets. My thesis therefore investigates the expression of the 
NMDA-activated glutamate receptor in human MKs and platelets. 
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Figure 6. Classification of glutamate receptors. GluR, glutamate receptors; mGluR, 
metabotrophic glutamate receptors; iGluR, ionotropic glutamate receptors 
1.3.1. NMDA receptor, an ionotropic glutamate receptor 
The first NMDAR subunit was identified in 1991 by Moryoshi et al, and denoted NR1. 
The NR2 subunit was identified by several groups in the early 1990s, with 4 different 
subtypes cloned, NR2A-D (Meguro et al, 1992; Monyer et al, 1992; Kutsuwark et al, 
1992; Ishii et al, 1993). A third subunit, NR3A was discovered in 1995 (Ciabarra et al; 
Sucher et al), with a second subtype, NR3B identified a few years later (Chatterton et al, 
2002). No subtypes of NR1 have been determined; however 8 splice variants are known 
(McBain and Mayer, 1994). Each subunit varies in amino acid number and molecular 
mass, detailed in table 4. Sequence homology varies between NR1 and the 4 NR2 
subtypes from 19-22 %, with 36-53 % homology between the NR2 subtypes. The 
sequence homology between the 2 NR3 subtypes is 47 % and they have 17-21 % 
homology with the NR1 and NR2 subunits (Chatterton et al, 2002). The main differences 
in sequences have been found in the M2 re-entrant loop and the C-terminus, particularly 
between the NR1 and NR2 subunits (figure 7). 
37 
C.M. HOBBS

CHAPTER 1: INTRODUCTION

SUBUNIT MOLECULAR MASS (kDa) AMINO ACID NUMBER 
NR1 105.5 938 
NR2A 178.0 1464 
NR2B 165.9 1482 
NR2C 136.5 1250 
NR2D 147.5 1340 
NR3A 124.5 1115 
NR3B 109.0 1002 
Table 4. Comparing the molecular mass and amino acid numbers of the NMDAR subunits 
(Moriyoshi et al, 1991; Ishii et al, 1993; Sucher et al, 1995; Ciabarra et al, 1995; Chatterton et al, 
2002). 
The NMDAR is tetrameric in composition, containing 2 NR1 subunits together in 
combination with NR2 and NR3 subunits (Schüler et al, 2008). It has been shown that 
NR1 subunits are required for the formation of stable, functioning receptors and that 
translocation from the endoplasmic reticulum (ER) to the cell membrane requires the 
formation of dimers of subunits consisting of 1 NR1 subunit and 1 other, either an NR2 or 
NR3 subunit (Pérez-Otano et al, 2001). While it is possible for 2 NR1 subunits to form a 
dimer and translocate to the cell membrane, they are unable to form functional receptors 
(Schüler et al, 2008). Dimers of 2NR2, NR2/NR3 or 2NR3 subunits are retained within 
the ER and are not released to the cell membrane (Pérez-Otano et al 2001). Upon reaching 
the cell membrane, dimers converge forming functional tetrameric receptors from dimers 
of dimers (Schüler et al, 2008; Schorge and Colquhoun, 2003). It is therefore possible for 
NMDARs to contain 2 different NR2 subunits e.g. NR1/ NR2A/ NR2D, 2 different NR3 
subunits e.g. NR1/ NR3A/ NR3B, or even a mix of 3 different subunits (tri-heteromeric), 
for example NR1/ NR2D/ NR3B (Pérez-Otano et al 2001). 
The structure of the NMDAR subunits has been determined through comparisons with 
potassium channels using a range of techniques including hydrophobicity plots and 
crystallisation studies, demonstrating that they consist of 3 transmembrane domains (M1, 
M3 and M4) with a re-entrant loop (M2), which forms the pore of the receptor (figure 7) 
(Wood et al, 1995). In the open state, the pore of the receptor is blocked by a magnesium 
2+
ion (Mg ), which is released upon depolarisation of the membrane, allowing the 
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movement of Ca
2+ 
and sodium (Na
+
) ions into, and potassium (K
+
) ions out of, the cell. 
2+ 
The strength of the bonds retaining the Mg within the pore is dependent on the subunits 
present in the receptor, for example if NR2A is present, a greater stimulus is required to 
remove the magnesium block than if NR2D is present (table 5) (Qian and Johnson, 2006; 
Clarke and Johnson, 2006). NR1/NR3 receptors have been shown to be less sensitive to 
block by magnesium ions than NR1/NR2 receptors (Chatterton et al, 2002). 
Figure 7. Structure of an NMDA receptor subunit. Illustrating the 3 transmembrane regions 
(M1, M3 and M4), and the re-entrant loop (M2). The intracellular N- (NH2) and extracellular 
C- (COOH) termini are also shown. 
Extracellular glutamate and NMDA are the main agonists of classical NR1/ NR2 
NMDARs and bind to the NR2 subunit. Full activation requires the binding of a 
co-agonist to the NR1 subunit, either glycine or D-serine (Matsui et al, 1995) (figure 8). In 
comparison, the NR1/ NR3 combination requires only the binding of glycine to both 
subunits for activation, forming an excitatory glycine receptor (Chatterton et al, 2002). A 
further difference between the combinations is that D-serine acts as an inhibitor rather than 
a co-agonist for NR1/ NR3 receptors (Chatterton et al, 2002) (figure 8). 
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Figure 8. Pharmacology of the NMDA receptor. A, the classic NMDAR subunit conformation, 
NR1/NR2, the pore of which is blocked by a magnesium ion (purple circle). The receptor is 
activated by binding of either NMDA or glutamate together with either of the co-agonists, glycine 
2+
or D-serine (B), following removal of the magnesium (Mg ) block through desensitisation of the 
membrane. This allows movement of the Ca
2+ 
and Na
+ 
into, and K
+ 
out of, the cell. C, activation 
can be inhibited through the application of either MK-801, an open channel blocker (red circle), or 
D-AP5, a competitive inhibitor which binds to the glutamate/ NMDA binding site. D, a third 
NMDA receptor subunit is known, NR3. In combination with NR1 an excitatory glycine receptor 
is formed, which does not require glutamate for activation. Here, D-serine acts as an inhibitor, and 
2+ 
the pore is not blocked by Mg . 
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NMDAR 
SUBUNIT 
AGONIST ANTAGONIST ION 
PERMEABILITY 
Mg
2+ 
BLOCK 
NR1/NR2 Glutamate 
with glycine 
or D-serine 
D-AP5 
MK-801 
Higher 
permeability to 
Ca
2+ 
than Na
+ 
in 
K
+ 
out 
Block varies with 
NR2 subunit: 
EC50- NR1/NR2A 
or NR2B 
1-10 µM 
- NR1/NR2C or 
NR2D ~130µM 
NR1/ NR3 Glycine D-serine 
MK-801 
5,7- (DCKA) 
Higher 
permeability to Na
+ 
than Ca
2+ 
K
+ 
out 
Low sensitivity 
to magnesium 
block 
Table 5. Comparing agonists and antagonists for different NMDA receptor subunit 
combinations. 5,7-dichlorokynurenic acid (5,7-DCKA)- glycine receptor antagonist; D-AP5 
(McBain and Mayer, 1994; Dingledine et al, 1999; Chatterton et al, 2002) 
NMDARs form complexes with other proteins located at the plasma membrane of cells, 
and activation of the NMDAR leads to the stimulation of the complexed proteins as well as 
2+ 2+ 2+ 
an influx of Ca causing the formation of a localised region of high Ca (Ca
microdomain) close to the intracellular face of the receptor (Hardingham et al, 2001). One 
2+
such protein is RasGRF1, which is stimulated by the increase in [Ca ]i and activates Ras, 
leading to phosphorylation and activation of ERK, part of the the MAPK pathway (Bading 
and Greenberg, 1991). This has in turn been demonstrated to play a role in signalling to 
downstream transcription factors leading to modulation of gene transcription and activation 
e.g. CREB (Hardingham et al, 2001; Klages et al, 1999). 
NMDAR activity can be modulated through post-translational modifications such as the 
S­nitrosylation of cysteine (cys) residues within the extracellular regions of the NR1 and 
NR2A subunit proteins by nitric oxide (NO). This inhibits NMDARs and desensitises 
those already active (Choi et al, 2000). S-nitrosylation of NMDARs has been demonstrated 
to occur within the brain and is hypothesised to limit their activation during excitotoxic 
events such as an ischemic attack where localised concentrations of glutamate are greatly 
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raised, leading to increased receptor activity (Choi et al, 2002, Jaffrey et al, 2001). This 
suggests a potential regulatory role in platelet NMDAR activation for NO which is 
constitutively released by endothelial NO synthase (eNOS) into the blood stream (Dimmler 
et al, 1999; Fulton et al, 1999). 
1.3.2. Receptor localisation 
NMDARs have been well characterised in the CNS where they have been localised both 
pre- and postsynaptically in neurones, glia and astrocytes. Several studies have 
demonstrated that NMDARs are implicated in the generation of long-term potential (LTP), 
an important facet of the learning and memory processes (Do et al, 2002), and NMDARs 
have also been shown to be expressed in peripheral, non-neuronal locations (table 6). 
NMDARs are widely expressed in bone cells particularly in osteoclasts and osteoblasts 
(Patton et al, 1998). These are known to release glutamate (section 1.2.4.1.) and this 
release has been demonstrated to activate NMDAR in the neighbouring cells. However, 
the function of NMDARs in these cells appears to be limited and is not well understood 
(Gu and Publicover, 2000). Other locations include skin, heart, lung, pancreas and the 
urogenital tract (table 6). My thesis focuses on the expression of NMDARs in human 
platelets and MKs. 
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CELL TYPE FUNCTION 
CNS Neurones 
Glia 
Astrocytes 
Synaptic signalling, mediate ischemic injury 
(Dingledine et al, 1999) 
Synaptic signalling, mediate ischemic injury 
(Vekhratsky and Kirchhoff, 2007) 
Synaptic signalling, mediate ischemic injury 
(Schipke et al, 2001) 
Bone Osteoblasts 
Osteoclasts 
Megakaryocytes 
Bone resorption (Patton et al, 1998*) 
Bone formation (Patton et al, 1998*) 
Platelet formation (Genever et al, 1999a) 
Blood Platelets Anti-platelet aggregation (Franconi et al, 
1996*, 1998*) 
Skin Keratinocytes Production of keratin, skin development 
(Genever et al, 1999b*) 
Pancreas Β-cells and islets of 
Langerhans 
Regulate secretion of insulin 
(Molńar et al, 1995) 
Heart Atrial and ventricular 
cells 
Modulate cardiac function (Leung et al, 2002; 
Skerry and Genever, 2001) 
Lung Lung Induce excitotoxicity (Dickman et al, 2004) 
Urogenital 
tract 
Renal medulla and 
cortex 
Bladder and prostate 
Cytoprotective (Skerry and Genever, 2001; 
Leung et al, 2001) 
Reproduction (in males) 
(Gonazlez-Cadavid et al, 2000*) 
Table 6. Location of NMDA receptors in different tissues and cell types with their function. 
*= studies in which endogenous receptors were studied rather than recombinant receptors. 
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1.3.2.1. Ionotropic glutamate receptor expression in megakaryocytes and platelets 
1.3.2.1.1. NMDA receptor expression in megakaryocytes 
NMDARs have previously been identified in CD34
+
-derived MKs from umbilical cord 
blood and MEG-01 cells (Genever et al, 1999; Hitchcock et al, 2003). In the initial study 
by Genever et al (1999), it was demonstrated that mRNA for the NR1 and NR2D subunits 
are expressed in human MEG-01 cells and rat bone marrow derived MKs. The NR1 
protein was expressed in both untreated MEG-01 cells and those treated with phorbol 12-
myristate 13-acetate (PMA) for 3 d. In comparison, mRNA was detected for NR1 and all 
NR2 subtypes in rat brain samples. Immunolocalisation studies detected the NR1 subunit 
protein in human MKs and MEG-01 cells as well as in human platelets. NMDARs were 
involved in PMA-mediated MEG-01 differentiation, where treatment with PMA increased 
the expression of CD41 attenuated by treatment with an NMDAR antagonist MK-801. 
This effect was also observed with the expression of CD61. The corresponding increase in 
MEG-01 cell size with PMA was also inhibited by the presence of MK-801. In addition, 
the adhesion of MEG-01 cells was investigated as another marker of differentiation. 
Adhesion was shown to increase with the presence of PMA, and then decrease with 
increasing concentrations of either MK-801 or D-AP5, another NMDA receptor specific 
inhibitor. The addition of NMDAR-specific inhibitors was demonstrated not to affect 
either the cell number or viability over the experiment. The adhesion experiments were 
repeated using the CMK cell line to confirm that the adhesion is not just specific to the 
MEG-01 cell line. The CMK cell line was derived from a Down’s syndrome patient 
suffering from acute megakaryoblastic leukaemia, and demonstrated to be an accurate 
megakaryocytic model (Sato et al, 1989). Therefore the effects of the inhibitors are 
indicative that NMDA receptors are expressed by MEG-01 cells and that they have a 
functional role. 
A second study extended this work using MKs derived from umbilical cord blood CD34
+ 
cells (Hitchcock et al, 2003). Here expression of NR2A and NR2D mRNA was shown. 
Proplatelet formation and cell size was investigated, and both shown to be reduced by the 
presence of MK-801; the MK-801 treated cells were found to be approximately half the 
size of the untreated cells. No difference was determined in the number or viability of the 
cells between treated and untreated cells. TPO-mediated increases in CD41a, CD42a and 
CD61 expression were reduced upon addition of MK-801. The ultrastructure of native 
MKs was also investigated following culture with TPO present, and either with and 
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without MK-801. This revealed that changes indicative of differentiation such as 
increasing cell size, formation of a multilobed nucleus and dilated demarcation membrane 
were lacking in MK-801 treated cells. This study indicates that NMDARs are implicated 
in differentiation of MKs derived from umbilical cord blood. My thesis will extend these 
studies to investigate the protein expression of the NR2 subunits and the contribution of 
NMDAR to the adhesion of MEG-01 cells to different substrates. 
1.3.2.1.2. NMDAR expression in platelets 
The first evidence to suggest the expression of NMDARs in platelets came from studies 
demonstrating binding of phencyclidine to platelet membranes (Jamieson et al, 1992). 
Phencyclidine (an NMDAR antagonist) is reported to bind with high affinity to NMDARs, 
thus suggesting the expression of this receptor in platelets; it has subsequently been 
demonstrated to also bind dopamine D2 receptors and serotonin 5HT2A receptors, both of 
which are known to be expressed at the platelet surface membranes (Dean and Copolov, 
3
1989; Kapur and Seeman, 2002). Further binding studies demonstrated that [ H]glutamate 
3
and [ H]MK801 bound to platelet membranes with affinities comparable to neuronal 
membranes (Franconi et al, 1996). Addition of NMDA only partially displaced 
3 3
[ H]glutamate binding. However [ H]glutamate binding was not increased by MK801 as 
would be predicted from studies in neurones. The expression of the NMDAR NR1 subunit 
has been demonstrated in human platelets by immunohistochemistry (Genever et al, 1999). 
As previously mentioned in section 1.2.4.2.1, NMDAR functional expression has been 
demonstrated in assays of intracellular calcium and implicated in anti-aggregatory 
responses (Franconi et al, 1996 and 1998). To date the functional expression of NMDARs 
in human platelets is poorly understood. My thesis therefore investigates the expression of 
NMDAR subunits, pharmacological properties and their role in ATP secretion. 
1.4. Current model of glutamate signalling in megakaryocyte and platelet function 
Glutamate has been shown to play a range of roles in MK and platelet function, through 
glutamate uptake via EAAT1-3 or through the binding of glutamate to NMDARs. The 
figure below illustrates the different roles of glutamate receptors in both MKs and platelets 
using the evidence gained from previous studies. 
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Figure 9. Demonstrating the different glutamate signalling pathways in MKs and platelets. 
1. Glutamate is taken up by both platelets (B) and MKs (A) through EAATs (excitatory amino acid 
transporters) and stored in dense granules via vesicular glutamate transporters (VGLUT) (2.). 
Activation of the cells, potentially by NMDARs (3.) triggers the release of the granule contents (4.) 
including glutamate into the extracellular space, which is able to further activate the NMDARs. 
This leads to increases in [Na
+
]i and particularly [Ca
2+
]i leading to the formation of Ca
2+ 
microdomains close to the intracellular face of the NMDAR which have been demonstrated to 
stimulate ERK activation via activation of RasGRF1 in MKs (5.), and potentially leading to 
modulation of gene transcription in the nucleus e.g. CREB phosphorylation (Hardingham et al, 
2001; Bading and Greenberg, 1991). 
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1.5. Aims of this study 
The hypothesis of this study is that functional NMDARs are expressed in the human 
megakaryocytic cell line, MEG-01, and primary human platelets, based on previous 
evidence in the literature which has reported the expression of the NMDA NR1 subunit 
protein and suggested a role for NMDARs in both MK and platelet function (Franconi et 
al, 1996 and 1998; Genever et al, 1999; Hitchcock et al, 2003). There was no evidence at 
the start of my study that functional AMPAR and KARs were expressed in either human 
MKs (neither native nor cell line) or human platelets, therefore the role of these in MK 
differentiation and platelet were not investigated. 
The overall aim of this study is therefore to determine the expression and role of NMDARs 
in the human megakaryocytic cell line, MEG-01, and primary human platelets. 
The individual aims are to: 
- determine which NMDAR subunits are expressed by MEG-01 cells and platelets. 
Evidence in the literature has demonstrated the expression of the NR1 subunit protein 
and treatment of native MKs with MK-801 inhibited MK differentiation. NR1 
subunits are unable to form functional receptors alone, therefore other NMDAR 
subunits are required to form a functional receptor (NR2A-D, NR3A, B), which have 
yet to be identified. 
- evaluate the functional expression of NMDARs in human platelets and MKs.  The 
expression of NMDR subunits does not necessarily determine that functional receptors 
are formed, therefore the responses induced by classic agonists can determine whether 
the receptors present are comparable to the properties of the same receptors described 
in the literature. 
- assess the pharmacological properties of platelet NMDARs. The sensitivity of 
NMDARs expressed in human platelets requires further determination from that 
ascertained in the published literature, such as dose responses to glutamate or NMDA 
and the role of inhibitors such as MK-801 and D-AP5 
- establish the functional role of platelet and MK NMDARs.  Determining the 
expression and pharmacology of the receptors can help in ascertaining their role in 
both MK differentiation and platelet production, as well as in platelet activation and 
aggregation. 
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CHAPTER 2 
METHODS 
2.1. Materials 
Table 7. General Reagents 
REAGENT SUPPLIER 
Acetic acid (glacial) Fisher Scientific (Loughborough, UK) 
Acetone Sigma Aldrich (Dorset, UK) 
Acetyl salicylic acid (ASA; aspirin) Sigma Aldrich (Dorset UK) 
Acrylamide mix (30 % protogel) Fisher Scientific (Loughborough, UK) 
Ammonium persulphate Fisher Scientific (Loughborough, UK) 
Apyrase VII Sigma Aldrich (Dorset, UK) 
Bradford proteins assay concentrate Bio-Rad (Hemel Hemstead, UK) 
Broad range biotinylated standards Bio-Rad (Hemel Hemstead, UK) 
Calcium chloride (CaCl2) Sigma Aldrich (Dorset, UK) 
Chloroform Fisher Scientific (Loughborough, UK) 
Coomassie brilliant blue R-250 Bio-Rad (Hemel Hemstead, UK) 
Crystal violet Sigma Aldrich (Dorset, UK) 
L-cysteine Sigma Aldrich (Dorset, UK) 
D-(+)-Glucose Sigma Aldrich (Dorset, UK) 
D-(2R)-amino-5-phosphonovaleric acid 
(D-AP5) 
Sigma Aldrich (Dorset, UK) 
Dimethyl sulfoxide Sigma Aldrich (Dorset, UK) 
Dithiothreitol (DTT) Sigma Aldrich (Dorset, UK) 
Disodium ethylenediamine tetraacetate 
(Na2EDTA) Sigma Aldrich (Dorset, UK) 
D-serine Sigma Aldrich (Dorset, UK) 
Ethidium bromide Sigma Aldrich (Dorset, UK) 
Ethylene diaminetetraacetic acid (EDTA) Sigma Aldrich (Dorset, UK) 
Ethylene glycol tetraacetic acid (EGTA) Sigma Aldrich (Dorset, UK) 
Enhanced chemiluminescent (ELC
TM
) 
Western Blotting detection reagents GE Healthcare (Amersham, UK) 
Ethanol Fisher Scientific (Loughborough, UK) 
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Fibrinogen Sigma Aldrich (Dorset, UK) 
L-glutamate Sigma Aldrich (Dorset, UK) 
Glycine (Western blotting buffers) Fisher Scientific (Loughborough, UK) 
Glycine (≥ 99 %; agonist) Sigma Aldrich (Dorset, UK) 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) Sigma Aldrich (Dorset, UK) 
Hydrochloric acid (HCl) Fisher Scientific (Loughborough, UK) 
Ionomycin Sigma Aldrich (Dorset, UK) 
Isopropanol Fisher Scientific (Loughborough, UK) 
Magnesium chloride (MgCl2) Sigma Aldrich (Dorset, UK) 
Methanol Fisher Scientific (Loughborough, UK) 
(+)-Dizocilpine hydrogen maleate 
(MK-801) Sigma Aldrich (Dorset, UK) 
Nitrocellulose membrane (0.2 �m) Bio-Rad (Hemel Hemstead, UK) 
N-methyl-D-aspartate (NMDA) Sigma Aldrich (Dorset, UK) 
Nonidet P-40 (NP-40) Pierce (Cramlington, UK) 
DEA NONOate Sigma Aldrich (Dorset, UK) 
Phosphate buffered saline (PBS) Sigma Aldrich (Dorset, UK) 
Pluronic acid F-127 Sigma Aldrich (Dorset, UK) 
Polyvinylidene fluoride membrane 
(PVDF) (Hybond; 0.2 �m) GE Healthcare (Amersham, UK) 
Potassium chloride (KCl) Sigma Aldrich (Dorset, UK) 
Precision plus protein standards 
(kaleidoscope) Bio-Rad (Hemel Hemstead, UK) 
Protease inhibitor cocktail (General use) Sigma Aldrich (Dorset, UK) 
Protein inhibitor cocktail (cell and tissue 
extract; PIC) Sigma Aldrich (Dorset, UK) 
RNaseA Invitrogen (Paisley, UK) 
Sample buffer 2x Sigma Aldrich (Dorset, UK) 
Skimmed milk powder Sigma Aldrich (Dorset, UK) 
Sodium chloride (NaCl) Sigma Aldrich (Dorset, UK) 
Sodium dodecyl sulphate (SDS) Fisher Scientific (Loughborough, UK) 
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Sodium fluoride (NaF) Sigma Aldrich (Dorset, UK) 
Sodium hydroxide (NaOH) Sigma Aldrich (Dorset, UK) 
Sodium nitrite (NaNO2) Sigma Aldrich (Dorset , UK) 
Tetramethylethylenediamine (TEMED) Sigma Aldrich (Dorset, UK) 
Thrombin (bovine) Sigma Aldrich (Dorset, UK) 
Tris (hydroxymethyl)-methylamine Fisher Scientific (Loughborough, UK) 
Tris base (Trizma) Sigma Aldrich (Dorset, UK) 
Trisodium citrate Fisher Scientific (Loughborough, UK) 
Triton X-100 Sigma Aldrich (Dorset, UK) 
Trizol Reagent Invitrogen (Paisley, UK) 
Tween-20 Sigma Aldrich (Dorset, UK) 
Table 8. Cell culture

REAGENT SUPPLIER 
Inactivated foetal bovine serum (FBS) Invitrogen (Paisley, UK) 
L-glutamine Invitrogen (Paisley, UK) 
Penicillin/ streptomycin Invitrogen (Paisley, UK) 
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich (Dorset, UK) 
RPMI-1640 Sigma Aldrich (Dorset, UK) 
Thrombopoietin (recombinant human; 
TPO) Peprotech (London, UK) 
Trypsin/ EDTA Invitrogen (Paisley, UK) 
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Table 9. Polymerase chain reaction reagents

REAGENT SUPPLIER 
Total RNA, human cerebellum Stratagene (Stockport, UK) 
DNase Ambion (Warrington, UK) 
10 x DNase buffer Ambion (Warrington, UK) 
DNase stop solution Qiagen (Crawley, UK) 
RNAsin PLUS Promega UK (Southampton, UK) 
Oligo dT Qiagen (Crawley, UK) 
5 x RT buffer Invitrogen (Paisley, UK) 
Superscript II Invitrogen (Paisley, UK) 
dATP Qiagen (Crawley, UK) 
dCTP Qiagen (Crawley, UK) 
dGTP Qiagen (Crawley, UK) 
dTTP Qiagen (Crawley, UK) 
5 x Green Flexi buffer Promega UK (Southampton, UK) 
Dithiothreitol (DTT) Promega UK (Southampton, UK) 
Magnesium chloride (MgCl2) Promega UK (Southampton, UK) 
Go-Taq Promega UK (Southampton, UK) 
Table 10. Antibodies

ANTIBODY SUPPLIER 
Polyclonal rabbit anti-β-actin Sigma Aldrich (Dorset, UK) 
Monoclonal mouse anti-NMDA NR1 BD Bioscience (Oxford, UK) 
Polyclonal rabbit anti-NR2A R&D Systems (Oxford, UK) 
Polyclonal goat anti-NR2D Santa Cruz Biotechnology (Wembley, UK) 
Monoclonal mouse anti-glutamate 
NMDA receptor NR3A/B Cambridge Bioscience (Cambridge, UK) 
Neutravidin-HRP Pierce (Cramlington, UK) 
Polyclonal Rabbit Anti-Mouse IgG/HRP DakoCytomation (Ely, UK) 
Polyclonal Swine Anti-Rabbit IgG/HRP DakoCytomation (Ely, UK) 
Polyclonal Rabbit Anti-Goat IgG/HRP DakoCytomation (Ely, UK) 
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Table 11. Fluorescent indicators

REAGENT SUPPLIER 
Adenosine 5′-triphosphate (ATP) assay 
mix Sigma Aldrich (Dorset, UK) 
Fluo-4 AM Invitrogen (Paisley, UK) 
2.2. Solutions 
2+
Table 12. Nominally (Ca )­free salt solution (saline) 
REAGENT CONCENTRATION (mM) 
NaCl 145 
HEPES 10 
Glucose 10 
KCl 5 
MgCl2 1 
Adjust final solution to pH 7.3 with 0.1 M NaOH. 
Table 13. Tris­acetate­EDTA (TAE) buffer 
REAGENT CONCENTRATION (mM) 
Tris base (Trizma) 40 
Na2EDTA 1 
Adjust pH to 7.6 with glacial acetic acid
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2.3. Cell isolation and cell culture 
2.3.1. Platelet preparation

Table 14. Acid­citrate­dextrose (ACD)

REAGENT CONCENTRATION (mM) 
Glucose 111 
Trisodium citrate 85 
Citric acid 78 
Human platelets were isolated as previously described by MacKenzie et al, 1996. Venous 
blood was taken with informed consent from healthy volunteers who had not taken any 
medicine, particularly aspirin, its derivatives or other anti-clotting agents, for 2 weeks prior 
to donation.  The pool of donors used consisted of 46 people, of whom 31 were male (24 
aged between 18 and 40 years, and 7, 40 years and over), and 15 female (10 aged between 
18 and 40 years, and 5 aged 40 and over) with 42 white European and the remaining 4 of 
other extraction. The blood was taken by the department phlebotomist, Mrs Jo Carter, in 
the departmental phlebotomy room. The isolated blood was immediately mixed with an 
anticoagulant (acid-citrate-dextrose; ACD; table 14) in the ratio 8.5 ml blood to 1.5 ml 
ACD. Platelet rich plasma (PRP) was obtained by centrifugation of whole blood for 5 min 
at 750 xg in a Beckman CS-15R centrifuge with S4180 rotor, and removing the upper 
(PRP) layer. PRP was maintained at 37 
o
C, and used within 6 h following isolation from 
-1 
whole blood and within 2 h of removal from plasma. Aspirin (100 µM) and 0.32 U ml
apyrase VII were added to the PRP immediately after isolation to minimise platelet 
activation by spontaneously released thromboxane or adenosine nucleotides respectively. 
Apyrase and aspirin were not added when platelets were required for Western blotting 
samples as they were lysed immediately after isolation from PRP (see section 2.4.2). 
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2.3.2. Culture of MEG­01 cells 
Table 15. Complete culture medium 
REAGENT CONCENTRATION 
RPMI-1640 
Inactivated FBS 10 % 
L-glutamine 2 mM 
Penicillin 100 U ml
-1 
Streptomycin 100 µg ml
-1 
The human megakaryoblastic cell line MEG-01 (American Type Culture Collection 
(ATCC), Middlesex, UK) was maintained in complete culture media (table 15) at 37 
o
C in 
a humidified atmosphere of 5 % CO2 and 95 % air. Undifferentiated cells were both 
loosely adherent and in suspension (Ogura, M. et al, 1985). Both cell populations were 
collected by pipetting without trypsin/ EDTA. The cells were centrifuged at 240 xg for 
4 min in a Beckman CS-15R centrifuge with S4180 rotor with the resulting suspension of 
cells resuspended and maintained in fresh complete culture medium at a cell density of 
5 -1 
1 x 10 cells ml twice a week. Cells were maintained in culture for 5 weeks, after which 
fresh cells were thawed. 
2.3.2.1. MEG­01 differentiation 
Two different methods were used to differentiate MEG-01 cells. In the first (method 1), 
MEG-01 cells were counted and resuspended in complete culture media at 
5 -1
1 x 10 cells ml , then treated acutely (2 h) with 10 nM PMA. Cells were centrifuged at 
240 xg for 4 min, resuspended at the same density in complete culture medium, and 
cultured for 3 d as described in section 2.3.2. Alternatively, method 2, cells were 
5 -1 
resuspended at 2.4 x 10 cells ml and treated chronically in complete medium with 10 nM 
PMA for 3 d. The cells were maintained at 37 
o
C as described in section 2.3.2. 
2.3.2.1.1. Cell morphology studies 
For analysis of cell morphology studies, bright field images were taken of the cells after 3 
d in culture using an Olympus Camedia digital camera (C-4040ZOOM) connected to an 
Olympus IX51 microscope. The area of the cells was measured using ImageJ software 
1.41o (NIH, USA), and the data analysed using GraphPad Prism version 4 (section 2.10). 
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2.3.2.1.2. Cell number studies 
MEG-01 cells were transferred from their culture flasks/ dishes into fresh tubes either by 
pipetting, or, when culturing on fibrinogen, adding enough 0.5 % trypsin/ EDTA to cover 
the cells and warming at 37 
o
C for 2-3 min before pipetting to ensure that all the cells were 
removed from the base of the container. A sample was then taken from each tube, counted 
5 times to give an average number of cells and the total number determined in each tube of 
cells. The results were collated and analysed using GraphPad Prism version (section 2.10). 
2.3.3. Freezing cells for storage 
Table 16. Freezing medium 
REAGENT VOLUME (%) 
RPMI complete media 80 
FBS 10 
DMSO 10 
6 -1 
Cells were counted and resuspended in freezing medium at 1 x 10 cells ml . 1 ml 
volumes of resuspended cells were aliquoted into cryotubes, and placed into a 
Cryo-freezing container (named commercially as ‘Mr Frosty’ (containing ispropan-2-ol; 
Nalgene Labware) overnight at -80 
o
C. This slows the cooling of the cells to 1 
o
C min
-1 
, 
reducing the risk of dehydration or ice crystals forming within the cells, maintaining their 
viability until required. The cells are then transferred to long-term storage in liquid 
nitrogen. 
2.3.4. Thawing cells 
Cells were removed from liquid nitrogen storage and thawed gently at 37 
o
C. They were 
removed from the cryotube and 4 ml complete medium added slowly drop-wise. The cells 
were then centrifuged at 240 xg for 4 min to remove the freezing medium, resuspended 
gently into 5 ml fresh complete medium, transferred into a T25 and placed at 37 
o
C as 
described in section 2.3.2. 
2.3.5. Fibrinogen­coating 
Fibrinogen is a soluble glycoprotein produced in the liver by hepatocytes, and MKs 
(Haidaris et al, 1989). It is involved in platelet adhesion and clot formation, forming a link 
between platelets by binding to the integrin αIIbβ3, which is expressed on their surfaces and 
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helping to strengthen the forming thrombus (Ni et al, 2000). Fibrinogen has been located 
in the blood marrow sinusoids, towards which MKs migrate as they start to differentiate, 
following a concentration gradient of stromal-derived factor-1 (SDF-1) (Wang et al, 1998). 
MKs bind to the fibrinogen via the αIIbβ3 integrin in the sinusoids, and reach terminal 
differentiation producing proplatelets. These extend into the bloodstream, eventually 
releasing individual platelets (Larson and Watson, 2006). Where indicated, fibrinogen-
coated surfaces were used to differentiate MEG-01 cells. 
Fibrinogen was solubilised by layering on top of warmed PBS and mixed gently on a 
-1 
warming magnetic stirrer (Stuart Scientific SB302, Lutterworth, UK) to give a 100 �g ml
solution, which was filtered using a 0.22 µm filter. Clear 96-well plates were coated with 
30 µl in each well, and 5 cm dishes (Nunc, Loughborough, UK) were coated with 1 ml. 
These were incubated at 37 
o
C for either 2 h or overnight, and any remaining solution 
removed (Larson and Watson, 2006; van Os et al, 2003). They were then used for either 
crystal violet experiments (clear 96-well plates; section 2.6) or MEG-01 differentiation 
(5 cm dishes; section 2.3.2.1). 
2.4. Polymerase chain reaction 
All stages of the polymerase chain reaction (PCR) must be carried out using sterile tips and 
tubes to prevent contamination or degradation of the RNA isolated or the products 
produced by PCR. 
2.4.1. Isolation of total RNA 
6
MEG-01 cells were cultured as described in section 2.3.2. Samples of 1.5 x 10 cells were 
taken and the cells washed in sterile PBS. The PBS was removed, each sample of cells 
resuspended in 500 µl of Trizol in the fume hood due to the phenol content of Trizol, then 
stored at -80 
o
C until required.  The samples were defrosted at RT for approximately 5 min. 
All of the following steps were carried out in a fume hood due to the toxic nature of the 
phenol in Trizol. 0.1 ml of chloroform was added to each sample which was then shaken 
vigorously for 15 s to ensure that the 2 solvents were completely mixed, incubated at RT 
for 2- 3 min, then centrifuged at 18000 xg at 4 
o
C for 15 min in an Eppendorf Centrifuge 
5417R centrifuge with an FA45-24-11 rotor. The clear, colourless upper layer containing 
the RNA was carefully removed to a fresh eppendorf tube, then mixed gently with 250 µl 
isopropanol and incubated at RT for 10 min. These were then centrifuged at 18000 xg at 
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4 
o
C for 10 min, and the supernatant discarded. The gelatinous pellet was washed by the 
gentle addition of 1 ml 75 % cold ethanol, without resuspending the pellet, then 
centrifuged again at 18000 xg for 10 min at 4 
o
C. The supernatant was discarded, 
removing as much as possible before leaving the pellets in air dry in the fume hood. Once 
dry, the pellets were resuspended in 10 µl RNase-free water, and can be stored at -80 
o
C 
until required or used immediately. 
2.4.2. Quantification of RNA 
Before the RNA can be reversed transcribed to cDNA, the concentration of RNA within 
each sample must be determined. A sample of the RNA obtained in section 2.3.2 was 
diluted 100 x in RNase-free water to give a final volume of 100 µl, with the remaining 
sample left on ice. The RNA quantification was carried out using a Pharmacia Biotech 
Gene Quant II, with a path length of 10 and dilution factor of 100. Milli Q water was used 
as a reference sample to give an absorbance setting of 0. The diluted RNA samples were 
then read and the concentration of RNA determined. The rest of the original RNA samples 
were stored at -80 
o
C until required. 
2.4.3. Reverse transcription 
In this step the RNA is reverse transcribed using PCR (RT-PCR) to generate single strands 
of cDNA.  The samples were treated with DNase to remove any DNA present in the 
samples and RNasin PLUS to prevent degradation of the RNA present (table 17) and 
heated at 37 
o
C for 30 min in PCR tubes. 
Table 17. Reaction mix for DNAse treatment of RNA 
REAGENT VOLUME (µl) 
2 µg RNA x 
DNase (2000 U ml
-1
) 1.0 
10 x DNase buffer 0.5 
RNA-free water x 
RNAsin PLUS (40 U ml
-1
) 0.5 
Total volume 5.5 µl 
Where the volume of RNA from each sample prepared in section 2.4.1 and quantified in 2.4.2 
together with the water, total 3.5 µl. 
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1 µl DNase stop solution was then added to each sample and heated at 65 
o
C for 10 min to 
inactivate the DNase, as the following step reverse transcribes the isolated RNA to cDNA 
and any active DNase would degrade this. Olio dT was then added to each sample, 
providing an anchor at poly-A tails of mRNA aiding the start of reverse transcription (Krug 
and Berger, 1987), and incubated for another 5 min at 65 
o
C. The samples were then 
briefly centrifuged to ensure that all of the liquid was at the bottom of the tubes, then 
incubated on ice for at least 1 min. 13 µl of RT-PCR stock solution (table 18) was 
subsequently added to each sample and mixed gently before being incubated at 42 
o
C for 
50 min, follow by 15 min at 72 
o
C to inactivate the reverse transcriptase (Superscript II) in 
a Techne TC-512 Thermal Cycler. 
Table 18. RT­PCR stock solution 
REAGENT VOLUME (µl) 
PCR water 6 
5 x RT buffer 4 
DTT (100 mM) 1 
dNTPs (10 mM) 1 
Superscript II (200 U µl
-1
) 1 
Total 13 µl 
dNTPs- deoxyribonucleotide triphosphates; Superscript II, reverse transcriptase. 
2.4.4. PCR­ β­actin and NMDAR subunits 
The reverse transcribed samples were then set up for PCR in PCR tubes containing, using 
primers detailed in tables 20 or 21: 
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Table 19. PCR stock solution

REAGENT VOLUME (µl) 
Water 15.6 
5 x Flexi buffer 5.0 
dNTPs (10 mM) 0.5 
MgCl2 (25 mM) 2.0 
Forward primer (25 pM) 0.4 
Reverse primer (25 pM) 0.4 
Go-Taq 0.1 
Total 24.0 µl 
Table 20. Primer sequences­ β­actin 
PRIMER SEQUENCE EXPECTED SIZE (BP) 
Β-actin Forward 
Reverse 
5’ – TAGGCACCAGGGTGTGATGG 
5’ - CATGGCTGGGGTGTTGAAGG 282 
Obtained with kind permission from Dr Heather Bone 
Table 21. Primer sequences­ NMDAR subunits

SUBUNIT PRIMER SEQUENCE EXPECTED SIZE (BP) 
NR1 Forward 
Reverse 
5’-CTTTCTGCCAGCGAGGACG 
5’- CATACTTGGAAGACATCAGC 336 
NR2A Forward 
Reverse 
5’- ATGTGGTGAGATGGAGGAGC 
5’- TCTTGAGGAGTTCATGTTGG 391 
NR2B Forward 
Reverse 
5’- TGGTATGATTGGAGAGGTGG 
5’- TTTGCCGATGGTGAAAGAGG 338 
NR2C Forward 
Reverse 
5’- CAGTGACAAGAAGTTTCAGC 
5’- ATGCCGTAGCCAGTGGTAGC 304 
NR2D Forward 
Reverse 
5’-GCTCACGCCCAAGGAGAAGG 
5’-AACCAGACGTAGCCAGATCC 366 
NR3A Forward 
Reverse 
5'- TCCAACCAGAACTTGCTCTC 
5'- GGATGCTCAATCAGGGTAA 352 
NR3B Forward 
Reverse 
5'- CATGGTCGGGGACAAGAC 
5'- GGACAGGTTGGAGGTGAGC 385 
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1 µl of cDNA was added to each tube and mixed gently. The tubes were then placed in a 
Techne TC-512 Thermal Cycler and run on the programme required (table 22). 
Optimisation was required for the annealing step for the NMDAR subunit primers, which 
used a temperature gradient across the Thermal Cycler from 53- 63 
o
C, in place of 62 
o
C 
used for the β-actin primers (table 22). The other steps of the programme remained the 
same. 
Table 22. PCR programme for β­actin 
TEMPERATURE (
o
C) TIME (s) 
Heated lid 105 -
Initial denaturation 94 300 
25 cycles- denaturation 94 30 
- annealing * 62 30 
- extension 72 45 
Final extension 72 5 
Hold 4 -
* the annealing temperature was varied as required the NMDAR primer sets. For optimisation, a 
temperature gradient was used from 53- 63 
o
C. 
Once the PCR programme was completed, the samples were run on a 2 % agarose-TAE gel 
-1 
bathed in TAE buffer for 1 h at 80 V. The gel was then soaked in 0.5 µg ml ethidium 
bromide-TAE solution for 30 min, before visualisation using a Syngene UV transluminator 
using GeneSNAP software version 7.07. 
2.5. Western blotting 
2.5.1. Determination of protein concentration 
The protein concentration for all samples run on Western blots was determined using the 
Bradford assay (Bradford, 1976). Bradford assay concentrate was diluted 10 fold, and split 
into 1 ml volumes for each sample. To these, 2 µl of the relevant sample was added and 
mixed well. 200 µl of each diluted sample was added to a 96 well clear plate in triplicate 
together with triplicate bovine serum albumin (BSA) standards ranging from 1 to 
-1 
32 µg ml , and the absorbance read at 595 nm. Protein samples were subsequently 
-1 
prepared with a final concentration of 1 µg �l with double deionised water, and 5 x 
sample buffer. 
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2.5.2. Preparation of MEG­01 cells and platelets 
Table 23. Lysis buffer A 
REAGENT CONCENTRATION (%) 
Protease inhibitor cocktail (General use) 
Triton X-100 1 
Table 24. Lysis buffer B

REAGENT CONCENTRATION 
NaCl 150 mM 
Tris (pH to 7.4) 20 mM 
MgCl2 1 mM 
CaCl2 1 mM 
Protease inhibitor cocktail (cell and tissue 
extract) 2 % 
Triton X-100 1 % 
Table 25. Laemmli sample buffer (5x)

REAGENT CONCENTRATION 
Tris-HCl (pH 6.8) 200 mM 
Glycerol 50 % 
2-mercaptoethanol 20 % 
SDS 10 % 
Bromophenol blue 0.01 % 
6
Protein samples were prepared using either 2 x 10 MEG-01 cells or 3 ml PRP, centrifuged 
at 240 xg for 4 min or 350 xg for 20 min respectively, and washed once in PBS. The cells 
were then resuspended in 100 µl lysis buffer A (table 23) containing 1 % Triton X-100 and 
protease inhibitors, incubated for 10 min on ice, and centrifuged at 19000 xg for 15 min at 
4 
o
C to pellet cell debris. The supernatant was retained and either used immediately or 
stored at -80 
o
C. Samples were assayed for protein content using the Bradford assay 
-1 
(section 2.5.1) and diluted as required to a final concentration of 1 �g �l with double 
distilled water and 5x sample buffer, such that approximately 15 µg of protein was loaded 
per lane. Samples were boiled at 100 
o
C for 10 min prior to loading onto the gel. This step 
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in combination with sodium dodecyl sulphate (SDS), which confers a negative charge over 
the whole protein, and 2-mercaptoethanol, which reduces disulphide bonds, in the sample 
buffer ensures that the protein runs through the gel matrix in a purely size-dependent 
manner. 
A second method with a longer lysis period was also used to solubilise membrane proteins 
for analysis by Western blot. This method is modified from Young et al, 2007, using a 
tris-based buffer in place of a phosphate-based lysis buffer. The extended lysis period is 
hypothesised to improve the solubilisation of membrane proteins, for example ion channel 
subunits. Triton X-100 is a non-ionic detergent which has previously been used for the 
recovery of membrane proteins for analysis by Western blot, for example by Sheu et al, 
(2004) in the localisation of matrix metalloproteinase-9, Merezhinskaya et al, (2006) 
investigating the expression of monocarboxylate transporter 4 and Jung et al, (2008), 
investigating the membrane localisation of phosphoinositol 4-kinase IIβ. 
6
MEG-01 cells (2 x 10 ) were washed in ice cold PBS to remove any remaining media, with 
centrifugation steps of 240 xg for 4 min. 3 ml PRP was centrifuged at 350 xg for 20 min to 
pellet the platelets. The platelet poor plasma (PPP) was discarded and the cells washed in 
warmed PBS. Both cell pellets were resuspended in 50 �l lysis buffer B (table 24) and 
rocked gently (Stuart Scientific, rocking platform STR9, Lutterworth, UK) at 4 
o
C for 
60 min. The cells were then centrifuged at 19000 xg for 10 min (Beckman CS-15R 
centrifuge, F3602 rotor). The supernatant containing solubilised membrane proteins was 
collected and either used immediately or stored at -80 
o
C. Samples were assayed for 
protein content using the Bradford assay (section 2.4.1) and diluted as required to a final 
-1 
concentration of 1 �g �l with double distilled water and 5x sample buffer. Samples were 
boiled at 100 
o
C for 10 min prior to loading onto the gel. 
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2.5.3. SDS­polyacrylamide gel electrophoresis (SDS­PAGE) 
Table 26. 8 % resolving gel (5 ml = 1 gel) 
REAGENT VOLUME (ml) 
Distilled water 2.3 
30 % Acrylamide 1.3 
1.5 M Tris (pH 8.8) 1.3 
10 % SDS 0.05 
10 % Ammonium persulphate 0.05 
TEMED 0.003 
Table 27. 5 % stacking gel (2ml = 1 gel)

REAGENT VOLUME (ml) 
Distilled water 1.36 
30 % Acrylamide 0.34 
1 M Tris (pH 6.8) 0.26 
10 % SDS 0.02 
10 % Ammonium persulphate 0.02 
TEMED 0.002 
Table 28. Running buffer

REAGENT CONCENTRATION 
Glycine 192 mM 
Tris 25 mM 
SDS 0.1 % 
Table 29. TGS running buffer

REAGENT CONCENTRATION 
Glycine 192 mM 
Tris 25 mM 
SDS 0.1 % 
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8 % SDS-polyacrylamide gels were cast in a Bio-Rad gel system (BioRad, UK), and run in 
a Bio-Rad Mini Protean II system containing running buffer (table 28) at constant 200 V 
for approximately 30 min. Alternatively, samples lysed in lysis buffer B were run at a 
constant 150 V for approximately 1 h with the system filled with TGS running buffer. A 
protein standard was run alongside the samples in both cases to estimate the size of 
proteins detected. 
2.5.4. Immunoblotting 
Table 30. Transfer buffer 
REAGENT CONCENTRATION 
Glycine 192 mM 
Tris 25 mM 
SDS 0.1 % 
Methanol 20 % 
Table 31. Wash buffer

REAGENT CONCENTRATION 
PBS tablets 1 per 200 ml double deionised water 
Tween-20 0.5 % 
Table 32. TG transfer buffer

REAGENT CONCENTRATION 
Glycine 192 mM 
Tris 25 mM 
Methanol 20 % 
Table 33. TTBS wash buffer

REAGENT CONCENTRATION 
Sodium chloride 500 mM 
Tris 20 mM 
pH 7.5 
Tween-20 0.2 % 
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Polyvinylidene difluoride (PVDF) membrane is inherently hydrophobic, and requires 
wetting before use as proteins will not bind to the dry membrane. Soaking the membrane 
in methanol reduces the hydrophobicity through the formation of hydrogen bonds between 
the methanol hydroxide groups and the fluoride groups of the PVDF. The membrane is 
then equilibrated in TG transfer buffer before immunoblotting. PVDF has a greater protein 
2 2
binding capacity than nitrocellulose, 140- 150 �g cm compared to 80- 100 �g cm 
respectively (Bio-Rad), which enables increased binding of protein to small areas of the 
membrane giving a higher signal-to-noise ratio, and therefore a clearer final image. 
The gels were removed from the glass plates, and transferred into a ‘sandwich’ containing 
(in order) sponge, filter paper, gel, nitrocellulose membrane (0.2 �m), filter paper and 
1
sponge, where both sponge and filter paper were pre-soaked in transfer buffer (table 30). 
This was placed into a cassette, and into the Bio-Rad transferring system with transfer 
2
buffer, then run at a constant 150 mA for approximately 2 h. Alternatively , PVDF 
membrane (0.2 �m) was used in place of nitrocellulose membrane. PVDF membrane was 
soaked in methanol for 2 min, followed by 2 min washing in cold TG transfer buffer 
(table) before placing in the sandwich. In this case transfer was carried out at a constant 
2
350 mA for approximately 40 min, and the tank filled with cold TG buffer . 
1 2
Membranes were incubated overnight in either 5 % skimmed milk-PBS (-TTBS (table 
33)) at 4 
o
C with constant, gentle rocking. The membrane was then incubated with the 
required antibody (see table 34) for 90 min at RT with constant rocking. The membrane 
was washed for 3 x 5 min in either PBS or TTBS, then incubated in secondary antibody 
diluted in 5 % skimmed milk- PBS (-TTBS) for 60 min at RT with constant rocking. The 
membrane was washed for 6 x 5 min in either PBS or TTBS and the protein visualised on 
X-ray film using ECL chemiluminescent detection agent. 
1 
Running buffer, transfer buffer and PBS were used when samples were lysed with lysis buffer A 
2 
TGS running buffer, TG transfer buffer and TTBS were used when samples were lysed with lysis buffer B 
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Table 34. Antibody concentrations

ANTIBODY CONCENTRATION USED 
Anti-β-actin 0.8 ng ml
-1 
Anti-NR1 0.5 µg ml
-1 
Anti-NR2A 0.2 �g ml
-1 
Anti-NR2D 0.2 �g ml
-1 
Anti-NR3A/B 0.32 µg ml
-1 
Polyclonal Rabbit Anti-Mouse IgG/HRP 0.26 mg ml
-1 
Polyclonal Rabbit Anti-Goat IgG/ HRP 0.13 mg ml
-1 
Polyclonal Swine Anti-Rabbit IgG/HRP 0.26 mg ml
-1 
NB All antibodies were diluted in 5 % skimmed milk-PBS (-TTBS) 
2.5.5. Membrane stripping

Table 35. Membrane stripping buffer (5x)

REAGENT AMOUNT 
SDS 10 g 
1M Tris-HCl pH 7.4 31.25 ml 
Double distilled H2O Make up to 100 ml 
Table 36. Membrane stripping buffer (1x)

REAGENT AMOUNT 
5x membrane stripping buffer 20 ml 
Double distilled H2O 80 ml 
2-mercaptoethanol 770 �l 
Membranes were stripped so that they could be re-probed with different antibodies, for 
example β-actin to validate whether loading of the samples was equal. 
The membrane was immersed in 1x stripping buffer such that its upper surface was just 
covered, and warmed at 60 
o
C for 20 min in a water bath. The membrane was then washed 
at least 3x for 20 min in wash buffer (PBS-tween or TTBS) and blocked in either 5 % BSA 
or milk as required overnight before probing with a different antibody (section 2.5.4). 
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2.5.6. Densitometry analysis 
The X-ray film onto which the proteins were visualised following immunoblotting (section 
2.5.4), was scanned using a Cannon Lide 70 and the image captured using Adobe 
Photoshop version 7.0. The pictures were then analysed using ImageJ software 1.41o 
(NIH, USA), where the area of the gel for each sample at the expected size for each 
subunit protein was identified and framed using a box of the same size for each band, then 
the arbitrary densitometry value taken. The values were normalised using the arbitrary 
densitometry value for the matched β-actin bands for each sample; each membrane from 
SDS-PAGE was split prior to immunoblotting at approximately 70 kDa such that the 
expression of the subunit proteins (100-180 kDa) could be determined on the top half and 
that of β-actin (44 kDa) on the lower half. The data was analysed using GraphPad Prism 
version 4 (section 2.10). 
2.6. Coomassie blue staining 
Coomassie brilliant blue R-250 binds non-specifically to virtually all proteins enabling 
visualisation of proteins on an SDS-polyacrylamide gel, and therefore assisting the 
comparison of the amount and size of proteins within samples. 
Table 37. Coomassie blue staining solution 
REAGENTS CONCENTRATION (%) 
Methanol 50 
Double deionised water 40 
Glacial acetic acid 10 
Coomassie brilliant blue R-250 0.05 (w/v) 
Table 38. Coomassie destaining solution

REAGENTS CONCENTRATION (%) 
Methanol 50 
Double deionised water 40 
Glacial acetic acid 10 
Samples were prepared using the membrane lysis protocol (section 2.5.2) and separated

using SDS-polyacrylamide gel electrophoresis (as described in section 2.5.3). The gel was
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then immersed in Coomassie blue staining solution (table 39) for approximately 30 min at 
RT with gentle rocking after which the staining solution (table 40) was replaced with 
destaining solution. This was in turn replaced approximately every hour with fresh 
destaining solution, and rocked gently at RT until the gel background was clear and blue 
bands clearly visible. 
2.7. Crystal violet staining 
Crystal violet or methyl violet 10B is a cell impermeable dye which is able to bind DNA 
following fixation of the cells. It is used in the determination of cell viability and adhesion 
assays (Genever et al, 1999) 
-5 -1 
MEG-01 cells were cultured at 2 x 10 ml in the presence or absence of 10 nM PMA for 
3 d in combination with varying concentrations (0-100 µM) of either MK-801 or D-AP5. 
The cells were washed 3 times with PBS to remove non-adherent cells, then fixed with 
70 % ethanol in double deionised water for 15 min at RT. The cells were washed with 
PBS and stained with 0.5 % crystal violet in double deionised water for 25 min. Excess 
dye was removed by washing several times with double deionised water. The dye was then 
eluted by adding a 50 % ethanol/ 0.1 M sodium citrate solution (pH 4.2) to the cells. 
Absorbance was read on a BMG multi-detection microplate reader (FLUOstar OPTIMA, 
BMG Labtech, Aylesbury, UK) at 570 nm and the data analysed using Prism Version 4 
(GraphPad Software, San Diego, CA, USA). 
2+ 
2.8. Measuring intracellular Ca in human platelets 
2+ 
Ca responses were detected in acutely isolated human platelets using the fluorescent 
indicator fluo-4, where an increase in fluorescence is indicative of an increase in 
2+ 
intracellular Ca (Baier et al, 2009; Grynkiewicz et al, 1985), and the dye exhibits a Kd 
2+
(Ca ) of 345 nm (Gee et al, 2000). Human platelets were loaded with fluo-4 using a 
membrane-permeant analogue, fluo-4AM. The addition of the acetylmethyl (AM) ester 
converts the charged fluo-4 molecule into an uncharged molecule which becomes 
membrane permeable. Non-specific esterases cleave the ester group once inside the cell, 
returning the fluo-4 to its original, charged state, which leaks out of the cells far more 
slowly than when bound to the AM group (Simpson, 2005). 
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PRP was prepared as previously described (section 2.3.1) and incubated with 5 �M fluo-
4AM and 0.02 % pluronic acid-F127 in the dark. Pluronic acid-F127 is a non-ionic 
detergent which facilitates solubilisation of water insoluble dyes, such as fluo-4AM, 
ensuring equal dispersal of the dye throughout the solution during cell dye loading. The 
PRP was centrifuged for 20 min at 350 xg and the PPP discarded. The platelet pellet was 
-1 
resuspended in an equal volume of saline containing 0.32 U ml apyrase grade VII. The 
fluo-4AM loaded suspension was added to a black-walled 96 well plate (Greiner Bio-One, 
Stonehouse, UK), and the recording started while the cells equilibrated to 37 
o
C for 60 s 
(figure 10). CaCl2 (1 mM) was then manually added to the cells, which were allowed to 
equilibrate for another 120 s, while still recording the fluorescence produced, after which 
the agonist or saline were applied using the inbuilt injectors in the microplate reader. 
Figure 10. Timeline for the fluo­4 assay. The platelets were maintained at 37 
o
C from time= 0 s, 
and were kept in the dark from loading with fluo-4AM. The first 60 s equilibrated the platelets to 
37 
o
C, with the following 120 s equilibrating the platelets to the increase in [Ca
2+
]. The addition of 
2+ .
ionomycin, an ionophore, leads to the maximal increase in [Ca ]i 
-1
Ionomycin (1 �g ml ) was added 180 s after the agonist to obtain maximal fluorescence. 
Antagonists were added at the start of the experiment (t=0). All measurements were 
performed at 37 
o
C with a BMG multi-detection microplate reader (FLUOstar OPTIMA, 
BMG Labtech, Aylesbury, UK). Fluo-4 was excited at 488 nm and fluorescence collected 
at 520 nm every 0.24- 8 s. Each condition was repeated in triplicate for each experiment 
and values normalised to the baseline and maximal fluorescence readings (equation 1). 
The increase in fluorescence due to the addition of calcium was subtracted from peak 
values to give responses solely due to the addition of the agonist. Curve fitting was 
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performed using Prism Version 4 (GraphPad Software) using a four parameter logistic 
equation (equation 2). 
Equation 1 
Where F is fluorescence, F0 is fluorescence at time = 0 s, and Fmax is maximum 
fluorescence. 
Equation 2 
Where x is the logarithm of the molar concentration of the drug, α is the maxima (max-
baseline), logA50 is the half maximal response and nH is the Hill slope. 
2.9. Measurement of ATP release from human platelets 
Luminescent firefly luciferase was used to detect the secretion of ATP from platelet 
electron dense granules into the external environment (McNicol and Israels, 1999). Firefly 
luciferase binds ATP in the presence of luciferin, the substrate for luciferase, leading 
indirectly to the production of light (figure 11). 
Figure 11. Mechanism of ATP detection by luciferase. Equation showing the process through 
which ATP is detected by luciferase, leading to the release of light which is detected by the 
photomultiplier tube in the luminometer (Sigma, www.sigma.co.uk). 
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A lyophilised powder luciferin-luciferase mix was used containing the firefly enzyme 
luciferase, luciferin, MgSO4, DTT, EDTA, BSA and tricine buffer salts. This was 
reconstituted in 5 ml double deionised water to give the stock solution (Sigma). 
In all experiments, PRP was centrifuged for 2 min at 140 xg in a Hermle Z160M centrifuge 
2+
and the platelet pellet resuspended in nominally Ca -free salt solution. The platelet 
suspension (25 µl per well) was placed in a white 96 well plate (Greiner Bio-One, 
Stonehouse, UK) with 15 µl platelet saline and 40 µl of 10 x diluted luciferin-luciferase 
mix per well. Antagonists and CaCl2 (1 mM final concentration) were added prior to the 
start of the assay. Agonists (10 µl) were injected using a computer controlled injector as 
indicated in figures 24 and 42. All measurements of luminescence were performed with a 
BMG multi-detection microplate reader (FLUOstar OPTIMA, BGM Labtech, Aylesbury, 
UK), and, where emitted, light was detected using photomultiplier tube. Luminescence 
was measured every 21 s. 
ATP standards (1 nM- 10 �M) were run alongside each experiment using half log serial 
dilutions, which were plotted against luminescence detected to produce a standard curve 
(figure 12). The increase in luminescence from baseline was measured and used to 
calculate the ATP concentration released using the standard curve determined for each 
experiment. Analysis was performed using Prism Version 4 (GraphPad Software). 
Figure 12. ATP calibration curve. A, to determine the sensitivity of the luciferase assay using 
known ATP concentrations from 1 nM to 10 �M ATP. B, showing the limit of detection is from 
10 nM ATP. Values represent mean ± s.e.m from 4 experiments. 
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2.10. Analysis 
Data analysis and graphical diagrams were produced using Prism Version 4 (Graphpad 
Software, San Diego CA, USA). Luminescence readings were converted to ATP 
concentrations using ATP-luminescence calibration curves (section 2.9; figure 12). 
Statistical significance of differences were analysed either by a one-way ANOVA with a 
Dunnetts posthoc test, a two-way ANOVA with Bonferroni post-hoc test, or alternatively 
a 2-tailed, unpaired student’s t test, as appropriate. Significance was reached when P< 0.05 
(GraphPad Prism). Data is expressed as mean ± standard error of the mean (± s.e.m), with 
n denoting the number of donors. 
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CHAPTER 3

GLUTAMATE­GATED ION CHANNELS

3.1. Summary 
In this chapter, it has been determined that: 
- the NMDA receptor subunit proteins NR1 and NR2D are expressed in human 
platelets, but not the NR2A subunit protein 
2+
- increases in [Ca ]i are observed upon external application of either glutamate or 
NMDA 
- ATP release can be elicited from human platelets upon external application of 
glutamate alone, and in combination with glycine, which can be inhibited by the 
additional presence of either MK-801 or D-AP5 
3.2. Introduction 
Previous studies have demonstrated that the NMDA NR1 subunit protein is expressed in 
human platelets (Genever et al, 1999) and have also shown that NMDARs are implicated 
in platelet activation (Franconi et al, 1996 and 1998). These studies have been extended to 
examine the expression of different NMDA subunit proteins in freshly isolated human 
platelets; NMDA NR1 subunits that contain the glycine binding site and whose presence is 
required for the formation of functioning NMDA receptors, together with NR2 subunits 
which bind glutamate and are inhibited by the binding of the antagonist D-AP5 (Matsui et 
al, 1995). 
3.3. Results 
3.3.1 Detection of NMDA receptor subunits by Western blot 
Figure 13 demonstrates that 4 different human platelet donors express the NMDA NR1 
subunit protein at approximately 120 kDa (donors 1, 3-5; with equal loading determined by 
the expression of β-actin). Donor 3 appears to demonstrate a lower level of expression of 
the NR1 subunit, however the density of the β-actin band is less than in the other 
3 expressing donors (n=6). Secondary bands were detected between 150 and 250 kDa in 
all donors.  These were reduced in intensity by increasing the boiling step prior to loading 
from 5 to 10 min. 
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Figure 13. Human platelets express NMDA receptor subunit NR1. Western blot 
demonstrating variation in expression of the NMDA NR1 subunit between different human donors 
(1-6), with loading was assessed by blotting for β-actin (expected size 42 kDa), from the same, 
subsequently stripped membrane. The arrows on the right side indicate sizes predicted by the 
protein standards (mol weight, molecular weight marker; kDa). Arrow on the left indicates the 
expected size of the NR1 subunit, 120 kDa. Number above the lanes indicates the donor from 
which sample was obtained; approximately 15 µg protein loaded of each sample determined by 
Bradford assay. Representative blot from 15 separate experiments. 
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Figure 14. Human platelets do not express detectable NMDA receptor subunit NR2A. 
Western blot demonstrating that the NMDA NR2A subunit is not detectable in 6 different human 
donors. The arrows on the right side indicate sizes predicted by the protein standards (mol weight, 
molecular weight marker; kDa). Arrow on the left indicates the expected size of the protein, 
180 kDa. Number above the lanes indicates the donor from which sample was obtained; 
approximately 15 µg protein loaded of each sample determined by Bradford assay. Representative 
blot from 4 separate experiments. 
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Figure 15. Human platelets express NMDA receptor subunit NR2D. Western blot 
demonstrating variation in expression of the NMDA NR2D subunit between different human 
donors with loading was assessed by blotting for β-actin (expected size 42 kDa), from the same 
stripped membrane. The arrows on the right side indicate sizes predicted by the protein standards 
(mol weight, molecular weight marker; kDa). Arrow on the left indicates the expected size of the 
protein, 150 kDa. Number above the lanes indicates the donor from which sample was obtained; 
approximately 15 µg protein loaded of each sample determined by Bradford assay. Representative 
blot from 5 separate experiments. 
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The NR2D subunit protein (estimated molecular weight 150 kDa) is expressed by all 
6 donors in figure 15 (n= 6) at different levels, with donor 2 clearly expressing the protein 
in larger amounts than others, while the β-actin blot below indicates that the loading of this 
sample is less than that for the other 5 donors suggesting that the level of expression is 
greater in this particular donor. In comparison there is no detectable evidence of NR2A 
protein expression in human platelets (figure 14), with no bands discernable in the Western 
blot at the expected size of 180 kDa with the antibody used (n= 6). 
3.3.2. Intracellular calcium responses to glutamate, NMDA and thrombin 
2+ 
Activation of NMDARs leads to an influx of Ca into cells increasing levels of 
2+ 
intracellular Ca . This can be measured by loading cells with a fluorescent dye, such as 
fluo-4AM which is used in these experiments (section 2.8). The data obtained is 
normalised against differences in cell numbers and variation in dye loading by the addition 
-1 2+ 
of 1 �g ml ionomycin, a Ca ionophore, to obtain the maximum fluorescence 
(100 % response; maximum response; MR) at the end of each experiment, thus giving each 
experiment an internal control. Each response is then calculated as a percentage of this 
value. A saline control was added to evaluate background changes in fluo-4 fluorescence, 
and was shown to evoke a small sustained increase of 10-20 % MR above baseline 
fluorescence in experiments to evaluate responses to glutamate and NMDA. 
3.3.2.1. Glutamate and thrombin responses 
The glutamate family of receptors were originally defined by their response to glutamate 
(Dingledene et al, 1999), so initial work investigated the effect of extracellular glutamate 
2+ 
on intracellular Ca in human platelets. Over the duration of each experiment 
2+
measurements of changes in fluorescence indicative of changes in [Ca ]i were taken 
between 1.5 and 5 h post isolation of platelets from whole blood. In initial experiments, a 
glutamate concentration response curve was performed in triplicate using platelets from 
-1
different donors, with triplicate repeats of thrombin (3 U ml ) and saline, as positive and 
negative controls respectively, also measured. 
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Figure 16. Glutamate evokes an intracellular calcium response in human platelets. 
Representative traces from 2 different donors exemplifying single kinetic responses to 300 µM 
2+ -1 
glutamate, saline (nominally Ca -free salt solution) and 3 U ml thrombin. A, B, kinetic traces 
demonstrating that 300 µM glutamate triggers an increase in fluo-4 fluorescence in human 
2+
platelets. C, D, Control responses to the addition of saline alone (nominally Ca -free salt 
-1 
solution). E, F, Representative traces illustrating the response to the addition of 3 U ml thrombin 
(positive control) from the same donor. The addition of agonists is indicated by an arrow. The 
% maximum response (% MR; 100 % response) is determined by the addition of 1 µg ml
ionomycin at the end of each experiment. G, H, Each histogram illustrates the peak responses 
from a single donor obtained within the first 2 h of each experiment (n=1). I, Demonstrates the 
variation in mean responses between responding donors to 0 and 300 �M glutamate (n=9). J, 
Demonstrates the variation in mean response between non-responding donors to 0 and 300 µM 
glutamate (n=14). Each point represents the mean value from a single experiment for each donor, 
with the points joined such that the data for each donor at 0 and 300 �M glutamate is linked. All 
data was obtained within the first 2 h of each experiment. 
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Figure 17. Glutamate evokes an intracellular calcium response in human platelets which 
varies between donors and decreases over the duration of each experiment. A, B, the data is 
split into donors which respond to glutamate (A) and those in which a response above control was 
not observed (B). The solid black bars represent the responses to glutamate in the first 2 h of the 
experiments with the black checked bars illustrating the responses after 2 h from the start of the 
experiments. The figures demonstrate that responses to glutamate decrease slightly over time at 30, 
100 and 300 �M glutamate with responses to saline remaining static in responding donors. In non-
responding donors, all responses to NMDA decrease over time, while responses to saline increase. 
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The numbers above the columns indicate the number of donors whose data is included (n=5-14). 
C, Kinetic traces from 1 experiment using platelets from 1 donor illustrating the decrease in 
response to 300 �M glutamate over the course of an experiment. D, Illustrates the responses to 
-1 
3 U ml thrombin (positive control) in the same experiment demonstrating that while responses to 
thrombin vary over the course of the experiment, they do not decrease overall. The first 
2 responses for both glutamate and thrombin were obtained within the first 2 h of the experiment, 
with the final response obtained over 2 h from the start of the experiment. Addition of the agonists 
is indicated by an arrow. The % maximum response (% MR; 100 % response) is determined by the 
-1 
addition of 1 µg ml ionomycin at the end of each experiment. The data indicates that there is a 
dose-dependent effect within the first 2 h of the experiment with responses peaking at 300 �M 
glutamate. ** P< 0.01 compared to 0 �M glutamate using a one-way ANOVA with Dunnetts post-
hoc test. 
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Figure 18. Comparison of the intracellular calcium responses evoked by glutamate and 
thrombin in human platelets. A, Histogram illustrates the peak responses of glutamate-evoked 
increases in fluo-4 fluorescence in human platelets (n=5-9 ± S.E.M), in comparison to those 
elicited in response to thrombin (B) in separate experiments (n=3-6 ± S.E.M.). All data was 
obtained within the first 2 h of each experiment. For the 2 agonists, the fluo-4 fluorescence 
increases with increasing agonist concentration, where the peak concentration response for 
-1
glutamate (300 µM) is 58.02 ± 7.17 % MR smaller than that for thrombin (3 U ml ). The 
-1 
maximum response is determined for each agonist by the addition of 1 µg ml ionomycin at the 
end of each experiment. Numbers above the columns indicates the number of donors from which 
data has been obtained for each concentration. * P< 0.05; ** P< 0.01 compared to 0 �M glutamate 
-1 
or 0 Uml thrombin using a one-way ANOVA with Dunnetts post-hoc test. 
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It was observed that responses to the extracellular application of glutamate varied between 
donors (figures 16A and B, G and H), where figure 16A demonstrates a rapid transient 
increase in response to glutamate in comparison to figure 16B which illustrates a response 
similar to that elicited by the addition of saline (figures 16C and D). As such I defined 
parameters to identify a clear ‘responder’ platelet sample from a ‘non-responder’ to the 
addition of extracellular glutamate. For the purpose of this study, a response to glutamate 
ws defined as an increase of at least 10 % MR above that evoked by the application of 
saline alone. This figure was used as the majority of responses to saline were between 
10- 20 % MR (10 % range) above baseline, therefore to determine whether the agonist had 
an effect above that of saline the fluorescence response needed to be greater than 10 % 
MR. Samples which did not elicit an increase 10 % MR or greater than that obtained with 
saline were designated non-responders (figure 16A and B). However, apparent non-
responders were not excluded from the study and all data is summarised as mean responses 
as well as the individual response for each experiment (figures 16 and 17) 
The data was also separated into responses obtained within the first 2 h from the start of an 
experiment and that obtained after 2 h to determine whether the response desensitised over 
the duration of the experiment (figure 17). The responses elicited following the application 
of extracellular glutamate were determined to decrease slightly over time, while 
maintaining the rapid, transient kinetic shape (figure 17E). The largest response in 
responding donors throughout the whole duration of the experiments is shown to be 
evoked with 300 �M glutamate in the first 2 h of the experiments (28.72 ± 3.44 % MR), 
decreasing after 2 h to 19.34 ± 4.55 % MR (n=9). The mean background response to saline 
varied slightly over time from 8.79 ± 1.07 to 9.98 ± 1.33 % MR and maintained a small 
sustained kinetic response throughout (figure 16C). In non-responding donors, saline 
responses were observed to increase from 5.81 ±1.02 to 13.31 ± 3.48 % MR (n=14) over 
the duration of the experiments. A small increase occurred in the first 2 h on the addition of 
30 µM glutamate in non-responders (11.33 ± 0.71 % MR), which did not reach the 
10 % MR increase above saline to reach a response. 
In comparison, thrombin was shown to stimulate a rapid sustained response to thrombin at 
-1 
3 U ml both in responding and non-responding donors, which varied slightly over time 
-1 
(figure 16F). The peak thrombin response shifts from 10 to 3 U ml during the 
experiments with mean responses of 90.29 ± 7.09 (0-2 h) and 92.21 ± 14.49 (>2 h) % MR 
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-1 
respectively (n=3 and 6) (Appendix I). It was decided to use 3 Uml thrombin as a 
-1 
positive control in the rest of the study. The response elicited with 3 Uml thrombin was 
shown to be 61.57 ± 7.86 % MR larger than the peak response in responding donors to 
glutamate (300 �M) (figure 18). From these data it was determined that the responses to 
glutamate become slightly desensitised over the course of the experiments and only data 
from the first 2 h of any experiment will be used for analysis. 
The data for all responding donors from the first 2 h of each experiment was pooled to 
demonstrate the variation in responses to 300 �M glutamate (figure 16I), where the data 
from non-responders was combined in figure 16J. These illustrate that fluorescence 
increases in 9 different donors with a mean increase of 19.93 ± 3.60 % MR above saline 
(responders), while the mean increase in non-responders is 3.14 ± 1.96 % MR above 
control. This illustrates the variation in responses observed upon the addition of glutamate 
to isolated human platelets. 
3.3.2.2. NMDA and thrombin responses 
The ionotropic glutamate receptor family is subdivided by reactivity to NMDA 
(Dingledene et al, 1999), and the expression of the NR1 and NR2D subunit proteins 
together with responses elicited to extracellular glutamate suggested the presence of 
NMDARs on human platelets,. The study was therefore extended to investigate the effect 
of NMDA on platelet functionality. 
As described in section 3.3.2.1, triplicate NMDA concentration response curves were 
-1
performed together, with triplicate repeats of thrombin (3 U ml ) and saline (positive and 
negative controls respectively) also assessed. Variation between donors was observed as 
illustrated in figure 19, with figure 19A illustrating a rapid, transient increase in response 
to extracellular NMDA in contrast to a small sustained response, comparable to that 
stimulated with saline (figure 19D). Therefore the data was again separated into that from 
responders and non-responders as previously (section 3.3.2.1). 
The responses were also observed to decrease over the course of the experiments, and data 
was again separated into that obtained within the first 2 h and that obtained afterward 
(figure 19). Increases in fluorescence at least 10 % MR above that induced by saline were 
shown to occur between 3 and 100 �M NMDA in responding donors (figure 20A), with 
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the peak responses elicited at 3 and 100 �M (30.08 ± 3.75 % MR (n=9) and 
29.52 ± 6.41 % MR (n=4) respectively). All responses to NMDA decrease after 2 h, where 
the peak response of 22.45 ± 5.55 % MR is obtained with 3 �M NMDA (n=9). Saline is 
the exception to this, with the responses increasing slightly from 7.30 ± 1.32 to 
10.14 ± 2.31 % MR (n=9) over the duration of the experiments. In non-responding donors, 
responses to saline increase over the duration of the experiments from 7.63 ± 1.30 to 
13.29 ± 3.12 % MR (n=6), above which no concentration of NMDA elicits a response. 
The kinetic responses remain rapid and transient throughout the experiments in responding 
donors (figure 20E). Thrombin stimulates a rapid sustained response throughout the 
-1
experiments (figure 20F), with the addition of extracellular thrombin (3 U ml ) stimulating 
a response 70.09 ± 8.019 % MR larger than the peak NMDA response (3 �M) (figure 21). 
From these data, it was determined that the responses to NMDA desensitise during the 
course of the experiments, and only data from the first 2 h of any experiment will be used 
for analysis. 
The data for all donors was separated into that from responders and non-responders and 
plotted to illustrate the variation in responses to 3 �M NMDA (figures 19I and J). It 
demonstrates that responses to 3 �M NMDA are highly varied between responding donors 
with a mean increase of 22.79 ± 4.95 % MR above that of saline, in comparison to the 
mean increase of 3.42 ± 1.49 % above control in non-responding donors. Overall, these 
data demonstrate that human platelets respond to both glutamate and NMDA leading to an 
2+
increase in [Ca ]i. For both agonists, the responses are variable between donors and 
desensitise following platelet isolation. 
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Figure 19. NMDA evokes an intracellular calcium response in human platelets. 
Representative traces from 2 different donors demonstrating single kinetic races in response to 
2+ -1 
3 µM NMDA, saline (nominally Ca -free salt solution) and 3 U ml thrombin. A, B, Kinetic 
traces illustrating that 3 µM NMDA elicits an increase in fluo-4 fluorescence in human platelets. 
2+
C, D, Control responses to the addition of saline alone (nominally Ca -free salt solution). 
-1 
E, F, Representative traces illustrating the response to the addition of 3 U ml thrombin (positive 
control) from the same donor. The addition of agonists is indicated by an arrow. The % maximum 
-1 
response (% MR; 100 % response) is determined by the addition of 1 µg ml ionomycin at the end 
of each experiment. G, H, Each histogram illustrates the peak responses from a single donor 
obtained within the first 2 h of each experiment (n=1). I, Demonstrates the variation in mean 
responses between responding donors to 0 and 3 �M NMDA (n=9). J, Demonstrates the variation 
in mean responses between non-responding donors to 0 and 3 µM NMDA (n=6). Each point 
represents the mean value from a single experiment for each donor, with the points joined such that 
the data for each donor at 0 and 3 �M NMDA is linked. All data was obtained within the first 2 h 
of each experiment. 
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Figure 20. NMDA evokes an intracellular calcium response in human platelets which varies 
between donors and decreases over the duration of each experiment. A, B, the data is split into 
donors who respond to NMDA (A) and those in which a response above control was not observed 
(B). Solid black bars illustrate the responses to glutamate in the first 2 h of the experiments with 
black checked bars representing the responses after 2 h from the start of the experiments. The 
figures demonstrate that responses to all concentrations of NMDA decrease over time with 
responses to saline increasing slightly in both responders and non-responders. The numbers above 
the columns indicate the number of donors whose data is included (n=4-9). C, Kinetic traces from 
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1 experiment using platelets from 1 donor illustrating the decrease in response to 3 �M NMDA 
-1 
over the course of an experiment. D, Illustrates the responses to 3 U ml thrombin (positive 
control) in the same experiment demonstrating that while responses to thrombin vary over the 
course of the experiment, they do not decrease overall. The first 2 responses for both NMDA and 
thrombin were obtained within the first 2 h of the experiment, with the final response obtained over 
2 h from the start of the experiment. Addition of the agonists is indicated by an arrow. The 
% maximum response (% MR; 100 % response) is determined by the addition of 1 µg ml
ionomycin at the end of each experiment. The data indicates that there is a dose-dependent effect 
within the first 2 h of the experiment with increases in response between 3 and 100 �M NMDA, 
with peaks at 3 and 100 �M NMDA. The smallest decrease over time is observed with 3 �M 
NMDA. * P< 0.05; ** P< 0.01 compared to 0 �M glutamate using a one-way ANOVA with 
Dunnetts post-hoc test. 
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Figure 21. Comparison of intracellular calcium responses evoked by NMDA and thrombin in 
human platelets. A, Histogram illustrates the peak responses of NMDA-evoked increases in 
fluo-4 fluorescence in human platelets (n=8-22 ± S.E.M.), in comparison to those elicited by the 
addition of thrombin (B) in separate experiments (n=3-6 ± S.E.M.). All data was obtained within 
the first 2 h of each experiment. In comparison to thrombin, NMDA-evoked fluo-4 fluorescence is 
not dose dependent. The maximum response is determined for each agonist by the addition of 
-1 
1 �g ml ionomycin at the end of each experiment. * P<0.05; ** P< 0.01 in comparison to 0 �M 
-1 
NMDA or 0 U ml thrombin using a one-way ANOVA with a Dunnetts post-hoc test. 
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3.3.3. Measurement of extracellular ATP secretion from human platelets 
ATP is secreted from activated platelets and can be detected using the firefly enzyme 
luciferase (Beigi et al, 1999). Light is produced in a manner directly proportional to ATP 
concentration, therefore by running known ATP concentrations for each experiment, the 
light recorded can be converted into ATP concentrations (figure 12). The sensitivity of the 
assay to ATP concentration was determined using a range of serial dilutions, and the 
resulting peak responses used to produce a standard curve. From this, the sensitivity of the 
method was shown to be > 10 nM ATP (figure 12B). 
Previous studies have shown that some chemicals have non-specific effects on the 
luciferin-luciferase assay (Reigada et al, 2006). Therefore, each chemical was tested prior 
to use in both the presence and absence of 100 nM ATP and compared to their equivalent 
controls to ensure that this was not the case (figure 22). 
3.3.3.1 Glutamate and thrombin responses 
Initial work investigated the ATP release from human platelets, where a glutamate 
concentration response was performed in triplicate, with triplicate repeats of thrombin 
-1
(3 U ml ) and paired saline responses (positive and negative controls) also assessed. The 
responses to extracellular glutamate varied in size between donors with platelets, with 
responders defined as those who produced an increase in ATP secretion of at least 
40 nM ATP above that obtained from the same donor with saline to at least 1 concentration 
of glutamate. No donors were found who did not give this response to at least 1 glutamate 
concentration (figure 23). The variation in responses to glutamate is also demonstrated in 
figures 24A, B, E and F. 
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Figure 22. Determining the effects of different chemicals used in this study on the ATP 
luciferin­luciferase assay under cell­free conditions. None of the agonists or antagonists tested 
quenched the luminescence produced by the binding of ATP to the luciferase enzyme. This 
indicates that changes in luminescence observed in the presence of platelets are due to that 
stimulated by the effect of the chemical on the cells as opposed to the luciferase enzyme. Values 
represent mean ± s.e.m.; n=3. Luminescence was converted to ATP concentrations using 
calibration curves, and normalised against that obtained when 100 nM ATP was added in absence 
of NMDAR agonists/ antagonists in cell-free conditions. 
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Figure 23. Glutamate­evoked ATP release changes over time. The data shows donors who 
responded to glutamate. No non-responders were found in the donors tested with extracellular 
glutamate. Solid black bars represent the responses to glutamate over the first 3 h of the 
experiments with black checked bars illustrating the responses 3 h from the start of the experiment. 
They demonstrate that largest responses are obtained with 250 �M glutamate in the first 3 h of the 
experiments. This effect is lost after 3 h, and the responses become more variable. The responses 
to saline remain static. The number of donors varies for each concentration of glutamate, with 
15 donors for 0 µM (saline); 3 for 0-3 h 1-30 µM; 3 at >3 h, 100 µM; and 13 donors for both bars at 
250 µM glutamate. **P< 0.01 in comparison to 0 �M glutamate using a one-way ANOVA with a 
Dunnetts post-hoc test. 
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Figure 24. Glutamate triggers ATP secretion from human platelets. A, B, Representative 
traces from 2 different donors illustrating single kinetic traces in response to 0, 100 and 300 µM 
-1
glutamate. C, D, Representative responses to the addition of thrombin (3 U ml ; positive control) 
for the same donors. The duration of agonist application is indicated by the line above each graph. 
Note the difference in scale for the thrombin response for the responding donor. E, F, Each 
histogram represents the responses from a single donor (n=1). G, Demonstrates the variation in 
mean responses between responding donors to 0 and 250 �M glutamate (where the response may 
not have been obtained on the addition of 250 µM glutamate) (n=12). Each point represents the 
mean value from a single experiment for each donor, with the points joined such that the data for 
each donor at 0 and 250 �M glutamate is linked. All data was obtained within the first 3 h of each 
experiment. 
Figure 25. Comparison of peak ATP release elicited by glutamate and thrombin. Histogram 
-1 
comparing the peak responses of glutamate (250 �M) and 3 U ml thrombin –evoked ATP release 
2+
from human platelets; n=13 ± S.E.M. for glutamate and control (nominally Ca -free salt solution) 
and n=6 ± S.E.M. for thrombin. This illustrates that glutamate-evoked ATP release is 
93.31 ± 5.90 % less than that stimulated by thrombin. ** P< 0.01 compared to control using a 
one-way ANOVA and Dunnetts post-hoc. Data was obtained in the first 3 h of each experiment. 
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Separating the data into that obtained within the first 3 h of the experiment and that 
obtained afterwards, demonstrates a dose-dependent trend in the data from responding 
donors which increases at 250 �M glutamate (122.78 ± 23.49 nM ATP, n=13; figure 22A). 
After 3 h, the response to 250 µM glutamate drops to 41.53 ± 11.09 nM ATP (n= 13). The 
background ATP release in response to saline decreases over time from 1.06 ± 1.02 to 
-0.46 ± 1.10 nM ATP. In comparison to thrombin responses, peak glutamate responses 
elicited with 250 �M glutamate are 93.31 ± 5.90 % smaller than that elicited with 3 U ml
thrombin (figure 25). From these data, it was determined that the ATP release stimulated 
by extracellular glutamate becomes more variable after 3 h of each experiment, therefore 
only data from this period of the experiments will be used for analysis. 
The data for 13 donors obtained within the first 3 h of their respective experiments was 
pooled to demonstrate that variation between donors in response to both saline and 250 �M 
glutamate (n=13; figure 24G). It illustrates that the increase in ATP release is highly 
varied with 3 donors showing a larger mean increase than the other 10 donors (mean ATP 
release of 319.44 ± 25.62 nM ATP), with another 3 demonstrating either a very small or no 
ATP release upon the addition of extracellular glutamate (23.10 ± 2.76 nM ATP). The 
remaining 7 donors demonstrate an average increase of 81.21 ± 11.23 nM ATP. Overall, 
these data demonstrate that extracellular glutamate triggers ATP secretion in human 
platelets that varies over time. 
3.3.3.2 Glutamate, glycine and inhibitors 
Full activation of NMDARs is achieved with the addition of a co-agonist, for example 
glycine, and the study was extended to investigate the effects of adding 2 different 
concentrations of glycine, 0.3 and 10 �M, in combination with glutamate. The study was 
taken further by testing the effect of the NMDAR specific inhibitors MK-801 and D-AP5 
on responses elicited by glutamate and glycine to further test the functionality of the 
hypothesised NMDA receptors. A high concentration of each of the inhibitors (100 µM) 
was used to ensure that the maximal effect of the inhibitors was obtained. IC50 values have 
been defined as 0.6 µM for MK-801 and 0.9 µM D-AP5 (Lombardi et al, 2001). 
The addition of 0.3 µM glycine with 250 µM glutamate was found to have no discernable 
effect on the overall ATP release (n=12 and 5 respectively; figure 26). This release is 
inhibited by the addition of either inhibitor (n=5). The data for the 5 donors on which 
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0.3 µM glycine was used is shown more clearly in figure 26D. It demonstrates that the 
addition of glutamate stimulates increases in 4 out of 5 donors above saline only, 1 of 
which shows a further increase with the addition of glycine, 2 demonstrating a decrease in 
ATP release, with the final 2 showing no observable change in ATP release. The addition 
of 100 µM MK-801 stimulated a large decrease in 1 donor, with little or no decrease in the 
other 4. In comparison, the addition of 100 µM D-AP5 caused a decrease in ATP release 
in 3 donors, and little of no effect in the remaining 5. 
Increasing the glycine concentration to 10 µM led to an inhibition of ATP release in 
comparison to that evoked with 250 µM glutamate alone (50.64 ± 9.25 nM ATP (n=8) 
compared to 131.51 ± 24.63 nM ATP (n=12)) (figure 28C). The addition of the inhibitors 
had no effect on ATP release above that induced with the addition of 10 µM glycine to 
glutamate (54.54 ± 21.49 nM ATP (n=7) with 100 µM MK-801 and 
51.53 ± 13.96 nM ATP (n=7) with 100 µM D-AP5). Displaying the data differently, figure 
28D illustrates the differences in responses between donors. Of the donors tested with 
glutamate, 5 demonstrate an increase in ATP release in, with little or no increase in the 
remaining 2 donors. The application of 10 µM glycine together with glutamate causes an 
increase in response in 1 donor, decrease in 3 donors, and little or no change in the 
remaining 3 donors. The presence of MK-801 increases ATP release in 2 donor and 
decreases in another 2. D-AP5 stimulates an increase in 2 donors, decreases in 2 and has 
no effect in the remaining 3. Overall, overall these data demonstrate that the concentration 
of glycine used in combination with glutamate affects the ability of the induced ATP 
secretion from human platelets to be inhibited by MK-801 or D-AP5. This is a small 
sample of donors with variable responses and further studies are required to fully 
characterise the action of MK-801 and D-AP5 on responses induced by glutamate alone, 
and further evaluate the additional action of glycine. 
97 
C.M. HOBBS

CHAPTER 3: GLUTAMATE-GATED ION CHANNELS

Figure 26. Glutamate and glycine (0.3 �M) trigger ATP release from human platelets which 
is inhibited by MK­801 and D­AP5. A, B, Histograms illustrate the variation in ATP release 
between 2 different donors in response to 250 µM glutamate alone or in combination with 
0.3 µM glycine and the effects of the inhibitors MK-801 or D-AP5 (each 100 µM) (n=1). 
C, Histogram illustrates the combined peak data from 5-12 different donors (numbers above the 
columns indicate the number of donors data is included (n=5-12 ± S.E.M.). D, Plot illustrates the 
variation between donors with glutamate increasing the ATP released in 4 donors, with the 
response further increased by the addition of glycine in 2 of the donors. The responses were 
inhibited in 3 out of 5 donors by MK-801 and in 4 out of 5 donors by D-AP5. This figure 
demonstrates that glutamate alone or in combination with glycine stimulates ATP release from 
human platelets which can be inhibited by either MK-801 or D-AP5 (n=5). Saline, nominally 
2+
Ca -free salt solution; glu, glutamate; gly, glycine, MK, MK-801; AP, D-AP5. ** P< 0.01 
compared to control using a one-way ANOVA with Dunnetts post-hoc test; Δ P< 0.05 compared to 
glu + gly using an unpaired, 2-tailed Students t-test. All data was obtained within the first 3 h of 
each experiment. 
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Figure 27. Glutamate and glycine evoke ATP release from human platelets which is inhibited 
by MK­801 and D­AP5. A, Representative single kinetic responses elicited by the addition of 
250 µM glutamate in the presence and absence of 0.3 µM glycine, and the effect of the inhibitors, 
MK-801 and D-AP5 (both 100 µM); B. Representative single kinetic responses elicited by the 
addition of 250 µM glutamate in the presence and absence of 10 µM glycine, and the effect of the 
inhibitors, MK-801 and D-AP5 (both 100 µM) (Genever et al, 1999; Hitchcock et al, 2003). 
Samples were taken from 2 different donors, with one represented in either A or B. 
Glu- glutamate; gly- glycine; MK- MK-801; AP- D-AP5. C, D, Representative traces from the 
-1 
same donors showing responses to 3 U ml thrombin (positive control). The lines indicate the 
2+
duration of application of the agonists, inhibitors and saline (nominally Ca -free salt solution). 
Data was obtained within the first 3 h of each experiment. 
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Figure 28. Glutamate and glycine (10 �M) trigger ATP release from human platelets which 
is not inhibited by MK­801 and D­AP5. A, B, Histograms illustrate the variation in ATP release 
between 2 different donors in response to 250 µM glutamate alone or in combination with 10 µM 
glycine and the effects of the inhibitors MK-801 or D-AP5 (each 100 µM) (n=1). C, Histogram 
illustrates the combined peak data from 7-12 different donors (numbers above the columns indicate 
the number of donors’ data included (n=7-12 ± S.E.M.). D, Plot illustrates the variation between 
donors, with glutamate increasing the ATP released in 5 donors, with the response further increased 
by the addition of glycine in 1 of the donors, with the response decreasing in another 4 donors. The 
responses were inhibited in 3 out of 6 donors by MK-801 and in 3 out of 6 donors by D-AP5. In 
1 donor the addition of MK-801 caused an increase in ATP release, as with 2 donors with D-AP5. 
This figure demonstrates that glutamate alone stimulates ATP release, however the addition of 
10 �M glycine has an inhibitory affect such that the further addition of inhibitors has no effect on 
2+
response (n=7-8). Saline, nominally Ca -free salt solution; glu, glutamate; gly, glycine, MK, 
MK-801; AP, D-AP5. ** P< 0.01 compared to control using a one-way ANOVA with Dunnetts 
post-hoc test; Δ P< 0.05 compared to glu + gly using an unpaired, 2-tailed Students t-test. All data 
was obtained within the first 3 h of each experiment. 
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3.4. Discussion 
In this study I have demonstrated that human platelets (i) express NMDAR NR1 and 
2+
NR2D subunits, (ii) glutamate and NMDA elicit an increase in cytosolic [Ca ]i in a 
percentage of donors and (iii) glutamate evokes ATP secretion sensitive to inhibition by 
NMDAR antagonists. 
3.4.1. NMDA receptor subunit expression 
Previous studies have demonstrated the expression of NMDAR NR1, NR2C and NR2D 
subunit mRNA in the MEG-01 cell line and NR2A and NR2D in native MKs, with the 
NR1 subunit protein also found to be expressed in human platelets (Genever et al, 1999; 
Hitchcock et al, 2003; Hitchcock, 2003). In this study, the expression of both NR1 and 
NR2D subunit proteins in human platelets has been determined (figures 13 and 15). The 
mRNA expression of another NR2 subunit, NR2A, has also been determined in primary 
MKs (Hitchcock et al, 2003). However, in this study, expression of the NR2A subunit 
protein in human platelets has not been detected (figure 14). Expression of the NR1 and 
NR2D subunit proteins suggests the presence of the classic NMDAR conformation, 
NR1/NR2 in human platelets, which requires either extracellular glutamate or NMDA for 
activation (Matsui et al, 1995). While the subunit proteins are present, it does not 
automatically follow that any receptors formed are functional; this therefore requires 
further investigation into known aspects of platelet activation. 
3.4.2. Donor variation 
Variation was detected in expression of the NR1 and NR2 subunit proteins between donors 
2+ 
(figures 13 and 15), which was also observed during measurements of Ca responses, 
2+ 
where a Ca response to glutamate or NMDA was not detected in 8 out of 24 donors 
2+ 
tested. The variations in Ca responses may be due to (i) the differences in protein 
expression or (ii) differences in the number of functional receptors formed. It is possible 
that the donors which express higher levels of the subunit proteins are more susceptible to 
glutamate and NMDA, and evoke larger responses. This is however dependent on the 
subunit proteins expressed forming functional receptors, the number of which may be low 
even with high levels of expression. 
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3.4.3. NMDA receptor­evoked calcium responses 
NMDAR activation leads to the opening of the receptor’s pore, through which cations 
including Ca
2+ 
and Na
+ 
pass and are predicted to regulate platelet activation. It can 
therefore be assumed that if functional NMDARs are expressed on human platelets, 
2+
stimulation by extracellular glutamate will induce an increase in [Ca ]i which can be 
detected, for example as in this study using the fluo-4 assay (section 3.3.2.). 
3.4.3.1. NMDAR desensitisation 
2+
In assays investigating changes in [Ca ]i, it was found that donors could be split into 
2 distinct groups; those which respond to extracellular glutamate, and those which do not 
(figure 16). It was also noted that responses to extracellular glutamate decrease over time, 
with the greatest decreases observed over 2 h from the start of the experiment, which was 
in total 3 to 3.5 h from the whole blood being taken from the donor (figure 17). In 
comparison, the responses to thrombin are only slightly affected by time (figure 17F). 
Desensitisation of platelet ionotropic receptors is not unknown, with the P2X1 receptor 
requiring the presence of apyrase (an ADP/ATPase) in the PRP following isolation, to 
maintain receptor activity (MacKenzie et al, 1996). It is predicted that endogenous ATP 
released from dense granules results in the desensitization of platelet P2X1 receptors 
(Mackenzie et al, 1996). I hypothesise that NMDARs may also undergo desensitisation as 
glutamate is known to be stored in dense granules and is therefore co-released with ATP 
(Zoia et al, 2004). Release of dense granule contents is important for signalling as it 
maintains activation of the original platelet and triggers activation of neighbouring cells, 
finally leading to thrombus formation. 
3.4.3.1.1. Calcium 
2+ 
Ca has been found to play a role in NMDAR desensitisation, with activation of 
2+ 2+ 
NMDARs leading to increases in [Ca ]i and the formation of Ca micro-domains close to 
the intracellular face of the receptors, reducing the open probability of the NMDARs, 
leading to desensitisation (Hardingham et al, 2001; Rosenmund and Westbrook, 1993). 
2+
This effect increases with rising extracellular [Ca ], where maximal desensitisation 
2+ 
reached at approximately 1 mM Ca (Legrendre et al, 1993). This effect is fully 
2+ 
reversible, with the rate of clearance from the cytoplasm limited by the movement of Ca
out of the cells through a combination of Na
+
/Ca
2+ 
exchangers and Ca
2+ 
ATPase-pumps 
located in the plasma membrane, both of which play a functional role in platelets (Harper 
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2+ 
and Sage, 2007; Brown and Dean, 2007). In neurones, voltage-gated Ca channels have 
2+ 
also been implicated in the Ca micro-domain formation, and hence NMDAR 
desensitisation. To date, these channels have not been found to be expressed in platelets 
(Mahaut-Smith et al, 1999), and are not expressed in MKs, with the sole exception of 
guinea pig MKs (Kawa et al, 1990). This suggests that the movement of ions through ion 
channels plays a more important regulatory role in platelets than in neurones. 
3.4.3.1.2. Fibrillar actin 
Fibrillar actin (F-actin) has been shown to play a role postsynaptically in NMDAR 
2+ 2+ 
desensitisation in combination with Ca (Rosenmund and Westbrook, 1993b). Ca is 
required for actin depolymerisation and a previous study has shown that treating cells with 
phalloidin, which inhibits the movement of actin filaments, maintaining them in the 
2+
polymerised state, prevents Ca -induced rundown of NMDARs (Rosenmund and 
Westbrook, 1993b). This suggests that actin depolymerisation, triggered by the influx of 
2+ 
Ca into the cell through the NMDAR leads to rundown of the receptor and could 
potentially be implicated in platelet activation, during which reorganisation of the platelet 
cytoskeleton is known to occur (Italiano et al, 1999; Italiano and Shivdasani, 2003). 
NMDAR desensitisation has also been investigated in other expression systems, for 
example HEK293 cells. Each study has shown variation in their results, demonstrating 
that responses in transfected cells can be just as varied as in native cells (Krupp et al, 1996; 
Medina et al, 1995; Kendrick et al, 1998). Therefore data obtained from transfected cells 
requires comparison with that from native cells to determine whether they represent an 
accurate model. 
3.4.3.2. Glutamate/ NMDA versus thrombin­mediated calcium responses 
In comparison to the responses elicited with thrombin, the maximal response obtained on 
the addition of extracellular glutamate was smaller by 58.02 ± 7.17 % MR (figure 18). 
Thrombin activates platelets through cleavage of the PAR1 and 4 receptors, which are 
known to induce platelet activation leading to full aggregation (Gambaryan et al, 2010). In 
2+ 
contrast, glutamate induces a small, rapid, transient influx of Ca into the platelet 
(figure 16A). It is possible that this small response plays a vital role in platelet activation, 
such as has already been determined for the extensively studied P2X1 receptor (Toth-
Zsamboki et al, 2003). Activation of P2X1 elicits a small, very rapid and transient 
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response to extracellular ATP, which is also smaller than that elicited by activation of 
GPCRs (MacKenzie et al, 1996). This stimulation primes platelets to other activating 
factors, for example low concentrations of collagen (Toth-Zsamboki et al, 2003). This 
small response has been demonstrated to play an important role in the initiation of 
thrombus formation using a P2X1 knockout model, and particularly at the high shear rates 
which occur in the microvascular (Hechler et al, 2003). However, P2X1 knockout mice 
displayed no spontaneous bleeding phenotype and the tail bleeding time was normal in the 
majority of the P2X1 knockout mice. This normal bleeding time observed in the P2X1 
knockout suggests that the absence of P2X1 only has a minor impact on primary 
haemostasis. Comparable results were observed with the P2Y1 knockout with no 
spontaneous bleeding phenotype, or GPVI knockout mice which demonstrated a normal 
tail bleeding time (Léon et al, 1999, Kato et al, 2003). This data might suggest that these 
receptors are more relevant to the pathophysiological conditions associated with increased 
thrombosis (Kato et al, 2003). The generation of a knockout model for the NMDAR NR1 
subunit protein has been shown to be neonatally lethal (Li et al, 1994; Forrest et al, 1994), 
however establishing a conditional knockdown has been previously demonstrated where 
the mice show a normal phenotype, and only exhibit effects of the loss of NR1 subunit 
function when required (Cui et al 2004). NR2D knockout mice have been shown to 
demonstrate a normal phenotype, with no detrimental effect on viability. The only change 
determined was a reduction in spontaneous exploratory behaviour (Ikeda et al, 1995). To 
date, no knockdown studies have been carried out to investigate the role of NMDARs in 
platelet function. It would therefore be interesting to determine whether, like the P2X1 
receptor, it has a role in the initiation of thrombus formation under conditions of elevated 
shear rate, or in another facet of platelet activation (MacKenzie et al, 1996). 
A range of concentrations of NMDA, glutamate and glycine are used in the literature, 
ranging from 1�M to 1mM NMDA, 100 �M to 1mM glutamate with between 10 and 
100 �M glycine (Krupp et al, 1996; Legrende et al, 1993; Choi and Lipton, 2000; Clarke 
and Johnson, 2006). In this study, two different concentrations of glycine are used, 0.3 and 
10 �M, in combination with 250 �M glutamate (figures 26 and 27), demonstrating a 
decrease in response in combination with 10 �m glycine in comparison to 0.3 �M. Further 
experiments could investigate whether this effect is specific to ATP secretion from human 
platelets as these previous studies primarily use electrophysiology to investigate the effects 
in neurones or transfected cells, or whether it extends to other assays for example 
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2+ 
Ca influx. Different combinations of NMDA or glutamate with glycine could determine 
the optimal combination for platelet activation, which could be compared to those 
determined for neuronal NMDARs to ascertain any differences in concentrations required 
for activation, and also any differences in the effects of inhibitors. 
3.4.3.3. Glutamate­mediated calcium responses versus ATP secretion 
In this study, it has been demonstrated that extracellular glutamate triggers the secretion of 
ATP, which is sensitive to partial inhibition by the NMDAR-specific antagonists MK-801 
2+ 
and D-AP5 (figures 26 and 27). In contrast to the Ca response assays, ATP secretion is 
detected at a ten-fold lower concentration of glutamate (figures 17 and 23). The increased 
sensitivity to glutamate in ATP assays may result from (i) differences in sensitivity 
2+ 
between the measurements of intracellular Ca versus ATP or (ii) activation of non-
NMDA glutamate receptors with increased glutamate sensitivity, but low Ca
2+ 
permeability. 
Firstly, the apparent increase in glutamate sensitivity observed in assays of ATP secretion 
2+ 
could be due to the formation of Ca micro-domains close to the intracellular face of the 
2+ 
NMDAR of Ca that has entered upon activation of the receptors, and has been 
demonstrated in hippocampal neurones (Hardingham et al, 2001). The rapid increase in 
2+
[Ca ]i may be sufficient to trigger movement of dense granules to the plasma membrane 
or the open canalicular system of the platelet, leading to the release of ATP, and could 
disperse too quickly for the increase to be detected by the fluo-4. 
Alternatively, as only partial inhibition of ATP secretion with MK-801 or D-AP5 was 
detected, this indicates that other glutamate-sensitive receptors which couple to ATP 
secretion are expressed. Two recent studies report the expression of AMPAR and KARs 
on human platelets, which elicit the influx of Na
+ 
and have low permeability to Ca
2+ 
(Morrell et al, 2008; Sun et al, 2009). Other studies have also demonstrated Na
+ 
influx 
into human platelets via transient receptor potential vanilloid 1 (TRPV1) channels which 
are activated by AA derivatives, for example leukotrienes, that have been shown to play a 
role in atherosclerosis (Harper et al, 2009). The influx of Na
+ 
has been shown to stimulate 
a secretion of serotonin from the dense granules which can then act on 5HT2A receptors on 
2+
the surface of platelets inducing increases in [Ca ]i (Harper et al, 2009). Release of 
serotonin from the dense granules suggests that the other contents are also released, 
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including ATP, ADP and glutamate, suggesting that other receptors are also activated 
2+ 
potentiating the increase in Ca influx. This work could be extended by loading cells with 
2+ 2+ 
Ca -sensitive dye and measuring the fluorescent peaks stimulated by the entry of Ca into 
2+ 
the cells (Sigimori et al, 1990). This can be calibrated using known concentrations of Ca
such that the changes in concentration of intracellular calcium can be determined. 
2+ 
Figure 29. Illustrating the differences in sensitivity between the Ca influx and the ATP 
2+ 
secretion assays. This demonstrates that while the influx of Ca from the activation of the 
NMDAR with a low concentration of glutamate (glu) might be sufficient to stimulate release of 
2+
ATP from dense granules, a higher concentration is required for cytoplasmic [Ca ] to trigger 
detectable fluorescence through binding to fluo-4. 
3.4.4. Previous studies 
3.4.4.1. NMDAR function in platelets 
Franconi et al (1996), have previously demonstrated that NMDARs play an 
anti-aggregatory role in platelets. Treatment of human platelets with either glutamate or 
NMDA alone was shown not to induce aggregation, however when the platelets were 
incubated with NMDA prior to the addition of AA, the aggregation induced by the AA was 
inhibited. This effect could be inhibited by pre-treatment with MK-801 prior to the 
addition of NMDA, however it was not observed with D-AP5. NMDA was also found to 
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inhibit the aggregating effect of ADP in a dose-dependent manner. The generation of 
cAMP was also investigated, and treatment with increasing concentrations of NMDA 
2+ 
shown to increase cAMP production in the presence of extracellular Ca . 
Figure 30. Effect of Na
+ 
influx into platelets. Na
+ 
occurs through the AMPA receptors 
(AMPAR) and kainate receptors (KAR), and to a lesser extent NMDARs (thin arrows). It has been 
demonstrated that AMPA and kainate alone can not aggregate platelets, but it is suggested that they 
2+ 
prime platelets for activation, potentially releasing Ca and ATP from the dense granules (grey) to 
assist in further platelet activation. TRPV1 receptors are also Na
+ 
permeable which has been 
shown to stimulate serotonin (5HT) release from dense granules, which in turn activates 5HT2A 
2+
receptors, increasing [Ca ]i. 
2+
In a second paper, this work was extended to determine the effects of NMDA on [Ca ]i 
levels (Franconi et al, 1998). Treating human platelets with NMDA alone, demonstrated a 
2+
dose-dependent increase in [Ca ]i with increasing NMDA concentration; this pattern was 
also shown with AA. Pre-treating the platelets with NMDA had no effect on changes in 
2+
[Ca ]i induced by the addition of AA. However increasing concentrations of NMDA 
inhibited platelet aggregation at lower concentrations of AA. The addition of NMDA had 
no effect on thromboxane-stimulated aggregation, but was found to inhibit thromboxane 
synthesis. Two different anti-aggregating agents were used, indomethacin and ASA to 
107 
C.M. HOBBS

CHAPTER 3: GLUTAMATE-GATED ION CHANNELS

determine whether inhibition of the cyclo-oxygenase (COX) cascade was implicated. It 
was found that each of the inhibitors separately reduced the maximum aggregation, the 
extra addition of increasing concentrations of NMDA caused an almost complete inhibition 
of aggregation. 
Comparing these investigations with this study demonstrates that they all observe increases 
2+
in [Ca ]i stimulated by increasing concentrations of NMDA (figures 19 and 20; Franconi 
2+
et al, 1998). In my study, changes in [Ca ]i are detected within seconds of the addition of 
2+
NMDA or glutamate (figures 19 and 16), however in experiments investigating [Ca ]i 
detailed in Franconi (1998), platelets were pre-incubated with NMDA for 100s before 
taking readings. Franconi had previously stated that neither glutamate nor NMDA added 
alone modified platelet functionality (1996), and in 1998 also notes that the anti-
aggregatory effect of NMDA does not vary within a 5-40 min interval. This suggests that 
the role of NMDAR in platelet activation is not sufficient alone to affect aggregation, but 
potentially plays a role in the initiation of the activation process, and further work is 
required to fully understand this role. 
3.4.4.2. Non­NMDAR expression and function in platelets 
It has previously been demonstrated that platelets release glutamate (D’Andrea et al, 
1991), however the role of glutamate has until recently not been investigated in platelet 
activation and thrombus formation. In 2008, Morrell et al, used an enzymatic probe to 
show that glutamate is released during thrombus formation. The levels of glutamate in 
control donors has been shown in previous studies to be approximately 120 µM (Castillo et 
al, 1996), and found to increase to over 200 µM in patients during from a stroke (Castillio 
et al, 1997). In comparison, Morrell et al (2008) demonstrated that while baseline levels of 
glutamate were found to be at approximately 100 �M, levels measured during platelet 
aggregation were found to reach 400 �M. 
The study by Morrell et al (2008) then demonstrated that the AMPAR subunit proteins, 
GluR1-4 are expressed on human platelets. AMPAR are also members of the glutamate 
ionotropic receptor family (figure 6), and are mainly permeable to Na
+
; however when the 
2+ 
receptors include GluR2 subunits they are also permeable to Ca (Morrell et al, 2008). 
This study demonstrates that glutamate alone is unable to activate human platelets, using 
changes in the binding of the PAC-1 antibody, which binds to the αIIbβ3 integrin, the 
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expression of which increases with platelet activation. Treatment of human platelets with 
glutamate prior to the addition of thrombin receptor-acting peptide (TRAP) however, 
increased platelet activation above that induced with TRAP alone. AMPA was found to 
have a similar pattern of activation as glutamate, which was shown to be inhibited by 
CNQX, an AMPAR inhibitor. Platelets were then isolated from GluR1 knockout mice and 
found to express the same baseline level of P-selectin as WT littermates. While an 
increase was then observed on stimulation with TRAP, when the cells were pre-stimulated 
with AMPA no further increase was observed in the GluR1
-/-
platelets. AMPA was then 
demonstrated to increase [Na
+
]i in platelets, which could be inhibited by CNQX. 
Electrophysiological data demonstrated the presence of functional AMPARs in bone 
marrow-derived MKs, the responses of which could be blocked by the addition of CNQX. 
While expression of the GluR2 subunit was demonstrated in human platelets, treating 
platelets with the GluR2-specific inhibitor Joro spider toxin had no effect in the Na
+ 
influx 
assay, suggesting that while the subunit is expressed, it does not form part of the functional 
2+
receptors; these are therefore Ca -impermeable. The role of AMPA in platelet 
aggregation was also investigated, and increasing concentrations of CNQX found to inhibit 
TRAP-induced aggregation. Pre-treatment with AMPA was found to enhance the initial 
stages of TRAP-induced aggregation, which was not as discernable towards the latter 
stages. The effects on tail-bleeding were also investigated, with GluR1 knockout and WT 
mice that were treated with CNQX exhibiting prolonged bleeding times in comparison to 
untreated WT mouse platelets. This also suggests that AMPARs are implicated in 
thrombus formation. 
This study was extended in 2009 to investigate the role of the KAR, another glutamatergic 
ionotropic receptor, by Sun et al. The KAR subunit proteins, GluR5 and 6 were shown to 
be expressed in human platelets, with the mRNA for both subunits demonstrated to be 
expressed in the megakaryoblastic, MEG-01 cell line. The addition of kainate alone to 
platelets was found to have no effect on platelet activation, however pre-treatment with 
kainate increased the level of activation in response to TRAP or thrombin. This was also 
shown using the GluR5 subunit-specific agonist 2-amino-3-(5-tert-butyl-3-hydroxy-4-
isoxazolyl)propionic acid (ATPA). GluR6 knockout mice were generated, and the activity 
of their platelets compared to their WT littermates. Thrombin was found to induce an 
increase in platelet activation which was potentiated by pre-treatment with kainate in WT 
mice. In GluR6 knockout platelets however, thrombin had no effect at all either with or 
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without kainate pre-treatment. Human platelets were used to determine whether the 
application of a specific kainate receptor antagonist, UBP302 (a GluR5-specific 
antagonist), had an effect on platelet aggregation, and was shown to have an inhibitory 
effect on platelets pre-treated with kainate then thrombin. Thromboxane production and 
release was also investigated, with both glutamate and kainate shown to cause increases in 
levels which could be inhibited by pre-treatment with either UBP301 (KAR antagonist) or 
indomethacin, a COX inhibitor. The duration of kainate pre-treatment was found to have 
an effect on platelet activation, which increased up until the final time point of 30 min. 
Differences in thromboxane production were also investigated between WT and GluR6 
knockout mice and found that while treatment with kainate increased thromboxane release 
slightly above control, in GluR6 knockout littermates, there was a decrease below control. 
Phosphorylation of MAPK p38 was also investigated, and it was found that treatment with 
kainate led to an increase in p38 phosphorylation, which was inhibited by UBP301. The 
phosphorylation of p38 was compared between WT and GluR6 knockout mice and found 
to be comparable. Treatment with kainate elicited further phosphorylation of p38 in WT 
platelets, however no further increase was stimulated in GluR6 knockout platelets. Again 
duration of kainate pre-treatment was investigated, and phosphorylation of p38 was shown 
to peak at 10 min of pre-treatment. An inhibitor of p38 was shown to prevent release of 
thromboxane in human platelets treated with kainate. Finally, ferric chloride injury in WT 
and GluR6 knockout mice demonstrated that vessel occlusion time increased in the 
absence of GluR6, as did the cessation of bleeding in the tail bleeding test. Vessel 
occlusion time was also investigated by treating WT mice with UBP302, showing that 
inhibition of the subunit also increased the time for vessel occlusion. 
Both papers suggest that if NMDARs are expressed in human platelets, they are not 
functional. Morrell et al (2008), used pre-treatment with 3-(2-Carboxypiperazin-
4-yl)propyl-1-phosphonic acid (CPP), a competitive NMDAR antagonist structurally 
similar to D-AP5 (Lehmann et al, 1987), which had no effect on TRAP-induced P-selectin 
expression. Sun et al (2009), treated human platelets with NMDA then stimulated them 
with TRAP. The addition of NMDA did not increase platelet activation above that induced 
by TRAP alone. Overall these two papers determine that the non-NMDARs, AMPA and 
kainate, play a role in platelet activation as well as in the initiation and continuation of 
thrombus formation, and suggest that NMDARs are not involved, even though they may be 
expressed in platelets. In contrast, this study demonstrates that NMDARs are implicated in 
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2+
platelet activation through increases in [Ca ]i and ATP secretion, which can be inhibited 
by MK-801 or D-AP5. The assays used to determine platelet activation in this study 
however are not the same as those used by Morrell and Sun, therefore further 
experimentation is required to determine the effects of NMDARs on TRAP or thrombin-
stimulated platelet activation and aggregation. The use of platelets from knockdown mice 
in combination with in vivo studies would also enable further comparison, to determine 
whether NMDARs are involved in the initiation and continuation of thrombus formation or 
whether they have a different role in platelet activation. This chapter also suggests that 
platelets could be used as model cells for these disorders as they express functional 
NMDARs together with serotonin and dopamine receptors as well as AMPAR and KARs, 
and are more easily obtainable than human neuronal tissue (Morrell et al, 2008; Sun et al, 
2009; Harper et al, 2009; Ricci et al, 2001). 
3.4.5. Clinical relevance and concluding remarks 
Overall, these data demonstrate that human platelets express functional NMDARs, which 
2+
can be stimulated by glutamate and NMDA to elicit increases in both [Ca ]i and ATP 
secretion. The addition of glycine together with glutamate has been demonstrated to have 
mixed effects, suggesting that differential expression of receptor subunits plays a role in 
the outcome of receptor activation. The NMDAR-specific antagonists, MK-801 and 
D-AP5 have both been found to inhibit responses elicited with glutamate, adding further 
weight to the functional role of the receptors. While the effect of NMDAR activation 
appears small in relation to that of thrombin, it is possible that the role of NMDARs is 
2+ 
comparable to that of P2X1 receptors, which elicit small Ca responses, but play an 
important role in both the initiation and the development of thrombus formation (Hechler 
et al, 2003). 
Glutamate receptors are highly expressed in the CNS and glutamate has been shown to 
play a major role in neuronal signalling (Vekhratsky and Kirchhoff, 2007; Dingledene et 
al, 1999). Therefore given that platelets can be used as neuronal models, they can be used 
to investigate the effects of neurodegenerative diseases such as Parkinson’s disease (PD) 
and AD together with schizophrenia, migraine and stroke, all of which have been 
demonstrated to have a glutamatergic facet, involving NMDARs. Further investigations 
into their inhibition or regulation could therefore lead to potential new drugs to control 
their activity, even though the effects induced are highly varied. During a stroke, the 
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localised level of glutamate increases massively, leading to excitotoxicity and cell death, 
not only of the cells immediately surrounding the insult, but also those which adjoin this 
region called the penumbra (Olney and Sharpe, 1969; Olney et al, 1971). In PD, 
glutamatergic signalling has been demonstrated to compensate for damaged dopaminergic 
signalling particularly in the striatum where the concentration of NMDARs is especially 
high and it has been demonstrated that treatment with NMDAR antagonists e.g. MK-801, 
have anti-parkinsonian effects (Porter et al, 1994). In AD, over-stimulation of NMDARs 
has been linked to the formation of neurofibrillary tangles within neurones which are 
believed to have a toxic effect on cells and detrimentally affect scores in behavioural 
studies (Couratier et al, 1996; Minkeviciene et al, 2004). NMDARs have also been 
implicated in schizophrenia following studies showing that phencyclidine, which blocks 
NMDARs, induced symptoms similar to schizophrenia in normal humans and enhanced 
symptoms in schizophrenics (Luby et al, 1959). Studies have shown that expression of 
NMDAR subunits is impaired or reduced and that sensitivity to glutamate is increased 
(Mohn et al, 1999; Berk et al, 2000), and it has been suggested that targeting regulation of 
glycine and D-serine levels in the brain could reduce the symptoms of schizophrenia 
(Kantrowitz and Javitt, 2010). Glutamate has been shown to play a role in migraine, with 
release demonstrated from platelets during attacks (D’Andrea et al, 1991), and NMDARs 
implicated in both pain pathways and in the generation of aura (Bereiter et al, 1996; 
Peeters et al, 2007). NMDAR antagonists have been demonstrated to reduce both these 
effects, suggesting that they could potentially be used to treat migraines (Bereiter et al, 
1996; Peeters et al, 2007). 
A study in 1984 demonstrated that excessive NMDAR activity underlies the damage 
caused during an ischemic insult, and suggested that blocking their activity may protect the 
brain against ischemic-induced damage (Simon et al, 1984). Following this discovery, 
many laboratories investigated the possibility of formulating NMDAR antagonists for 
medicinal use in humans. Several studies were carried out which reached stage III of 
clinical trials, but were halted due to concerns over the potential increased death risk and 
adverse neurological effects including hallucinations, drowsiness, confusion and agitation 
together with increased cardiovascular instability (Morris et al, 1999; Albers et al, 1999). 
One drug, memantine, however has gone through clinical trials and is currently used to 
treat moderate-severe AD in the US. Memantine is a low affinity, uncompetitive, open 
channel blocker with a rapid on/off rate, which enables it to prevent excessive NMDR 
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stimulation while having little to no effect on subsequent normal, physiological signalling, 
which was a major problem with other drugs trialled (Chen et al, 1992). It has been 
demonstrated to reduce the size of ischemic infarcts up to 2 h after the start of the event 
(Chen et al, 1998) to inhibit migraine-associated aura (Peeters et al, 2007), and to reduce 
neurofibrillary tangles in culture together with improving behavioural scores in AD mouse 
models (Minkeviciene et al, 2004; Li et al, 2004). Memantine has also been shown to 
have no effect on learning or LTP in rats, which has been demonstrated to be due to the 
drug blocking only extrasynaptic NMDARs, and not those in the synapse, in comparison to 
other drugs trialled which blocked both (Chen et al, 1998). Blocking extrasynaptic 
NMDARs prevents suppression of CREB activation, which leads to eventual cell death by 
necrosis. Activation of synaptic NMDARs enables the retention of normal receptor 
signalling which in turn promotes the continuation of CREB activation promoting the 
transcription of anti-apoptotic factors such as Bcl-2 (Hardingham et al, 2002). This 
demonstrates that while further investigation is required to fully understand the function of 
NMDARs in neurological disorders, some progress is being made with the development of 
memantine suggesting that NMDAR antagonists can play a role, and that platelets can be 
used as neuronal models in which to test them. 
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CHAPTER 4

GLYCINE­GATED ION CHANNELS

4.1. Summary 
In this chapter, it has been demonstrated that: 
- the NMDA NR3 subunit protein is expressed in human platelets 
- extracellular application of glycine is shown to induce increases in intracellular 
calcium, with the additional presence of D-serine having varied effects 
- ATP release is stimulated by the addition of extracellular glycine, and inhibited by 
D-serine 
4.2. Introduction 
This thesis investigates the role of NMDARs in platelet and MK function. In addition to 
the classical NMDAR conformation consisting of NR1/ NR2 subunit proteins, the existence 
of the glycine-binding NR3 subunits has also been determined (Ciabarra et al, 1995; Sucher 
et al, 1995; Chatterton et al, 2002). To date, the expression of NR3 subunits has been 
demonstrated in motor neurones (Nishi et al, 2001), glia and oligodendrocytes 
(Verkhratsky and Kirchoff, 2007), and myelinating cells (Káradóttir et al, 20005) together 
with mature myelin (Micu et al, 2006). The NR1/NR3 conformation is activated by glycine 
alone, due to the absence of glutamate-binding NR2 subunits. This activation has been 
shown to be inhibited by the presence of D-serine (Chatterton et al, 2002). In this chapter, 
the potential functional expression of NR3 subunit containing NMDA receptors in human 
platelets has been investigated. 
4.3. Results 
4.3.1. Detection of NMDA proteins by Western blot 
The expression of NMDA NR1 subunit proteins by human platelets has been demonstrated 
in Chapter 3 (figure 13). The expression of NMDA NR3 subunit proteins was investigated 
by performing Western blots using platelet samples from different human donors. A band 
running between 100 and 120 kDa was detected with an anti-NR3 antibody in 3 different 
platelet samples (figure 31), which corresponds to the predicted molecular weight for NR3 
of 116 kDa (Ciabarra et al, 1995; Sucher et al, 1995; Chatterton et al, 2002). This suggests 
the potential for the formation of NMDARs containing both NR1 and NR3 subunit 
proteins. 
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Figure 31. Human platelets express NMDA receptor subunit NR3. Western blots 
demonstrating expression of the NMDA NR3 subunit in 3 different human donors (1-3). The bands 
are from 3 different gels indicated by the surrounding boxes. Number above the lanes indicates the 
donor from which sample was obtained; approximately 15 µg protein loaded of each sample 
determined by Bradford assay. The arrows on the right side indicate sizes predicted by the protein 
standards (mol marker, molecular weight marker; kDa) with the arrow on the left side indicating the 
expected size of the NR3 subunit, 116 kDa. 
4.3.2. Intracellular calcium responses to glycine, D­serine and thrombin 
4.3.2.1. Glycine and thrombin responses 
To determine whether the potential NR1/NR3 combination of subunits is functional, the 
2+
effect of extracellular glycine on [Ca ]i in fluo-4 loaded human platelets was investigated. 
In these experiments, all responses are normalised to the fluorescence response evoked by 
the addition of ionomycin, a calcium ionophore, described as the maximal response where 
responses are expressed as a percentage of the maximal responses (Lui and Hermann, 
1978). Moreover, a saline control was added to evaluate background changes in fluo-4 
fluorescence. The saline control evoked a small sustained increase, 10-20 % MR above 
baseline fluorescence in experiments to evaluate the responses to glycine and D-serine 
(figure 32C and D). This background response was comparable to that detected in 
Chapter 3 when glutamate responses were evaluated. 
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Figure 32. Glycine evokes an intracellular calcium response in human platelets. 
Representative traces from 2 different donors illustrating single kinetic responses to 3 �M glycine, 
2+ -1 
saline (nominally Ca -free salt solution) and 3 U ml thrombin recorded within the first 2 h of each 
separate experiment. A, B, Kinetic traces comparing the responses to 0.3 �M between the 2 donors, 
illustrating an increase in fluorescence in 1 donor (responder) but not in the other (non-responder). 
C, D, Representative responses to the addition of saline from the 2 donors. E, F, Representative 
-1 
traces illustrating the response to the application of 3 U ml thrombin (positive control). The 
addition of agonists and saline are indicated by an arrow. The % maximum response (% MR; 
-1 
100 % response) is determined by the addition of 1 µg ml ionomycin at the end of each 
experiment. G, Histogram illustrates the peak responses from a single donor obtained within the 
first 2 h of each experiment (n=1). H, Demonstrates the variation in mean responses between 
donors to 0 and 3 µM glycine (n=10). I, Demonstrates the variation in mean response between non-
responding donors to 0 and 3 µM glycine (n=6). Each point represents the mean value from a single 
experiment for each donor, with the points joined such that the data for each donor at 0 and 0.3 µM 
glycine is linked. All data was obtained within the first 2 h of each experiment. 
117 
C.M. HOBBS

CHAPTER 4: GLYCINE-GATED ION CHANNELS

Figure 33. Glycine­evoked intracellular calcium responses vary between donors and decrease 
over time. A, B, The data is split into donors whose platelets responded to glycine (A) and those in 
which a response above control was not observed (B). Solid black bars represent the responses to 
glycine over the first 2 h of the experiments with black checked bars illustrating the responses after 
2 h. They demonstrate that the responses to glycine decrease after the first 2 h after the beginning 
of the experiment, with the responses elicited by saline increasing after this time. The numbers 
above the columns indicate the number of donors’ data included (n= 1- 12). C, Kinetic traces from 
1 experiment using platelets from 1 donor illustrating the decrease in response to 0.3 µM glycine 
-1 
over the course of the experiment. D, Illustrates the responses to 3 U ml thrombin (positive 
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control) in the same experiment demonstrating that while the responses to thrombin vary over the 
course of an experiment, they do not decrease overall. The first 2 responses for both glycine and 
thrombin were obtained within the first 2 h of the experiment, with the final response obtained over 
2 h from the start of the experiment. Addition of the agonists is indicated by an arrow. The 
% maximum response (% MR; 100 % response) is determined by the addition of 1 µg ml
ionomycin at the end of each experiment. The data indicates that there is no overall dose-dependent 
effect of the addition of glycine to human platelets. 
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Figure 34. Comparison of the intracellular calcium responses evoked by glycine and 
thrombin in human platelets. A, Histogram illustrates the peak responses of glycine-evoked 
increases in fluo-4 fluorescence in responding human platelets in the first 2 h of the experiments 
(n= 3-12 ± S.E.M.), in comparison to those elicited by thrombin (B) in unpaired experiments 
(n= 3-6 ± S.E.M.). The responses to all glycine concentrations were observed to decrease over the 
duration of the experiment (figure 29), therefore only data obtained in the first 2 h is shown here. 
The thrombin responses did not vary to such an extent during the experiment and therefore all 
responses are shown for each concentration. While responses to thrombin increase in a dose-
dependent manner, no such effect is apparent with the extracellular addition of glycine. The 
-1
maximum response was determined by the addition of ionomycin (1 ug ml ) at the end of each 
-1 
experiment. * P< 0.05; ** P< 0.01 compared to either 0 �M glycine or 0 U ml thrombin using a 
one-way ANOVA with Dunnetts post-hoc test. 
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2+
Over the duration of each experiment measurements of [Ca ]i were taken between 1.5 and 
5 h post isolation of the platelets. In these experiments a glycine concentration response 
-1
curve was performed in triplicate, with triplicate repeats of thrombin (3 U ml ) and saline, 
as positive and negative controls respectively, also assessed. It was observed that responses 
to extracellular glycine varied between donors as illustrated in figure 32, where one 
2+
demonstrates a rapid, transient increase in [Ca ]i (figure 32A), in response to glycine while 
in other donors glycine elicited a response comparable to that stimulated by the addition of 
saline (figure 32B). Therefore data was separated into that from donors who responded to 
the application of extracellular glycine (responders), where responses to 1 or more 
concentrations of glycine were observed of at least 10 % MR above that elicited by saline 
from the same donor, and from those who did not (non-responders) (figure 33). 
It was also apparent that over the course of the experiments the responses to extracellular 
glycine decreased, with the greatest reduction observed after 2 h from the start of the 
experiments (figure 33E). The data was therefore separated into responses obtained within 
the first 2 h, and those obtained after 2 h (figure 33). The applications of glycine within the 
first 2 h were shown to increase above responses obtained for saline from 0.01 to 30 µM 
with the exceptions of 0.03 and 1 µM glycine in responding donors (figure 33A). The 
greatest increase was with 3 µM glycine which peaked at 22.42 ± 3.58 % MR (n=10) in 
comparison to 11.16 ± 0.93 % MR (n=12) with saline. The response elicited by saline 
increased over the course of the experiments to 14.22 ± 1.88 % MR (n=12) after 2 h from 
the start and constitutes a small sustained response (figure 32C). The peak glycine 
concentration drops to 0.3 µM over 2 h from the duration of the experiments 
(16.68 ± 5.70 % MR; n=11), with only 0.3-3 µM glycine eliciting responses above that 
induced by the addition of saline (figure 32C). In the non-responding donors, the increase 
2+
in [Ca ]i stimulated by the addition of saline increases from 14.80 ± 2.41 to 
16.64 ± 6.38 % MR (n=4) over the experiment. 
In comparison it was observed that thrombin triggered a rapid, sustained response in all 
donors throughout the experiments (figures 33F). The peak response to thrombin was 
-1 
demonstrated to shift from 10 to 3 U ml during the experiments with mean responses of 
90.29 ± 7.09 and 92.21 ± 14.49 % maximum response respectively (n=3 and 6) 
-1 
(Appendix I). This also demonstrates that the mean peak response to thrombin at 3 U ml
is 64.32 ± 7.22 % MR larger than the mean peak response for glycine (3 �M) in responding 
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donors in the first 2 h of each experiment. From these data, it was determined that the 
glycine response is desensitised during the course of the experiments, and only data from 
the first 2 h of any experiment will be used for analysis. Collectively, these data 
2+ 
demonstrate that extracellular glycine triggers a Ca response in human platelets that 
desensitises over time. 
The data for all donors from the first 2 h of each experiment was pooled to demonstrate the 
2+
variation in responses to 3 �M glycine (figure 32I). It illustrates that [Ca ]i in platelets 
from 6 different donors increases upon external application with 3 �M glycine above 
control, with no variation from control in the remaining 4 donors. An example dose 
response data was obtained between different donors, illustrated in figure 32G. 
4.3.2.2. D­serine responses 
D-serine has a varied role as both a co-agonist for the classical NMDA NR1/ NR2 receptor 
and as an inhibitor in the NR1/NR3 receptor (Dingledine et al, 1999; Chatterton et al, 
2002). It is therefore important to determine whether D-serine alone elicits a response from 
human platelets. 
The addition of extracellular D-serine to fluo-4 loaded human platelets evokes a small 
sustained increase in fluorescence which is comparable to that elicited by the addition of 
saline alone (figure 35A and C, and B and D). No differences were observed over the 
course of the experiments in the responses to each concentration of D-serine, therefore all 
the data for each experiment was pooled. The largest increase above control was 
demonstrated to be with the extracellular application of 10 �M D-serine, with a mean 
increase of 3.17 ± 1.24 % MR above that induced with saline. The variation between 
donors is small with a range of individual responses from different donors between 6.73 
and 15.27 % MR (n=5) (figure 36D). Thrombin responses were maintained between 80 
2+
and 90 % MR. From this data, it was determined that D-serine does not invoke a [Ca ]i 
response in platelets. 
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Figure 35. D­serine does not evoke an intracellular calcium response in human platelets. 
Representative single kinetic traces from 2 different donors illustrating variation in response to 
2+ -1 
10 �M D-serine, saline (nominally Ca -free salt solution) and 3 U ml thrombin. 
A, B, Representative traces demonstrating that 10 �M D-serine does not trigger an increase in 
fluo-4 fluorescence in human platelets. C, D, Control responses to the addition of saline alone 
2+ -1 
(nominally Ca -free salt solution). E, F, Representative traces illustrating the response to 3 U ml
thrombin (positive control) from the same donor. The addition of agonist or saline is indicated by 
an arrow. The % maximum response (% MR; 100 % response) is determined by the addition of 
-1 
1 µg ml ionomycin at the end of each experiment. 
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Figure 36. D­serine does not evoke an intracellular calcium response in human platelets. 
A, B, Each histogram represents the peak responses from a single donor where each concentration is 
assessed in triplicate (n=1). C, histogram illustrates the combined peak responses from 5 different 
donors (n=5 ± S.E.M). D, Comparing the variation in mean peak responses to 0 and 10 �M 
D-serine, which has the largest mean peak response, between donors (n= 5). Overall, D-serine does 
2+ 
not stimulate an intracellular Ca response in human platelets. For all concentration responses the 
-1 
maximum response (100 %) was obtained by the addition of 1 �g ml ionomycin at the end of each 
experiment. All data was obtained within the first 2 h of each experiment. 
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4.3.2.3. Glycine and D­serine responses 
2+
As glycine has been shown to stimulate an increase in [Ca ]i in human platelets (section 
4.3.2.1.), with D-serine alone triggering no effect (section 4.3.2.2.), the next step is to 
determine whether the glycine-induced responses can be inhibited by D-serine which is 
indicative of the NR1/ NR3 subunit combination. 
The presence of D-serine induced mixed effects on the response elicited by the addition of 
external glycine as illustrated in figures 37A and B. These are also illustrated in figure 38D 
where the glycine-evoked response is either inhibited, potentiated or there is no observed 
effect on the response elicited with glycine alone. Example histograms are shown in figure 
38A and B also demonstrating the variation between donors using only data obtained 
within the first 2 h of each experiment. When pooled (figure 38C), the data indicates that 
there is a peak in response at 3 �M glycine (24.70 ± 1.67 % MR compared to 
11.06 ± 4.26 % MR with saline alone; n=8). This is mirrored by an increase in response 
with the addition of 10 �M D-serine, where the response is 22.23 ± 3.61 % MR (n=8) 
compared to that of the saline and D-serine control (11.71 ± 1.56 % MR; n=8). The 
difference between the 2 peaks is only 3.12 ± 6.03 % MR and suggests that the addition of 
D-serine has little effect on the glycine-induced response. However, figure 38D which 
compares the mean data from the 8 different donors demonstrates that there is a greater 
variety in response than indicated in the pooled data. It shows that in 5 out of 8 donors the 
2+
application of 3 �M extracellular glycine stimulates an increase in [Ca ]i, while there is no 
effect induced by the addition of 10 �M D-serine alone. The mixed effects of D-serine on 
glycine responses were shown to consist of potentiation in 3 donors, inhibition in 3 donors 
and no apparent effect in the remaining 2. The kinetic responses are illustrated in figure 
37A and B showing that responses to extracellular glycine are rapid and transient both with 
and without D-serine. Together, this demonstrates that the responses induced by 
extracellular glycine are differentially affected by the addition of extracellular D-serine. 
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Figure 37. Glycine evokes an intracellular calcium response which is affected by the presence 
of D­serine in human platelets. Representative traces from 2 different donors demonstrating 
single kinetic responses to 3 µM glycine alone and in combination with 10 µM D-serine, saline 
2+ -1 
(nominally Ca -free salt solution) and 3 U ml thrombin. A, B, Kinetic traces demonstrating that 
3 �M glycine triggers an increase in fluo-4 fluorescence in human platelets which is modified by 
2+ 
the presence of 10 �M D-serine. C, D, Control responses to the addition of saline (nominally Ca -
-1 
free salt solution). E, F, Representative traces illustrating the response to the addition of 3 U ml
thrombin (positive control) from the same donor. The addition of the agonist and saline are 
indicated by an arrow; the antagonist (D-serine) or saline were added at the beginning of the 
experiment. The % maximum response (% MR; 100 % response) is determined by the addition of 
-1 
1 µg ml ionomycin at the end of each experiment. All data was obtained within the first 2 h of 
each experiment. 
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Figure 38. Glycine evokes an increase in intracellular response in human platelets which is 
altered by the presence of D­serine. A, B, Each histogram represents the peak responses from a 
single donor where all combinations of glycine and D-serine are repeated in duplicate (n= 1). 
C, Histogram illustrates the combined peak response data from 8 different donors (n=8 ± S.E.M.) 
D, The before-after plot illustrates the combined mean peak response data from 8 different donors 
(n=8 ± S.E.M.). This demonstrates the addition of 3 �M glycine elicits an increase in fluorescence 
in 5 donors with no increase in the other 3 above saline responses. The further addition of 10 �M 
D-serine inhibits the response in 3 donors, potentiates the responses in another 3 with no effect in 
the final 2 donors. D-serine alone has no effect on fluo-4 fluorescence. The maximum response 
-1
(100 %) was obtained by adding ionomycin (1 �g ml ) at the end of each experiment. All data was 
obtained within the first 2 h of each experiment. 
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4.3.3. Measurement of extracellular ATP secretion from human platelets 
As in Chapter 3, ATP release was investigated using the luciferase assay to determine the 
effects of extracellular glycine. Responses were converted to ATP concentrations using 
calibration curves constructed using known ATP concentrations (section 2.9). Paired saline 
controls were run in each experiment as negative controls to evaluate background changes 
in the levels of ATP detected. The addition of extracellular saline elicited a small sustained 
response in both responders and non-responders, 0-20 nM above baseline ATP levels in 
experiments to evaluate responses to glycine and D-serine comparable to that obtained in 
Chapter 3 (figure 23). 
4.3.3.1. Glycine and thrombin responses 
As in section 4.3.2.1, variation was seen in responses between donors to extracellular 
glycine as well as over the duration of the experiment. The data was therefore separated 
into that from donors who responded to at least 1 concentration of extracellular glycine, 
showing an increase in ATP concentration at least 40 nM above that of the saline response 
from the same donor, as well as by time (figures 39A and B; figure 40). 
The combined data of responding donors for the first 2 h of each experiment demonstrate a 
bell-shaped dose response which peaks between 0.1 and 0.3 �M glycine (205.78 ± 89.93 
and 126.43 ± 3.54 nM ATP released, n= 5 and 13 respectively; figure 40), where responses 
to glycine were shown to be rapid and sustained (figure 39A). The clear dose response 
effect is lost after 2h, shifting to a general trend which increases towards 1 �M glycine 
(228.40 ± 228.43 nM ATP, n=3), with the mean response at 0.3 �M glycine decreasing to 
110.85 ± 47.72 nM ATP (n=8). The response to saline decreases from 2.44 ± 1.62 to 
1.62 ± 2.61 nM ATP (n=8) over the duration of the experiment. In non-responding donors, 
the response to saline decreases over the experiment from -1.50 ± 1.04 nM ATP to 
-4.06 ± 2.73 nM ATP (n=4). The only concentration of glycine tested in donors whose 
platelets did not respond was 0.3 µM, which increased to 37.58 ± 28.99 nM ATP from 
3.03 ± 0.75 nM ATP over the duration of the experiments. However, as the increase did 
not occur within the first 3 h of the tests, it does not qualify as a response. The application 
-1
of extracellular thrombin (3 U ml ) elicited a rapid, transient in both responders and 
non-responders (figures 40C and D), which increases slightly from 7768.41 ± 1794.74 to 
8708.30 ± 2883.09 nM ATP (n=6) over the duration of the experiment. 
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Figure 39. Glycine triggers ATP secretion from human platelets. A, B, Representative traces 
from 2 different donors illustrating single kinetic responses of ATP release elicited by the addition 
of 0, 0.1 and 0.3 µM glycine to human platelets. C, D, representative responses to the addition of 
-1 
3 U ml thrombin (positive control) for the same 2 donors. Lines indicate the duration of 
2+
application of the agonist or nominally Ca -free salt solution (saline). E, F, Each histogram 
represents the peak responses from a single donor (n=1). G, Demonstrates the variation in mean 
responses between responding donors to 0 and 0.3 �M glycine (n=8); the concentrations of glycine 
to which these donors responded may not include 0.3 µM. Each point represents the mean value 
from a single experiment for each donor, with the points joined such that the data for each donor at 
0 and 0.3�M glycine is linked. All data was obtained within the first 3 h of each experiment. 
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Figure 40. Glycine­evoked ATP release changes over time. A, B, The data is split into donors 
which responded to glycine (A) and those in which a response above control was not observed (B). 
Solid black bars represent responses to glycine over the first 3 h of the experiments, with responses 
after 3 h shown in black checked bars. They demonstrate that the ATP released on the application 
of extracellular glycine becomes increasingly variable more than 3 h from the start of the 
experiments with the responses to saline doubling after this time, from 2.78 ± 5.25 to 
5.12 ± 1.74 nM ATP in responding donors, but decreasing in non-donors from 0.27 ± 0.95 to 
-5.52 ± 4.18 nM ATP. ATP release in the non-donors following application of extracellular glycine 
also decreases over the duration of the experiments (B). The numbers above the columns indicate 
the number of donors’ data included (n=0-8). **P< 0.01 in comparison to 0 �M glycine using a 
one-way ANOVA with a Dunnetts post-hoc test. All data was obtained within the first 3 h of each 
experiment. 
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Figure 41. Comparison of peak ATP release evoked by thrombin and glycine. Histogram 
-1
illustrates the peak responses for glycine (0.3 �M) and thrombin (3 U ml )- evoked ATP release in 
2+
human platelets (n= 8 ± S.E.M. for saline (nominally Ca -free salt solution) and glycine; 
n= 6 ± S.E.M for thrombin). This illustrates that thrombin elicits a 97.31 ± 4.44 % increase in ATP 
release than glycine. Data was obtained within the first 3 h of each experiment from responding 
2+
donors. ** P< 0.01 compared to saline (nominally Ca -free salt solution) using one-way ANOVA 
2+
with Dunnetts post-hoc test, ΔΔΔ P< 0.001 compared to saline (nominally Ca -free salt solution) 
using an unpaired, two-tailed Students t-test. 
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This again demonstrates that the ATP response to thrombin is significantly greater than the 
peak response to extracellular glycine, producing a difference of 7525.64 ± 1797.91 nM 
ATP between the peak responses (figure 41). 
The pooled data for responding donors to 0.3 �M glycine in the first 2 h of each experiment 
illustrates the variation between responses from each donors (figure 39D). It demonstrates 
that out of 8 donors who respond to at least 1 concentration of glycine (from a total of 
13 donors), 7 donors elicit a release of ATP from the platelets in response to the addition of 
0.3 �M extracellular glycine, with 1 donor showing no apparent increase in ATP release 
above control at this concentration of glycine. Overall, these data demonstrate that 
extracellular glycine triggers ATP secretion in human platelets that varies over time and 
donor. 
4.3.3.2. Glycine and D­serine responses 
As ATP responses are elicited by the application of extracellular glycine in 13 out of 
17 donors, the next stage is to determine whether the release of ATP stimulated by glycine 
can then be inhibited by the additional presence of 10 �M D-serine. In this study, D-serine 
2+
alone has been shown to have no affect on changes in [Ca ]i,(figure 43), however its effects 
on ATP secretion must also be determined. 
Extracellular D-serine (10 µM) was added to isolated human platelets and induced 
inhibition in 4 donors, an increase in 1 donor, and no effect above saline in the remaining 6 
(figure 43D). Of the 13 donors used in these experiments, 5 demonstrated an increase in 
ATP release with the addition of glycine, of which 4 are inhibited by the presence of 
D-serine. The remaining donors showed no response to the addition of glycine, with no 
further effects with D-serine. This data is pooled in figure 43C, showing that overall the 
addition of glycine stimulates an increase in ATP concentration of 59.75 ± 21.09 nM above 
control. This was decreased by 34.69 ± 22.44 nM by the addition of D-serine. The kinetic 
responses were shown to be rapid and sustained both with and without D-serine (figures 
42A and B), with variation between donors also illustrated in figures 43A and B. Overall 
this demonstrates that where an increase in ATP release from human platelets is obtained 
by the extracellular application of glycine, it can, in general, be partially inhibited by the 
addition of D-serine. 
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Figure 42. Glycine triggers ATP secretion from human platelets which can be inhibited by 
D­serine. A, B, Representative responses elicited by the addition of 3 �M glycine to luciferase-
containing human platelet suspension in the presence and absence of 10 �M D-serine. Each trace 
represents single responses from 2 different donors. C, D, Representative responses to the addition 
-1
of thrombin (3 U ml ; positive control) for the same respective donors. The lines indicate the 
2+
duration of application of agonist, inhibitor and saline (nominally Ca -free salt solution). Data was 
obtained within the first 3 h of each experiment. 
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Figure 43. Glycine triggers ATP secretion from human platelets which is inhibited by 
D­serine. A, B, Each histogram exemplifies the peak responses from a single donor (n=1). 
C, Histogram illustrates the combined peak response data from different responding donors 
2+
(n=5 ± S.E.M.). Saline, nominally Ca -free salt solution; Gly, glycine; D-ser, D-serine. D, Plot 
demonstrates the combined mean peak response data from different responding donors (n=5). This 
demonstrates that 10 µM D-serine (D-ser) alone leads to a decrease in response in 2 donors with no 
effect in the remaining 2. The addition of 0.3 �M glycine (gly) elicits increased ATP release in 
5 donors, of which responses in 4 are inhibited by the addition of D-serine. There is no effect on 
2+
the remaining donor. ** P< 0.01 compared to saline (nominally Ca -free salt solution) using one-
way ANOVA with Dunnetts post-hoc test. The data was obtained within the first 3 h of each 
experiment. 
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4.4. Discussion 
In this study I have demonstrated that human platelets (i) express NMDAR NR3 subunits, 
2+
(ii) glycine elicits an increase in cytosolic [Ca ]i in a percentage of donors and (iii) glycine 
evokes ATP secretion sensitive to partial inhibition by D-serine. 
4.4.1. Expression of NMDA receptor NR3 subunits 
Expression of the NMDAR NR3 subunit protein was originally identified in the brain 
(Wong et al, 2002; Wee et al, 2008), and the mRNA has more recently been detected in the 
rat stomach (Wantanabe et al, 2008). This study has determined for the first time that the 
NR3 subunit protein is expressed in human platelets, which is also the first demonstration 
of its protein expression outside the CNS. Previous studies have shown that NR1 and NR3 
subunits can form a functional receptor which requires only the binding of glycine for 
activation (Chatterton et al, 2002). As expression of the NR1 subunit protein has 
previously been demonstrated in human platelets (figure 13; Genever et al, 1999), it is 
possible that functional NR1/ NR3 receptors are present. To determine this, the same 
2+ 
assays used to determine receptor function in Chapter 3 were used, Ca influx and ATP 
release. 
4.4.2. Glycine­evoked calcium responses 
2+
As demonstrated in the previous chapter, changes in [Ca ]i could be separated into the 
donors which did and those which did not respond to the application of extracellular 
glycine (figure 32). The timing of the recordings was also shown to have an effect on the 
responses obtained, with the greatest changes occurring over 2 h from the start of the 
experiment, which was in total 3 to 3.5 h from the whole blood being taken from the donor 
(figure 31). In comparison, the responses to thrombin vary only slightly over the duration 
of the experiment (figure 32F). The overall trend is for responses to decrease over the 
course of the experiments, and as with the NR1/ NR2 combination of subunit proteins, it 
suggests that the receptor is desensitising. The receptors have been demonstrated to rapidly 
resensitise upon removal of glycine, showing that this modulation is rapidly reversible 
(Awobuluyi et al, 2007). Desensitisation has been shown to be induced by the binding of 
glycine to the NR1 subunit through point mutagenesis and the use of a specific NR1 
subunit antagonist (MDL-29951), where inhibition of the subunit increases currents 
induced by extracellular glycine through binding to the NR3 subunit (Awobuluyi et al, 
2007; Madry et al, 2008). 
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2+ 
As previously mentioned, the formation of Ca micro-domains close to the intracellular 
face of NR1/ NR2 NMDARs has been found to play a role in desensitisation of the 
2+ 
receptor, where increases in the level of Ca decreases the open probability of the receptors 
2+ 
(Rosenmund and Westbrook, 1993). NR1/ NR3 receptors are less permeable to Ca than 
2+ 
NR1/NR2 receptors (Chatterton et al, 2002), which suggests that the formation of Ca
2+ 
micro-domains could be slower as the Ca influx is reduced. Given the lack of voltage-
2+ 
gated Ca channels in human platelets (Doyle and Rüegg, 1985), other receptors may also 
be involved, for example Na
+ 
permeable channels which can induce the release of either 
2+ 
calcium from intracellular stores or the release of ATP to trigger further influx of Ca into 
the cell (figure 30). 
Another factor that may contribute to receptor desensitisation is the NMDAR subunit 
conformation of the receptors on the platelets. This is the first demonstration of NR3 
subunits in platelets and it unknown what the contribution of NR3 subunits is to the final 
receptor assembly. The presence of the NR3 subunit in tri-heteromeric receptors decreases 
the responses evoked by activating the receptor, which has the effect of reducing the influx 
2+ 
of Ca into the cell (Ciabarra et al, 1995; Sucher et al, 1995). It is not known 
2+ 
comparatively, what the differences in Ca permeability are between the different 
combinations of subunits (NR1/ NR2, NR1/ NR3 and NR1/ NR2/ NR3), however this 
could be investigated by transfecting cells without native expression of NMDAR subunit 
proteins with the required subunits and determine the differences. Concatemers could be 
used to ensure that equal amounts of DNA were inserted for each subunit required, for 
example NR1, NR2D and NR3A, varying the subunits included. However, as in native 
cells the exact combinations of subunits would not be known, but could potentially be 
extrapolated using a range of different combinations of subunits e.g. NR1/NR2D, 
NR1/NR3A, NR1/NR2D/NR3A. 
4.4.3. Glycine versus thrombin­evoked calcium responses 
2+ 
The peak Ca response induced by 3 �M glycine is 67.32 ± 7.22 % smaller than that 
-1 
elicited by 3 U ml thrombin (figure 34). As described in Chapter 3, it is possible that the 
2+
increase in [Ca ]i induced by stimulation of NR1/ NR3 receptors plays an important role in 
2+ 
platelet activation, possibly akin to that of P2X1 that induces a small Ca influx on 
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activation, but which plays an important role in the initiation and continuation of thrombus 
formation (Hechler et al, 2003). 
4.4.4. Receptor pharmacology: the action of D­serine 
The absence of the NR2 subunit in NR1/ NR3 NMDARs means that not only is glutamate 
not required for receptor activation, but also that the receptor can not be inhibited by 
D-AP5, which competitively binds to the glutamate binding site (Costa et al, 2009). It has 
also been shown that the open channel blocker MK-801, has little or no effect on the 
receptor (Chatterton et al¸ 2002). Instead, D-serine which acts as a co-agonist to glutamate 
or NMDA in classic NMDAR conformations has been found to inhibit NR1/ NR3 glycine-
induced responses in transfected oocytes (Chatterton et al, 2002). Prior to investigating 
whether D-serine has an inhibitory effect on glycine applied extracellularly to human 
platelets, it was important to determine whether extracellular D-serine alone could elicit 
2+
increases in [Ca ]i.. D-serine binds to the NR1 subunit, so it is hypothetically possible that 
in native platelets D-serine could act as a co-agonist for glycine in NR1/ NR3 receptors, or 
even stimulate responses alone. Alternatively, it could repeat the results of Chatterton et al 
(2002), and inhibit the glycine-elicited responses. The NR2D subunit is also expressed in 
human platelets (figure 15), therefore it is possible that D-serine could stimulate a small 
response from NMDARs in the NR1/ NR2D subunit conformation either alone, or in 
combination with glutamate secreted by platelets which may have become activated by the 
addition of D-serine, or through the mechanical stimulation during platelet isolation. While 
a small response was observed upon the addition of D-serine to the platelets, it was 
comparable to that stimulated by the addition of saline, repeating findings published by 
Chatterton et al (2002), and demonstrating that D-serine alone does not induce an increase 
2+
in [Ca ]i (figure 36). 
A recent study has demonstrated that the activity of the ionotropic serotonin receptor, 5HT3 
which is expressed in human platelets, is modulated by D-serine (Derkach et al, 1989; 
Shad, 2006). The presence of D-serine increases the sensitivity of the receptors to 
2+ 
serotonin, which have been demonstrated to be permeable to a range of ions including Ca , 
Na
+ 
and K
+ 
(Derkach et al, 1989; Yang, 1990). This suggests that activation of platelets by 
other agonists,  for example glutamate, which trigger release of the contents of dense 
granules, that includes serotonin, can then trigger further stimulation of the same and 
nearby platelets through activation of the 5HT3 receptors, which are sensitised by the 
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presence of D-serine which also has a role in NMDAR activation. In the case of NR1/NR3 
NMDARs, D-serine acts as an inhibitor (Chatterton et al, 2002), however in this study it 
was only demonstrated to act as a partial inhibitor. I hypothesise that D-serine inhibits 
NR1/NR3 NMDARs, but may also potentiate 5HT3 receptor activation through serotonin 
released from the dense granules. This could be further investigated using 5HT3 
antagonists, for example ICS 205-930 or GR 38032F, to determine the role played by the 
receptor in platelet activation triggered by glycine in the presence of D-serine (Derkach et 
al, 1989) (figure 44). 
The addition of D-serine to human platelets in combination with glycine had a mixed effect 
2+
on [Ca ]i (figures 37A and B), either inhibiting (3 donors), potentiating (3 donors), or 
having no effect on the glycine-elicited response in the 2 remaining donors (figure 38D). 
However overall there was no net change in the mean ± S.D. % MR either with or without 
D-serine (figure 38C). Further study is therefore required to determine whether D-serine 
has a role to play in NMDAR modulation and then whether it extends to a functional role in 
platelet activation. D-serine is known to act as a co-agonist in classic NR1/NR2 NMDAR 
combinations and has more recently been determined to act as an inhibitor in the NR1/NR3 
subunit conformation (Dingledine et al, 1999; Chatterton et al, 2002). NMDARs can exist 
as not only as heteromeric but also as triheteromeric receptors, where the presence of the 
NR3 subunit leads to a decrease in response to glutamate/ NMDA and glycine to that 
obtained with the classic NR1/NR2 combination (Ciabarra et al, 1995; Sucher et al, 1995). 
In this study the NR1, NR2D and NR3 subunits have been shown to be expressed in human 
platelets (figures 13, 15 and 31), suggesting that several different combinations of receptor 
subunits are present e.g. NR1/ NR2D, NR1/ NR3 (A or B), NR1/ NR3A, NR1/ NR3B and 
NR1/ NR2D/ NR3 (A or B). It is therefore possible that in human platelets, the NR3 
subunit has a regulatory role in the level of NMDAR activation, with the simplest 
explanation for the differences observed with D-serine in combination with glycine being 
differential expression of NMDAR subunits between donors. The development of a 
selective NR3 antagonist will help to identify specific NR1/ NR3 responses. Currently, 
there are only a couple of differences between NR1/ NR3 and other glycine-activated 
receptors. Glycine receptors (GlyR) which permit influx of Cl 
-
, are widely expressed in the 
CNS particularly in inhibitory interneurones in the spinal cord and are reversibly inhibited 
by strychnine (Curtis et al, 1967). To date they have not been identified in platelets, and 
therefore further investigation is required to determine whether they are expressed, and 
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whether the receptors are functional. In other cell types, GlyRs have been shown to play a 
mixed role, with some studies demonstrating that stimulation of GlyRs leads to an increase 
2+
and others showing a decrease in [Ca ]i; for example in oligodendrite progenitor cells, 
2+ 2+ 
stimulation of GlyRs lead to activation of voltage gated Ca channel and an influx of Ca
(Belachew et al, 2000), and it is thought that in neutrophils stimulation of GlyRs leads to 
2+ 
attenuation of Ca influx (Wheeler et al, 2000). In comparison, NR1/ NR3 receptors 
induce an excitatory response and are therefore termed excitatory glycine receptors 
(Chatterton et al, 2002). They are strychnine-insensitive, enabling strychnine to be used to 
selectively inhibit activation of GlyRs (Chatterton et al, 2002). However this does not 
select between responses evoked by activation of NR1/ NR3 or NR1/ NR2 receptors given 
that glutamate may be secreted from platelet granules in response to the mechanical 
stimulation of agonist addition. 
4.4.5. Glycine­mediated ATP release 
In this study, glycine has been demonstrated to evoke the secretion of ATP from human 
platelets. The data from the ATP assay also illustrated a split in donors between responders 
and non-responders, with time also having an effect on the responses recorded (figures 39 
and 40). As in Chapter 3, a 10 fold lower concentration of glycine was required to 
2+ 
stimulate an increase above that induced by saline (0.001 �M) than in the Ca assay 
2+ 
(0.01 �M) (figure 23 and 40). This difference could be due to the formation of Ca
2+ 
micro-domains following Ca entry through the NR1/ NR3 receptor (figure 29), which is 
sufficient to stimulate the release of ATP from the dense granules at lower concentrations 
2+ 
than required to elicit a detectable response from the fluo-4 in the Ca assay. This could 
be tested by increasing the concentration of the fluo-4 used, or by reducing the 
concentration of the luciferase used in the ATP assay. High speed fluorescent imaging of 
2+ 
Ca movement could also be used. Recordings using the plate reader are limited to every 
2+ 2+ 
0.1 s, which means that faster bursts of Ca (or Ca spikes) may either not be detected or 
the peak of the bursts missed, whereas a high speed system is able to take up to 
-1 
200-400 frames s enabling a higher resolution and more accurate picture of the responses 
triggered (Sigimori et al, 1990). 
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Figure 44. The potential actions of D­serine on glycine­mediated calcium influx. A, illustrates 
the excitatory glycine receptor, NR1/NR3, which is activated by glycine and inhibited by D-serine. 
In this study, 10 µM D-serine induced only a partial inhibition, however a larger concentration may 
2+ 
induce full inhibition of Ca influx. B, another variation is the effect on the classic NR1/NR2 
NMDA subunit combination. Here D-serine acts as a co-agonist to glutamate or NMDA, but its 
role in the presence of only glycine is unknown. If the response to glycine is only partially 
inhibited, it is possible that the response will be sufficient to trigger glutamate release from the 
dense granules into the extracellular environment which could activate the NR1/NR2 receptor in a 
more classical manner, either by glutamate and glycine, or glutamate and D-serine. 
C, demonstrates the hypothetical role of GlyRs, which are not themselves affected by D-serine, but 
2+
through their activation by glycine by can affect [Ca ]i. D, illustrates the sensitisation effect of 
D-serine on 5HT3 receptors, which can be activated at lower concentrations of serotonin (5HT) in 
2+
the presence of D-serine. Serotonin is released by activation of platelets and influx of Ca , for 
2+ 
example by stimulation of NR1/NR2 NMDARs by glutamate and glycine or D-serine. Ca is also 
able to enter cells through the 5HT3 receptors. 
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The addition of D-serine alone to isolated human platelets induces a mixed ATP response, 
with no effect in 6 donors, an increased response in 1 donor, and inhibition of responses 
from that elicited with saline in the remaining 5 donors (figure 43). The ATP response 
elicited by the addition of glycine is variable between donors, and a partial inhibition is 
observed of the largest responses to extracellular glycine (figure 43). Overall, D-serine 
causes an inhibition in the responses elicited by glycine, but within the donors, those which 
generate the greater ATP release in responses to glycine are partially inhibited. This might 
suggest that (i) the expression of a second non-NMDA glycine receptor, (ii) an assembly of 
novel NR3 containing receptors with lower sensitivity to D-serine or an insufficient 
concentration of D-serine, or (iii) the concentrations published were determined using 
heterologous expression systems and therefore may differ in native systems. 
2+ 
Differences in the results obtained for the 2 different assays (changes in intracellular Ca
and ATP release) are apparent with no net change in the mean ± S.D. with the fluo-4 assay, 
and a noticeable, but not significant, inhibition with the addition of D-serine in ATP release 
(figures 38 and 43). The data is not directly comparable as different donors were used for 
each type of assay and the preparatory methods for the platelets were not the same. The 
data can therefore only be compared within each method. To obtain comparable data and 
to determine whether there are differences between the data obtained with the 2 methods, 
the platelet preparation for the ATP release assay should be changed to that used in the 
2+ 
intracellular Ca assay which has been published (MacKenzie et al, 1996) and experiments 
2+
carried out in parallel for both ATP release and changes in [Ca ]i. 
4.4.6. Clinical relevance and overall conclusions 
Until recently, glycine was thought to be implicated only in inhibitory pathways, but 
functional studies on the NR3 subunit discovered that when expressed in combination with 
the NR1 subunit protein, it elicited an excitatory response (Chatterton et al, 2002). Glycine 
has been found to be stored in human platelets, and levels have been shown to become 
raised during migraines (D’Andrea et al, 1991). Dysregulated glycine secretion could lead 
to stimulation of inhibitory glycine signalling pathways in the brain if signalling is raised, 
or could lead to stimulation of NR1/ NR3 receptors expressed on platelets. Little is known 
about the effects of glycine secreted from human platelets, and so further study is required. 
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Previous studies have been carried out on NR3 subunits which have been localised in rat 
brain or using cDNA isolated from rat brain and transfected in oocytes (Chatterton et al, 
2002; Ciabarra et al, 1995; Sucher et al, 1995), but not from human cells or tissue, making 
this study one of the first to investigate the role of endogenous human NR1/ NR3 receptors. 
Therefore, all known pharmacology is derived from, and compared to, that of the rat NR3 
subunit, which could potentially demonstrate variations in potency for example to glycine, 
with the human NR3 subunits. Knockouts have been developed of both NR3 subtypes, 
with the NR3A knockout showing enhanced responses to NMDA in comparison to WT 
littermates (Das et al, 1998). The number of dendritic spines was also found to increase. 
The mice were found to be viable and fertile with no apparent behavioural abnormalities 
(Das et al, 1998). Another study demonstrated that the NR3B knockout was also viable 
and fertile, with increased sociable behaviour but also exhibited increased anxiety 
especially in new environments (Niemann et al, 2007). Motor learning and co-ordination is 
mildly impaired in the knockout mice and activity in their home cages is also reduced 
(Niemann et al, 2007). These studies describe varied roles for each of the NR3 subunits, 
however further investigation is required in the animal models to more fully identify the 
role of the NR3 subunits in platelet activation. Further study is also required into the role 
of the NR3 subunit in human platelets, which would be aided by the development of a 
specific NR3 subunit inhibitor. 
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CHAPTER 5

MEGAKARYOCYTES

5.1. Summary 
In this chapter, it has been demonstrated that: 
- MEG-01 cells express the NMDA NR1 subunit proteins, but have not been found to 
express the NR2A or NR2D subunit proteins 
- MEG-01 cells treated with PMA, in the presence or absence of fibrinogen, resulted 
in cell adhesion and an increase in cell size 
- PMA-induced changes in MEG-01 morphology and cell size, in the presence or 
absence of fibrinogen, were not affected by NMDAR inhibitors. 
- PMA-induced MEG-01 adhesion to tissue culture plastic is potentiated by NMDAR 
inhibitors 
- Fibrinogen-dependent MEG-01 adhesion is inhibited by both NMDAR inhibitors, 
D-AP5 and MK-801 
5.2. Introduction 
In previous chapters, it has been demonstrated that human platelets express the NMDAR 
NR1, NR2D and NR3 subunit proteins (figures 12, 14 and 30). Evidence for the presence 
of functional NMDAR has also been presented, including increased ATP release with the 
addition of glutamate and increases in fluorescence indicative of increased intracellular 
2+ 
Ca on the addition of either glutamate or NMDA to fluo-4 loaded platelets (figures 23 and 
26). These are indicative of the classic NMDA receptor NR1/NR2 complex. Another 
combination of subunits has also been determined, NR1/NR3, which is activated by glycine 
alone due to the lack of an NR2 subunit protein (Chatterton et al, 2002), and has also been 
demonstrated to be functional in human platelets (figures 32 and 38). 
NMDAR have been primarily characterised in the brain, where they have been shown to be 
involved in the learning and memory pathways (Do et al, 2002). More recently a role has 
been suggested for NMDAR in MK differentiation (Genever et al, 1999; Hitchcock et al, 
2003). During this process (section 1.1.3.3.), platelets are formed from the cytoplasmic 
contents and membrane of the parent MK, suggesting that proteins present in the parent cell 
are present into the daughter platelets (Italiano Jr et al, 2003; Patel et al, 2005). This study 
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was therefore extended to investigate the expression and functional role of NMDAR in MK 
differentiation using the megakaryoblastic cell line MEG-01, which was used in the initial 
study (Genever et al, 1999). 
The MEG-01 cell line was established in 1985 by Ogura et al, using megakaryoblastic bone 
marrow cells isolated from the bone marrow of a male patient with Philadelphia 
chromosome positive chronic myelogenous leukaemia. The cells were assessed and tested 
for a range of markers to determine whether they are a suitable model for native 
megakaryocytes, which are detailed in table 39. 
Indicates... MEG-01 cells Native MKs 
Acid phosphatase Lysosomal enzymes + + 
α-naphthyl acetate 
esterase 
Non-specific monocyte and 
MK esterase 
+ + 
Periodic-Schiff reaction Presence of carbohydrates + -
Naphthol AS-D 
choloroacetate 
Granulocytes and mast cells - -
α-naphthyl butyrate 
esterase 
Late stage monocytes - -
Leukocyte alkaline 
phosphatase 
Late stage/ mature MKs - -
Myeloperoxidase Neutrophils - + 
Platelet peroxidise Mature MKs to platelets - -
Platelet GPIIb/IIIa Present from megakaryoblast 
stage to platelets 
+ + 
α-granules Mature MKs - -
Demarcation 
membrane 
Mature MKs - -
Table 39. Tests used to determine how megakaryocyte­like the MEG­01 cell line is (Pombo et 
al, 1987; Sun et al, 2006; Morgan and Brodsky, 1985; Okabayash et al, 2009; Werzel et al, 1967; 
Larson et al, 2006; Vainchenker et al, 1982). 
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This demonstrates that MEG-01 cells can be used as models for immature native MKs or 
megakaryoblasts, as they have similar properties, with the exception of the positive 
response to the periodic-Schiff reaction and the negative response to myleperoxidase, 
which is indicative of acute megakaryocytic leukaemia (Sun et al, 2006). NMDARs have 
previously been identified in MKs in 2 studies described in section 1.3.2.1.1. 
5.2.1. PMA­ induced differentiation 
PMA has been demonstrated to stimulate MK differentiation in both cell lines and in native 
MKs (Genever et al, 1999; Nagata et al, 1996; Lumelsky and Schwartz, 1997). It binds to 
the cell membrane, through which it is able to pass partially into the cell while remaining 
attached to the membrane (Zhang et al, 1995). PMA has been shown to mimic the action 
of DAG in its ability to bind the members of the protein kinase C (PKC) family (Zhang et 
al, 1995). 
PKC isoforms can be separated into three groups; conventional (cPKC), novel (nPKC) and 
2+ 
atypical (aPKC). cPKC isoforms, α, βI, βII and γ, are activated by DAG, Ca and 
phospholipid (PL) whereas the novel isoforms (δ, ε, η and θ) require only DAG and PL. In 
2+ 
comparison, aPKC isoforms are insensitive to DAG and Ca (Kikkawa et al, 1982; Ohno 
et al, 1988; Ono et al, 1989). PKC is located in the cytosol of cells, and translocates to the 
cell membrane where it tethers loosely in an open, inactive conformation. A 
pseudosubstrate is held within the substrate-binding cavity, which is released upon the 
enzyme tethering, exposing the C-terminus to the cytosol (Dutil and Newton, 2000). The 
hydrophobic region of the C-terminus is then bound by phosphoinositide-dependent kinase-
1 (PDK-1) whose main substrate is Akt, but has been shown to also phosphorylate the 
activation loop of all PKC isoforms (figure 45) (Alessi et al, 1997; Gao et al, 2001; Dutil et 
al, 1998; Le Good et al, 1998; Chou et al, 1998). This action leads to the dissociation of 
PDK-1, exposing the C-terminus which enables further autophosphorylation of the turn 
(c, n and a isoforms) and the hydrophobic (c and n isoforms) motifs of the PKC. In 
combination with the re-association of the pseudosubstrate with the substrate-binding 
cavity, this converts the enzyme to its mature, inactive form, which dissociates from the 
membrane and returns to the cytosol (Newton, 2003). 
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Figure 45. Schematic demonstrating the roles of the pseudosubstrate in regulation of PKC 
2+ 
activity. C1 domain, contains the DAG (diacylglycerol) binding site; C2 domain contains the Ca
binding site (only present in conventional isoforms of PKC); PS, phosphatidylserine; PDK-1, 
phosphoinositide-dependent kinase-1; light grey circles indicate sites of phosphorylation, numbers 
indicate amino acid number phosphorylated; black rectangle, pseudosubstrate sequence; open 
rectangle, active site. 1, the activation loop of PKC is exposed, enabling phosphorylation by PDK-
1. 2, this initial phosphorylation leads to autophosphorylation of the turn and hydrophobic motifs, 
which is halted by movement of the pseudosubstrate into the active site forming a catalytically 
competent, but inactive conformation, and the enzyme localises to the cytosol. 3, Production of 
DAG leads to PKC translocation to the plasma membrane, where changes in conformation through 
2+ 
binding of the C1 domain to DAG and C2 to Ca (cPKC only) cause the release of the 
pseudosubstrate from the active site, activating the enzyme. Adapted from Dutil and Newton, 2000. 
2+
Under normal activation conditions, production of DAG and an increase in [Ca ]i targets 
2+ 
the mature, inactive PKC to the membrane through binding of Ca to the C2 region and the 
membrane-bound DAG to the C1 region (Nalefski and Newton, 2001). The affinity for 
DAG has been demonstrated to be greater in the C1 region of nPKC isoforms to aid binding 
2+ 
to the cell membrane, as they are lacking the additional binding mediated by Ca through 
the C2 region present in conventional isoforms (Giorgione et al, 2006). This binding leads 
to the release of the pseudosubstrate enabling substrate binding, phosphorylation and the 
induction of intracellular signalling pathways e.g. the Ras/ Raf/ MEK pathway (Griner and 
Kazanietz, 2007). Once activated by DAG, desensitisation is rapid, with heat-shock 
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protein 70 (HSP70) demonstrated to bind the dephosphorylated turn motif and stabilise the 
enzyme as it returns to the cytosol. The enzyme can then be rephosphorylated and recycled 
(Gao and Newton, 2002). When cells are stimulated with PMA, the mature, inactive PKC 
translocates to the membrane, binding through the C1 domain to the PMA, and triggering 
conformational changes which enable its activation. Binding of PKC to PMA leads to 
prolonged activation of the enzyme, resulting in slow dephosphorylation, down-regulation 
and disassociation with the membrane (Hansra et al, 1999). 
Different PKC isoforms have been identified in platelets and MKs, the conventional α and 
β isoforms and the novel isoforms, δ and θ, together with the novel ε isoform in MKs and 
the atypical ζ isoform additionally expressed in platelets (Crosby and Poole, 2002; 
Grabarek et al, 1992; Nagata et al, 1996; Baldassare et al, 1992). The roles of activated 
PKC differ between MKs and platelets, from stimulating differentiation of MKs through an 
increase in synthesis of dense and α-granules for packaging within platelets, to an increase 
in expression of αIIbβ3, and inducing changes in cell shape (Nagata et al, 1996; Goto et al, 
1992). In platelets, PKC has been demonstrated to induce expression of vWF and 
fibrinogen at the cell surface and stimulate thrombus formation (Konopatskaya et al, 2005). 
From previous studies, it can be concluded that both PKC and NMDARs have a role in MK 
differentiation both in the MEG-01 cell line and in native MKs (Genever et al, 1999; 
Hitchcock et al, 2003; Nagata et al, 1996; Goto et al, 1992; Konopatskaya et al, 2005). 
These studies were extended by investigating the expression of NMDA receptor subunit 
proteins in MEG-01 cells differentiated with PMA. 
5.2.2. Fibrinogen 
Fibrinogen is a soluble glycoprotein produced by hepatocytes in the liver and in MKs, and 
is known to be involved in platelet adhesion and clot formation through binding to the 
integrin αIIbβ3 (Haidaris et al, 1989). Approximately 80000 copies of αIIbβ3 are present on 
the surface of unstimulated platelets, with additional monomers present within granules 
which are able to translocate to the membrane upon platelet activation (Wagner et al, 
1996). There is also evidence that fibrinogen has a role in MK differentiation. Fibrinogen 
has been located in the blood sinusoids along which MKs migrate following an SDF-1 
gradient as they differentiate (Wang et al, 1998). MKs finally adhere to fibrinogen in the 
sinusoids via the integrin and continue to differentiate, eventually producing proplatelets 
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which extend into the blood stream to release the individual platelets (Larson and Watson, 
2006). The integrins have been found to be expressed only in more mature MKs, limiting 
fibrinogen-binding to cells which are ready to develop into proplatelets (Shiraga et al, 
1999). 
The binding of αIIbβ3 to fibrinogen involves 2 different signalling pathways- an inside-out 
and an outside-in. For the initiation of inside-out signalling, activation of the integrin is 
required, for example by TPO, thrombin or SDF, to stimulate binding to fibrinogen. Other 
signalling pathways have been found to regulate inside-out signalling such as PI3K and 
PKC, with their inhibitors (wortmannin and bisindolymaleimide) shown to block signalling 
by αIIbβ3, although not fibrinogen binding (Jiroušková et al, 2007). It has been shown that 
the TF, NF-E2, is required for terminal differentiation of MKs, and knockout of the p45 
subunit prevents activation of NF-E2, inhibiting fibrinogen binding. The cytoplasmic tail 
of the β3 integrin has been shown to interact with a number of different proteins including 
the cytoskeletal proteins talin, α-actinin and filamin (Calderwood et al, 1999; Bennett, 
2005). Talin is known to also bind to actin, which has a major role in the structure of the 
cytoskeleton (Jiang et al, 2003). The second pathway, outside-in signalling, is triggered by 
the adhesion of MKs to fibrinogen via the αIIbβ3 integrin, which has been found to trigger 
activation of Rho GTPases including Rac and Rho. These play a role in cell spreading and 
cytoskeletal re-organisation, which has been observed in previous studies in MKs on 
culturing with fibrinogen (Shiraga et al, 1999). This combination of signalling pathways 
leads to changes in MK cell shape which characterise the later stages of differentiation. 
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5.3. Results 
5.3.1. Detection of NMDAR subunit proteins by Western blot 
The expression of NMDA NR1, NR2D and NR3 subunit proteins in human platelets has 
been demonstrated in Chapters 3 and 4 (figures 13, 15 and 31). The expression of these 
subunits together with that of the NR2A subunit was investigated in the undifferentiated 
megakaryoblastic cell line, MEG-01 by performing Western blots. These demonstrated 
that a band was detected between 100 and 150 kDa with an anti-NR1 antibody (figure 46), 
which corresponds to the expected molecular weight of the NR1 subunit (Moryoshi et al, 
1991). This is in agreement with previous reports demonstrating the expression of the NR1 
subunit protein in MEG-01 cells by Western blot (Genever et al, 1999). No bands were 
detected at the expected molecular weights for NR2A (figure 47) or NR2D (figure 48) in 
undifferentiated MEG-01 cells. From this data only the NMDA NR1 subunit protein 
appears to be expressed in undifferentiated MEG-01 cells. 
5.3.2. Detection of NMDAR subunit mRNA by RT­PCR 
Previous studies have demonstrated that mRNA for the NR1 and NR2D subunits is 
expressed in MEG-01 cells (Genever et al, 1999). This was repeated and expanded to 
investigate the expression of mRNA for all 7 NMDAR subunits; NR1, NR2A-D and NR3A 
and B. The optimal annealing temperatures for each set of primers was determined by 
setting up temperature gradients from 53- 63 
o
C on the Thermal Cycler (section 2.4.4), and 
using reverse transcribed human cerebellum samples (section 2.4.3). No bands were visible 
for the NR2D primers at either 30 or 35 cycles, not the NR3B primers at 35 cycles. From 
this the optimal temperatures and cycle numbers were determined (figure 49; table 40). 
Table 40. Determining cycle numbers and annealing temperature for NMDAR primers 
SUBUNIT CYCLE NUMBER ANNEALING TEMPERATURE (
o
C) 
NR1 30 59 
NR2A 33 57 
NR2B 33 61 
NR2C 33 61 
NR2D - -
NR3A 35 57 
NR3B - -
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PCR was therefore carried out on the remaining sets of primers using the cycle number and 
annealing temperatures detailed in table 40 following the programme listed in section 2.4.4 
(figure 50). Reversed transcribed human cerebellum samples were also run alongside 
MEG-01 samples for each NMDAR subunit tested as a positive control as mRNA of all 
NMDAR subunits have been demonstrated in the cerebellum (Bessho et al, 1994; Monyer 
et al, 1994; Wong et al, 2002; Wee et al, 2008). MEG-01 and human cerebellum samples 
were also tested for the presence of β-actin cDNA to determine whether the loading of 
samples was comparable (section 2.4.4) (figure 50). This demonstrated that while all of the 
subunits tested were positive in the human cerebellum samples, no bands were detectable in 
either of the MEG-01 samples which were from 2 different passage numbers (M1- passage 
10; M2- passage 12) of the same original sample (ATCC). Bands for β-actin were present 
for all of the samples and appeared to be equally loaded (figure 50). This demonstrates that 
mRNA does not appear to be expressed in MEG-01 cells at the time the samples were 
taken. 
5.3.3. Effect of NMDAR inhibitors on cell morphology 
Previous studies have reported that NMDARs play an important role in MK differentiation 
and have dramatic effects on cell morphology. Hitchcock et al (2003) demonstrated using 
ultrastructural analysis that during TPO-stimulated differentiation of CD34
+
-derived MKs 
increased in size, induced the development of a multi-lobed nucleus, formation of 
α-granules and demarcation membrane together with formation of proplatelets in the 
absence of fibrinogen. These morphological changes could be inhibited by culturing the 
cells with the additional presence of MK-801. It is hypothesised that NMDARs are critical 
for the formation of platelets, and treatment of CD34
+
-derived MKs with MK-801 has lead 
to a reduction of both the number of proplatelet forming MKs and the area of the MKs 
(Hitchcock et al, 2003). The number of MKs present at the end of the experiments is not 
affected by the presence of the NMDAR specific inhibitor (Hitchcock et al, 2003). 
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Figure 46. MEG­01 cells express NMDA receptor subunits NR1. Western blot demonstrating 
the expression of the NMDA NR1 subunit in undifferentiated MEG-01 human megakaryoblastic 
cells (M) and 1 human platelet donor (P; positive control) which were run on the same gel. The blot 
was split into two at approximately 70 kDa, with the top half probed for NR1 expression, and the 
lower half for β-actin to assess loading (expected size 42 kDa). The arrows on the right side 
indicate sizes predicted by protein standards (mol weight, molecular weight marker; kDa). Arrow 
on the left indicates the expected size of the NR1 subunit, 120 kDa. Representative blot from 
12 different experiments. Approximately 15 µg protein was loaded for each sample using the 
Bradford assay to determine the protein concentration of each sample (section 2.4.1). 
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Figure 47. MEG­01 cells do not express detectable NMDA receptors subunit NR2A. Western 
blot demonstrating that expression of the NR2A subunit protein was not detected in undifferentiated 
MEG-01 human megakaryoblastic cells (M). The platelet sample (P) alongside demonstrates the 
apparent lack of NR2A expression in human platelets. The arrows on the right side indicate sizes 
predicted by the protein standards (mol weight, molecular weight marker; kDa). Arrow on the left 
indicates the expected size of the NR2A subunit, 180 kDa. Representative blot from 3 separate 
experiments. Approximately 15 µg protein was loaded for each sample using the Bradford assay to 
determine the protein concentration of each sample (section 2.4.1). 
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Figure 48. MEG­01 cells do not express detectable NMDA subunit NR2D. Western blot 
demonstrating that NR2D subunit protein expression was not detected in undifferentiated MEG-01 
human megakaryoblastic cells (M). The platelet sample (P) run on the same gel demonstrates that 
NR2D is expressed in human platelets (positive control). The arrows on the right side indicate sizes 
predicted by the protein standards (mol weight, molecular weight; kDa). Arrow on the left indicates 
the expected size of the NR2D subunit, 150 kDa. Representative blot from 3 separate experiments. 
Approximately 15 µg protein was loaded for each sample using the Bradford assay to determine the 
protein concentration of each sample (section 2.4.1). 
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Figure 49. Temperature gradients to determine the optimal annealing temperatures for 
NMDAR subunit primers. A, Initially the primer sets for NR1, NR2A and NR2D were tested 
using 30 cycles of annealing, extension and melting. A gradient of 53- 63 
o
C for the annealing step 
were tested; temperatures are indicated above the relevant lane. Bands were visible for NR1 and 
NR2A but not NR2D primer sets at the expected sizes of 336, 391 and 336 bp respectively. B, The 
remaining primer sets were tested using the same gradient, using 35 cycles, the NR2D set were 
re-tested. Bands were visible at the expected sizes for NR2B (338 bp), NR2C (304 bp) and NR3A 
(352 bp), but not for NR2D (336 bp) or NR3B (385 bp). The PCR product of approximately 1 µg 
reverse transcribed RNA was loaded per sample. 
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Figure 50. MEG­01 cells do not appear to express mRNA for the NMDAR subunits NR1, 
NR2A­C or NR3A. Two different MEG-01 samples were compared to that from human 
cerebellum demonstrating that the mRNA of subunits NR1, NR2A-C and NR3A are present in 
human cerebellum, but do not appear to be present in either MEG-1 sample at the time that the 
samples were taken. The samples on the right illustrate that β-actin mRNA is present in all 
3 samples, and that the amount appears to be equal. The PCR product of approximately 1 µg 
reverse transcribed RNA was loaded per sample. 
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TPO has been shown to be the primary physiological regulator (Szalai et al, 2006) for 
megakaryocyte differentiation (figure 1), however PMA can also be used (Genever et al, 
1999). PMA has previously been demonstrated to stimulate MK differentiation in both 
native MKs and MEG-01 cells, stimulating an increase in cell size, ploidy and adhesion, 
which have all been described as markers of MK differentiation (Hitchcock et al, 2003; 
Genever et al, 1999; Murate et al, 1991). PMA-mediated changes in MEG-01 cell 
morphology when cultured in tissue-culture treated flasks (section 2.3.2.1.) were 
characterised and the study extended by culturing MEG-01 cells in fibrinogen-coated dishes 
to compare differences. Additionally, the role of NMDAR in PMA-induced changes in cell 
morphology was investigated using the selective antagonists MK-801 and D-AP5. 
5.3.3.1 Cell morphology in the absence of fibrinogen 
Different methods were tested to differentiate MEG-01 cells using PMA in the absence of 
fibrinogen from 2 different published methods. The first method was described by Nagata 
et al (1996) where 1 x 10
5 
cells ml
-1 
were treated with for 2 h with 10 nM PMA at 37 
o
C, 
5 -1 
washed, then resuspended at 1 x 10 cells ml in fresh media and cultured for 3 d (section 
2.3.2.1). The second method, described by Lacabaratz-porret et al (2000) used 
5 -1 
2.4 x 10 cells ml and treated MEG-01 cells for 3 d with 10 nM PMA in culture. Cultures 
using both methods were set up with either 10 nM PMA or 0.001 % DMSO (v/v) as a 
vehicle control and photographs taken after 3 d. The cells were then measured (section 
2.3.2.1.1), and the results compared (figure 51). Figures 51 shows representative 
photographs, which demonstrate that cells treated with DMSO remain round and bright 
when either method 1 or method 2 was used. PMA treatment with method 1 stimulated a 
2
greater increase in size than in the DMSO match control (349.33 ± 22.75 �m compared to 
2
217.45 ± 10.57 �m respectively) with some cells appearing to adhere to the bottom of the 
flask. The cells treated with PMA in method 2 are also larger in size than the DMSO 
2 2
controls, 483.82 ± 70.03 �m and 163.89 ± 3.04 �m respectively with the cells also 
becoming more irregular in shape and a larger proportion appearing to adhere to the bottom 
of the flask. The overall increase in cell size is greater using method 2, with an increase of 
2 2
319.95 ± 70.10 �m in comparison to 131.80 ± 25.06 �m with method 1. Increase in cell 
size is one of the markers of MK differentiation and is being investigated in this study 
(Italiano Jr et al, 2003; Patel et al, 2005). Therefore method 2 will be used for subsequent 
experiments requiring PMA induced MK differentiation. 
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Figure 51. The size of MEG­01 cells increases with PMA­treatment. Representative pictures 
comparing the different treatments- method 1 where MEG-01 cells were exposed to 10 nM PMA 
5 -1 
for 2 h, washed then cultured at 1 x 10 cells ml and method 2 where MEG-01 cells were 
5 -1 
chronically exposed to PMA (10 nM, 3 d) at 2.4 x 10 cells ml (section 2.3.2.1). The histogram 
compares the differences in cell size with the 2 different methods. There is no difference between 
the DMSO-treated cells with either method 1 (2h exposure) or method 2 (3 d exposure), with the 
PMA-treated cells becoming generally larger in size than DMSO-treated cells with either method. 
Overall, the cells treated with PMA using method 2 are larger than those treated using method 1 
2 2
(483.82 ± 70.03 �m in comparison to 349.33 ± 22.75 �m respectively). The data is pooled from 3 
experiments (n=3) with 4-8 photographs taken for each treatment for each experiment, and analysed 
as described in section 2.3.2.1. *** P< 0.01 compared to the respective DMSO control using an 
unpaired, two-tailed Students t-test. Original magnification x 400, scale bar represents 10 �M. 
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5.3.3.2. Expression of NMDAR subunits in PMA­treated MEG­01 cells 
MEG-01 cells were set up as described in section 2.3.2.1 (method 2) with either PMA 
(10 nM) or DMSO (0.001 % v/v) together with either MK-801 (100 �M) or D-AP5 
(100 �M); samples were taken after 3 d in culture. The samples were prepared as described 
previously (lysis buffer B, section 2.4.3). Samples were run on 8 % SDS gels, transferred 
onto PVDF membrane (section 2.3.3-4), then probed for either the NR1, NR2A or NR2D 
subunit proteins (figures 52-4). Densitometry analysis was carried out on bands at the 
expected size for each subunit and was normalised against the intensity of bands obtained 
for the β-actin equal loading from the same blots (section 2.4.6). This is illustrated in 
figure 55. The NR1 subunit protein was shown to be expressed by both untreated and all 
treated MEG-01 cells, as well as in 2 different human platelet samples (figure 52). 
However, no overall differences were determined between the untreated or any of the 
differently treated MEG-01 cells. The combined analysis for donor 1 indicates that relative 
expression is 59.18 ± 39.61 % greater than that in untreated MEG-01 cells, with donor 2 
showing a 10.98 ± 32.25 % increase in NR1 subunit protein expression above the untreated 
MEG-01 cells (figure 55). 
In contrast, the expression of the NR2A subunit protein in MEG-01 cells is unclear. It does 
not appear to be expressed either by untreated MEG-01 cells or platelets (figures 14 and 
47), however figure 53 demonstrates that there may be low level expression following 
treatment with PMA. Expression of the NR2D protein could not be detected in MEG-01 
cells either with or without treatment (figure 48 and 54), however it is shown to be 
expressed in human platelets (figure 15 and 54) which are the terminal stage of MK 
differentiation. Using densitometry analysis, it was determined that the bands obtained at 
the expected size of 150 kDa in the platelet samples (figure 55) are 164.26 ± 25.87 % and 
86.66 ± 9.75 % more intense than the matching β-actin expression for each donor 
respectively. Comparatively, the levels measured in the MEG-01 samples are between 5.81 
± 2.74 % and 16.56 ± 7.00 % of the matching expression levels of β-actin. 
This data therefore indicates that the NR1 subunit protein is expressed by both MEG-01 
cells and human platelets, with the NR2D subunit also expressed in human platelets but 
was not detected in MEG-01 cells. The NR2A subunit was not detected in human platelets, 
however its expression was potentially increased following PMA treatment for 3 d. 
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Figure 52. NMDA NR1 subunit expression in MEG­01 cells is not altered by PMA treatment 
or the presence of inhibitors. Western blot demonstrating the differences in expression of the 
NMDA NR1 subunit between undifferentiated MEG-01 cells (MEG-01), differentiated MEG-01 
cells and platelets from two different donors (1 and 2) to represent terminal differentiation and as a 
positive control (figure 12). MEG-01 cells were treated for 3d in culture (section 2.3.2.1, method 2) 
with 10 nM PMA or DMSO (0.001 % v/v; vehicle control) in the presence or absence of the NMDA 
inhibitors MK-801 (100 �M) or D-AP5 (100 �M). The blot was split into 2 pieces at approximately 
70 kDa, with the top half probed for NR1 expression, and the lower half for β-actin to compare 
sample loading (expected size 42 kDa). This blot is representative of 4 separate experiments, 
indicating that there is no discernible effect on NR1 expression through PMA treatment, with no 
apparent effect induced by the inhibitors. The arrows on the right indicate sizes predicated by the 
protein standards (mol weight, molecular weight marker; kDa). Arrow on the left indicates the 
expected size of the NR1 subunit, 120 kDa. Approximately 15 µg protein was loaded for each 
sample using the Bradford assay to determine the protein concentration of each sample (section 
2.4.1). 
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Figure 53. MEG­01 cells potentially express NMDA NR2A subunits when treated with PMA. 
Western blot demonstrating the differences in expression of the NMDA NR2A subunit between 
undifferentiated MEG-01 cells (MEG-01), differentiated MEG-01 cells and platelets from two 
different donors (1 and 2) to represent terminal differentiation, where NR2A is not expressed 
(figure 13). MEG-01 cells were treated for 3d in culture (section 2.3.2.1, method 2) with 
10 nM PMA or DMSO (0.001 % v/v; vehicle control) in the presence or absence of the NMDA 
inhibitors MK-801 (100 �M) or D-AP5 (100 �M). The blot was stripped (section 2.4.5.) and 
reprobed for β-actin to compare the loading of the sample. This is illustrated in the lower blot with 
an expected size of 42 kDa. This blot is representative of 2 separate experiments, indicating that 
there is a potentially discernible effect on NR2A expression through PMA treatment. The arrows 
on the right indicate sizes predicted by the protein standards (mol weight, molecular weight marker; 
kDa). Arrow on the left indicates the expected size of the NR2A subunit, 180 kDa. Approximately 
15 µg protein was loaded for each sample using the Bradford assay to determine the protein 
concentration of each sample (section 2.4.1). 
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Figure 54. MEG­01 cells do not express NMDA NR2D subunits when treated with PMA. 
Western blot demonstrating the differences in expression of the NMDA NR2D subunit between 
undifferentiated MEG-01 cells (MEG-01), differentiated MEG-01 cells and platelets from two 
different donors (1 and 2) to represent terminal differentiation and as a positive control (figure 14). 
MEG-01 cells were treated for 3d in culture (section 2.3.2.1, method 2) with 10 nM PMA or DMSO 
(0.001 % v/v; vehicle control) in the presence or absence of the NMDA inhibitors MK-801 
(100 �M) or D-AP5 (100 �M). The blot was split into 2 pieces at approximately 70 kDa, with the 
top half probed for NR2D expression, and the lower half for β-actin to compare sample loading 
(expected size 42 kDa). This blot is representative of 3 separate experiments, indicating that there 
is no discernible effect on NR2D expression through PMA treatment. The arrows on the right 
indicate sizes predicted by the protein standards (mol weight, molecular weight markers; kDa). 
Arrow on the left indicates the expected size of the NR2D subunit, 150 kDa. Approximately 15 µg 
protein was loaded for each sample using the Bradford assay to determine the protein concentration 
of each sample (section 2.4.1). 
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Figure 55. Differentiation of MEG­01 cells with PMA does not lead to changes in expression 
of NMDA receptor subunit proteins NR1, NR2A or NR2D. A, illustrates the expression of NR1 
subunit proteins using densitometry (section 2.4.6.), shown as a percentage of β-actin expression 
(n=4). It demonstrates that treating MEG-01 cells with PMA for 3 d in culture has no effect on 
NR1 expression. The presence of either MK-801 or D-AP5 also has no effect. Samples were made 
from the platelets of 2 different human donors (donor 1 and donor 2), which illustrate the variation 
in expression between donors, and demonstrate that in these donors, NR1 expression is greater than 
in MEG-01 cells (143.50 ± 35.85 and 95.03 ± 27.59 % β-actin expression respectively compared to 
untreated MEG-01 cells (84.32 ± 16.85 % β-actin expression)). B, Illustrates the lack of NR2A 
subunit protein expression, showing no change in expression with PMA or either of the inhibitors, 
together a lack of expression in the 2 platelet samples as previously demonstrated (figure 13) (n=2). 
C, Illustrates expression of the NR2D subunit protein (n=3), demonstrating that there is no change 
in expression with PMA-treatment and no effect with either of the inhibitors. There is an increase 
in NR2D expression in both platelet samples of 164.26 ± 25.86 and 86.76 ± 9.75 % β-actin 
expression above that of untreated MEG-01 cells, again demonstrating differences in expression of 
NMDA receptor subunit proteins between donors. D, DMSO; P, PMA; AP, D-AP5; MK, MK-801; 
n= the number of different sets of treated MEG-01 samples and untreated human platelet samples 
run on Western blots and probed with each respective antibody; the same 2 platelet samples were 
run alongside these each time (donor 1 and 2). ** P< 0.01 using a one-way ANOVA with Dunnetts 
post-hoc test in comparison to the MEG-01 sample. 
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5.3.3.3. NMDAR­independent PMA­induced changes in MEG­01 morphology in the 
absence of fibrinogen 
MEG-01 cells were cultured for 3 d using method 2 (section 2.3.2.1) with the addition of 
either 100 �M D-AP5 or 100 �M MK-801, both NMDAR specific antagonists. Figure 56 
illustrates representative photographs taken after 3 d in culture. These show that the 
vehicle-treated cells (DMSO) remain round and bright even in the presence of either 
inhibitor, with no apparent effect on cell number. The presence of PMA leads to increases 
in both an increase in cell size and in the irregularity of the cells’ surface membrane. 
Neither factor is affected by the presence of either MK-801 or D-AP5 whether with or 
without PMA. The histogram illustrates the pooled results from 3 separate experiments. 
The data demonstrates that the mean size of the cells remains at approximately 205.96 ± 
2
5.73 �m with the addition of inhibitors in untreated cells increasing to a mean size of 
2
452.40 ± 19.14 �m in the presence of PMA. The PMA-induced increase in cell size is not 
affected by the presence of MK-801 or D-AP5 (figure 56). 
5.3.3.4. MEG­01 cell morphology in the presence of fibrinogen 
-1 
Dishes were coated with 100 ng ml fibrinogen prior to setting up cultures for 
differentiation (sections 2.3.5 and 2.3.2.1). MEG-01 cells were plated at a density of 
5 -1 
1 x 10 cells ml as initial experiments demonstrated that when cultured at 
5 -1 
2.4 x 10 cells ml in the presence of fibrinogen, the cells formed clumps, adhering to each 
other and forming a fully confluent layer making it difficult to determine the size and shape 
5 -1 
of the cells. The density of the cells was therefore decreased to 1 x 10 cells ml . The cells 
were then treated with either 10 nM PMA or the vehicle control (0.001 % v/v DMSO) for 
3 d (section 2.3.2.1). Photographs were taken after 3 d (figure 58) and the cells measured. 
This data was then compared to that obtained from cells cultured without fibrinogen (figure 
56). Pooled data from 3 separate unpaired experiments demonstrated that culturing 
DMSO-treated MEG-01 cells in the presence of fibrinogen has no effect on the morphology 
of the cells which remain generally spherical with regular membranes (figure 58). Treating 
cells with 10 nM PMA in the presence of fibrinogen leads to an increase in cell size 
together with an increase in the irregularity of both the cell membrane and the cell shape 
previously observed in cells cultured without fibrinogen (figure 56). Changes in cell size 
are detailed in table 41 and illustrated in the histogram in figure 57. The presence of PMA 
significantly increases the size of the cells above that of the control cells, both in the 
presence and absence of fibrinogen. The addition of fibrinogen had no effect on this 
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pattern (figure 57), however it was determined that the size of both the control cells and 
those treated with PMA decreased in comparison to the non-fibrinogen treated cells. 
Fibrinogen 
PMA - + 
- 205.96 ± 5.73 452.45 ± 24.66 
+ 170.96 ± 5.70 304.88 ± 13.00 
Cell size (µm
2
) 
2
Table 41. Comparing the effects of PMA and fibrinogen on the size (µm ) of MEG­01 cells in 
culture for 3 d. 
5.3.3.5. NMDAR­independent PMA­induced changes in MEG­01 morphology in the 
presence of fibrinogen 
MEG-01 cell cultures were set up in the presence and absence of PMA (10 nM), together 
with either 100 �M MK-801 or 100 �M D-AP5 as previously described (section 2.3.2.1.). 
Photographs were taken after 3 d (figure 57) and the cells measured (section 2.3.2.1.1.). 
The photographs illustrate that as previously shown without fibrinogen (figure 56), cells 
treated with either inhibitor in the presence of DMSO remain mainly spherical with regular 
membranes. The cells treated with PMA and fibrinogen, both with and without inhibitors, 
appear larger in size with more irregular shape and cell membranes than the DMSO 
controls. The data indicates both in table 42 and figure 57 that the presence of either 
D-AP5 or MK-801 causes the vehicle control treated cells to decrease in size from those 
cultured in the absence of any inhibitor. However, while there is an apparent effect on cell 
size when treated with both 10 nM PMA and 100 µM MK-801, the decrease is not 
significant given the decrease in size of the control cells with the addition of MK-801. 
Although PMA has been shown to increase the size of MEG-01 cells cultured in the 
presence of fibrinogen, the increase is smaller than in the absence of fibrinogen (figure 52). 
The presence of the NMDAR inhibitors D-AP5 and MK-801 therefore have effect only on 
the size of MEG-01 cells after 3 d in culture without PMA in the presence of fibrinogen. 
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Figure 56. Inhibitors do not affect the size of MEG­01 cells when cultured in either the 
presence or absence of PMA and in the absence of fibrinogen. Representative pictures of MEG-
01 cells cultured in the presence of either 10 nM PMA or a vehicle control (0.001 % DMSO v/v) in 
combination with either 100 µM D-AP5 (AP) or 100 µM MK-801 over 3 d using method 2 (section 
2.3.2.1). Photographs were taken of the cells (5-8 per condition), measured and analysed as 
described in section 2.3.2.1. These illustrate that the presence of PMA over 3d increase the size of 
the cells, which become more irregular in shape and are fewer in number than those treated with 
DMSO. The addition of the inhibitors (inhib) does not have any further effects on the size or shape 
of the MEG-01 cells. The histogram illustrates pooled cell measurements from 3 separate 
experiments. While treatment with PMA increases the size of cells from 205.96 ± 5.73 to 
2
452.40 ± 19.14 �m , the addition of inhibitors have no effect on either PMA- or DMSO-treated 
cells. *** P< 0.001 using two-way ANOVA with Bonferroni post-hoc test comparing the 2 sources 
of variation in the data, the use of PMA/ DMSO and the concentration of inhibitor, where PMA is 
shown to have an extremely significant effect, but the effect of inhibitors is not significant. In 
addition, *** P< 001 when compared to the respective 0 nM PMA (DMSO control) controls using 
two-tailed, unpaired Student t-tests. Original magnification x 400, scale bar represents 10 µM. 
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Figure 57. Inhibitors have an effect on cell size in the presence of PMA on a fibrinogen­coated 
surface. MEG-01 cells were cultured in the presence of either 10 nM PMA or a vehicle control 
(0.001 % DMSO v/v) with either 100 �M D-AP5 or 100 �M MK-801 over 3 d (method 2, section 
2.3.2.1). Photographs were then taken of the cells (5-8 per treatment combination), measured and 
analysed as described in section 2.3.2.1. Representative pictures of MEG-01 cells treated for 3 d 
with either DMSO (0.001 % v/v) or 10 nM PMA in the presence and absence of either 
100 µM D-AP5 (AP) or 100 µM MK-801 (MK) on a fibrinogen-coated surface are shown above. 
These illustrate that the presence of PMA over 3d increase the size of the cells, which also become 
more irregular in shape but are fewer in number than those treated with DMSO. The addition of 
the inhibitors (inhib) does not appear to further affect the shape of the MEG-01 cells. The 
histogram illustrates pooled data from 3 separate experiments. Co-addition of NMDAR inhibitors 
attenuates the increase in cell size with significance achieved for MK-801 in both conditions 
(DMSO or PMA) and for D-AP5 in control DMSO treated MEG01 cells. *** P< 0.001 using a 
two-way ANOVA with Bonferroni post-hoc test comparing the effects of PMA and the presence of 
the inhibitors, showing that the addition of PMA has an extremely significant effect; also 
*** P< 0.001 using two-tailed, unpaired Student t-test comparing the pair of bars for each inhibitor 
treatment i.e. saline with 0 nM PMA (DMSO control) to saline with 10 nM PMA. ΔΔ P< 0.01 
using a one-way ANOVA with Dunnetts post-hoc test comparing data with their respective baseline 
controls (either saline with 0 nM PMA (DMSO control) or saline with 10 nM PMA). Original 
magnification x 400, scale bar represents 10 µM. 
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Figure 58. Culturing MEG­01 cells in the presence of fibrinogen leads to a reduction in cell 
size when PMA is also present. Comparing the changes in cell size and shape when MEG-01 cells 
-1 
are cultured in the presence and absence of 100 ng ml fibrinogen (fib) for 3 d. The representative 
photographs demonstrate that in both cases, cells treated with DMSO remain spherical with regular 
membranes, while those treated with PMA become larger, and less regular in shape. The histogram 
illustrates that the increase in cell size when MEG-01 cells are cultured with PMA is maintained 
2
when fibrinogen is present (134.37 ± 14.19 �m ). However, this increase in size is reduced when 
2
MEG-01 cells are cultured without fibrinogen (246.49 ± 25.32 �m ). *** P< 0.001 compared to 
each - fibrinogen control, ΔΔΔ P< 0.001 compared to 0 nM PMA control for either with or without 
fibrinogen, both using unpaired, two-tailed Students t-tests. 
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PMA 
Inhibitor 
- + 
- 170.51 ± 5.69 304.88 ± 13.00 
D-AP5 148.65 ± 4.76 302.94 ± 12.35 
MK-801 119.17 ± 3.46 242.56 ± 10.43 
Cell size (µm
2
) 
Table 42. Comparing the effects of the NMDAR inhibitors, MK­801 and D­AP5, on the size of 
2
MEG­01 cells (µm ) in the presence of fibrinogen and the presence and absence of PMA for 
3 d. 
5.3.4. MEG­01 cell adhesion studies 
Previous studies have demonstrated that NMDAR function is critical for PMA-mediated 
MEG-01 cell adhesion, which was repeated using the CMK cell line to ascertain that this 
result was not particular to the MEG-01 cell line (Genever et al, 1999). This earlier study 
use the crystal violet adhesion assay to demonstrate that adhesion of both MEG-01 and 
CMK cells are increased in the presence of PMA using the crystal violet adhesion assay, 
and that this increase can be inhibited by the addition of increasing concentrations of either 
MK-801 or D-AP5 (Genever et al, 1999). These experiments were performed using 
96-well plates, which following the original study were not coated with an adhesion 
protein. This study has been extended to investigate the functional involvement of 
NMDAR in MEG-01 cell adhesion to fibrinogen-coated surfaces, which mimic conditions 
in the vascular sinusoids towards which MKs migrate as they differentiate in the bone 
marrow (Larson and Watson, 2006). Initially, the original study was repeated with 
MEG-01 cells, followed by an investigation into the action of NMDAR antagonists on 
fibrinogen-dependent cell adhesion. 
5.3.4.1. NMDAR inhibition potentiates MEG­01 cell adhesion to uncoated 96­well plates 
For each condition, increasing concentrations of NMDAR antagonists (MK-801 or 
D-AP5), were added to the MEG-01 cell culture. Adhesion was measured using a crystal 
violet assay which measures the absorbance of crystal violet taken up adherent MEG-01 
cells which remain after non- and loosely adherent cells are washed off. The dye is then 
released from the cells by treatment with a citric acid solution, and the absorbance 
measured at 570 nm (section 2.7; Genever et al, 1999). The crystal violet adhesion assay 
5 -1
was performed using 96-well plates with an initial cell density of 2.4 x 10 ml , with either 
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no inhibitors or combinations of PMA, MK-801 and D-AP5. The results from 3 separate 
experiments were pooled and demonstrate that the presence of PMA increases adhesion 
where absorbance increases from 0.093 ± 0.016 to 0.22 ± 0.037 in the presence of PMA 
(figure 59A). The addition of D-AP5 has no effect on absorbance in the absence of PMA. 
However, culturing MEG-01 cells in the presence of both PMA and D-AP5 increases 
MEG-01 adhesion where the absorbance increases from 0.22 ± 0.037 with PMA alone to 
0.39 ± 0.043 with co-addition of 10 �M D-AP5 (figure 59B). 
The addition of MK-801 together with PMA also causes an increase in absorbance above 
that with PMA alone, but only at 100 �M MK-801 (0.21 ± 0.037 with PMA alone, 
increasing to 0.29 ± 0.045 with MK-801). This is mirrored in the absence of PMA, where 
only the addition of 100 �M MK-801 stimulates an increase above control (0.093 ± 0.12 
increasing to 0.15 ± 0.024). There is no effect with other concentrations of MK-801. 
To determine whether the presence of PMA or either inhibitor had an adverse effect on total 
cell number, matching plates were set up at the same time with the same combinations of 
4 -1
PMA and inhibitor concentrations and the same cell density (2.5 x 10 cells well ). This is 
important to ensure that changes in cell adhesion do not reflect a change in total cell 
number. After 3 d, the cells were removed using 0.5 % trypsin/ EDTA and counted using a 
haemocytometer (section 2.3.2.1.2.). The addition of either inhibitor had a small effect on 
total cell number in the absence of PMA, or with MK-801 in the presence of PMA. In 
contrast, the inhibition stimulated by PMA was mitigated by the addition of 10 µM D-AP5 
4 3 -1 4 3 -1 
(2.3 x 10 ± 2.8 x 10 cells well increasing to 4.8 x 10 ± 6.8 x 10 cells well
respectively) (figure 59C). Overall, the presence of PMA increases adhesion while 
decreasing cell number, with a trend towards a decrease in cell number observed with the 
highest concentrations of NMDAR antagonists in the absence of PMA. 
5.3.4.2. NMDAR inhibition attenuates fibrinogen­dependent MEG­01 cell adhesion 
Crystal violet adhesion assays were repeated using fibrinogen-coated plates with a cell 
4 -1 
density of 1 x 10 cells ml with the same combinations of PMA, MK-801 and D-AP5 as 
previously described (section 5.3.3.1). The data from 3 separate experiments was pooled 
and the effect of fibrinogen on adhesion compared in the presence and absence of PMA 
(figure 60). This demonstrates a small increase in adhesion above the baseline in the 
absence of PMA, where DMSO treatment without fibrinogen produced an absorbance 
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reading of 0.093 ± 0.012 which increased to 0.13 ± 0.0046 when the cells were cultured in 
the presence of fibrinogen. The presence of PMA also leads to an increase in adhesion, 
where absorbance increases to 0.22 ± 0.037 in the absence and 0.28 ± 0.026 in the presence 
of fibrinogen respectively. This indicates that the presence of fibrinogen increases 
MEG-01 adhesion in both the presence and absence of PMA. 
The addition of the inhibitors MK-801 or D-AP5 were shown to have no effect on the 
adhesion of MEG-01 cells when cultured in a fibrinogen-coated 96-well plate in the 
absence of PMA (figures 60A and B). The increase in adhesion induced by the addition of 
PMA, is shown to be reduced by the presence of either inhibitor. D-AP5 induces inhibition 
at 1 and 10 �M concentrations, causing the absorbance measured to decrease from 
0.28 ± 0.026 with PMA alone to 0.21 ± 0.014 and 0.19 ± 0.014 respectively. D-AP5 at 
100 �M has no effect on absorbance in the presence of PMA. MK-801 has an overall 
inhibitory effect on MEG-01 cells cultured in the presence of PMA and fibrinogen. This is 
shown to be dose dependent (figure 61B), with the largest decrease in absorbance 
demonstrated with 100 �M MK-801 (PMA alone, 0.28 ± 0.026 decreasing to 0.19 ± 0.015 
with 100 �M MK-801; P< 0.01). 
As previously described in section 5.3.3.1., paired plates were set up at the same time as 
4
those for the crystal violet adhesion assay, with the same numbers of cell per well (1 x 10 ) 
and concentrations of PMA, MK-801 and D-AP5, to determine whether changes in 
absorbance are not a reflection of changes in cell number. As previously (figure 59), the 
presence of PMA when culturing MEG-01 cells prevents an increase in cell number, with 
4 -1 
cells cultured in the absence of PMA increasing from 1 x 10 cells well when the plates 
4 3 -1
were plated to 1.9 x 10 ± 2.3 x 10 cells well , in comparison to those cultured with PMA 
4 3 -1
(0.90 x 10 ± 3.2 x 10 cells well ) (figure 61C and D). This pattern is similar to that of 
MEG-01 cells cultured in the presence and absence of PMA without fibrinogen, where 
DMSO-treated cells increase in number over 3 d in culture, with no change observed in the 
-1 
number of cells well when treated with PMA (figure 59C and D. 
The addition of D-AP5 to DMSO-treated control cells stimulated an increase in cell number 
above that of just DMSO-treated cells with the largest increase with 1�M D-AP5, from 
4 3 -1 4 3 -1 
1.9 x 10 ± 2.3 x 10 cells well to 2.7 x 10 ± 3.7 x 10 cells well (figure 61C). The 
presence of MK-801 also induced an increase in cell number above that of control cells, 
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4 3 -1

with the largest increase again with 1 �M (DMSO alone, 1.9 x 10 ± 2.3 x 10 cells well ; 
4 3 -1

DMSO with 1 �M MK-801, 2.7 x 10 ± 5.6 x 10 cells well ) (figure 61D). The number of 
-1 
cells well then decreases with increasing concentration of both inhibitors towards that of 
4 3 -1

the DMSO-only treated cells (DMSO alone, 1.9 x 10 ± 2.3 x 10 cells well ; 
4 3 -1

100 �M D-AP5, 2.5 x 10 ± 3.8 x 10 cells well ; 100 �M MK-801,

4 3 -1

1.9 x 10 ± 3.0 x 10 cells well ). Together this indicates that both inhibitors have an 
inhibitory effect at specific concentrations on the adhesion of MEG-01 cells cultured in the 
presence of fibrinogen and the absence of PMA, with peak increases in cell number 
observed at 1 �M of both D-AP5 and MK-801. 
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Figure 59. PMA increases adhesion of MEG­01 cells and inhibits cell proliferation, with 
differing actions of inhibitors in the absence of fibrinogen. MEG-01 cells were treated with 
either 10 nM PMA or vehicle control (0.001 % v/v DMSO) for 3d in culture at a density of 
4 -1 
2.4 x 10 cells well (section 2.8) in the presence of increasing concentrations of either D-AP5 or 
MK-801. A, B, Illustrates the differences in adhesion in the presence or absence of PMA. In 
DMSO treated cells (control cells; solid black bars), the addition of D-AP5 has no effect on 
absorption, however the presence of 100 �M MK-801 leads to an increase of 0.079 ± 0.027 above 
the DMSO-only control. In comparison, there is a significant increase in adhesion above baseline 
with the addition of PMA alone and in combination with both inhibitors. The increase in absorption 
with D-AP5 is greatest with 10 �M D-AP5 at 0.17 ± 0.057 above the PMA control with the addition 
of MK-801 leading to an increase in adhesion with 100 �M MK-801 to 0.074 ± 0.059 above the 
PMA control. C, D, Parallel plates were set up at the same time as those for the crystal violet 
adhesion assays and cultured for 3 d with the same combinations of PMA and inhibitor 
concentrations. The cells were removed from the plates with 0.5 % trypsin/ EDTA and counted 
using a haemocytometer. These figures illustrate the total number of cells in each well after 3 d 
4
without fibrinogen. At day 0, 2.4 x 10 cells were plated into each well. All control cells (without 
PMA; solid black bars), both with and without inhibitors, increased in number over 3 d. In 
4 -1 
comparison, the number of PMA-treated cells did not increase above 2.4 x 10 cells well with any 
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combination of MK-801. The addition of PMA together with D-P5 at 1 and 10 �M concentrations 
leads to increases above that of PMA alone, peaking at 10 �M D-AP5 with an increase of 
4 3 -1 
2.5 x 10 ± 7.4 x 10 cells well above PMA control cells. Δ P< 0.05 compared to 0 µM inhibitor in 
combination with either 0 µM or 10 µM PMA using a one-way ANOVA with a Dunnetts post-hoc 
test. * P< 0.05, ** P < 0.01. *** P < 0.001 using a two-way ANOVA with a Bonferroni post-hoc 
test comparing the 2 sources of variation in the data (DMSO/ PMA and concentrations of 
inhibitors), where the stars refer to differences found by the post-hoc test between the DMSO and 
PMA mean data for each concentration of inhibitor. In all figures, the two-way ANOVA shows that 
the effect of PMA on the results is extremely significant, with the presence of D-AP5 having a 
significant effect on the results. MK-801 was shown to have no effect. 
Figure 60. Fibrinogen increases adhesion of MEG­01 cells in the presence and absence of 
PMA. This illustrates the changes in adhesion (measured by crystal violet absorbance at 570 nm) 
caused by the presence of fibrinogen during culture, and represents the pooled data from unpaired 
separate experiments with each condition repeated in triplicate in all experiments (n=3 ± S.E.M.). It 
demonstrates that the presence of fibrinogen induces an increase in absorption of 0.036 ± 0.012 in 
the absence and an increase of 0.068 ± 0.046 in the presence of 10 nM PMA. ** P< 0.01, 
*** P< 0.001, compared to the respective control using an unpaired, two-tailed Students t-test. 
∇ P< 0.05 compared to–fibrinogen with 0 nM PMA using an unpaired, two-tailed Students t-test. 
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Figure 61. PMA increases adhesion of MEG­01 cells and inhibits cell proliferation, with 
differing actions of inhibitors in the presence of fibrinogen. MEG-01 cells were treated with 
either 10 nM PMA or vehicle control (0.001 % v/v DMSO) for 3d in culture (section 2.8) in the 
presence of increasing concentrations of either D-AP5 or MK-801 on a fibrinogen-coated surface. 
A, B, Illustrates the decrease in adhesion with increasing concentrations of either D-AP5 or 
MK-801 in combination with 10 nM PMA when MEG-01 cells are cultured on a fibrinogen-coated 
surface. The decrease in absorption from that induced with PMA alone is greatest with 
10 �M D-AP5 (0.091 ± 0.030) and 100 �M MK-801 (0.089 ± 0.035). The presence of either 
inhibitor has no effect on cells treated with DMSO. C, D, Parallel plates were set up at the same 
4 -1
times as those for the crystal violet adhesion assay at a density of 1 x 10 cells well , and cultured 
for 3 d with the same combinations of PMA and increasing inhibitor concentrations. The cells were 
removed from the plates with 0.5 % trypsin/ EDTA and counted using a haemocytometer. These 
figures illustrated the total number of cells per well after 3 d in culture in the presence of fibrinogen. 
A lower cell density was used compared to when cells were cultured in the absence of fibrinogen, 
due to cells forming large clumps in the wells and becoming fully confluent within 1.5- 2 d. 
Therefore the starting cell density was decreased. Cells treated with PMA both with and without 
4 -1 
inhibitor remained static at approximately 1.0 x 10 cells well . DMSO-treated cells approximately 
double in number, with a further increase induced by the addition of D-AP5 of around 
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3 3 -1

7.5 x 10 ± 4.0 x 10 cells well . The addition of 1 �M MK-801 evokes a mean increase of 
3 3 -1

7.7 x 10 ± 6.0 x 10 cells well , with increasing concentrations of MK-801 appearing to decrease 
-1 4 3 -1

the number of cells well back to that induced with DMSO alone (1.9 x 10 ± 2.3 x 10 cells well ). 
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5.4. Discussion 
The aim of this chapter was to determine which NMDAR subunit proteins were expressed 
by the human megakaryoblastic cell line, MEG-01, and if they are, whether NMDARs play 
a role in MK differentiation and adhesion. 
5.4.1. MEG­01 differentiation 
Two published methods for MEG-01 differentiation were compared (section 2.3.2.1), of 
which Nagata et al (1996) (method 1), determined both morphological and ultrastructural 
changes, and Lacabaratz-porret et al (2000) (method 2), demonstrated increases in GPIIIa 
(CD61) expression upon treating the cells with PMA; these changes are all indicative of 
MK differentiation (Genever et al, 1999). In this study, changes in cell size and shape were 
being investigated, therefore a method was required in which observable and measureable 
changes in both of these characteristics could be determined. It was established that 
method 2, with the higher density of MEG-01 cells treated for 3 d with PMA, induced the 
greater change in both cell size and shape, and was therefore used for further investigation 
into MEG-01 cell differentiation (figure 51). 
5.4.2. MEG­01 expression of NMDAR subunits 
It was demonstrated that undifferentiated MEG-01 cells express the NR1 subunit protein, 
but do not appear to express the NR2A or NR2D subunit (figures 43-44). Both the NR1 
and NR2D subunit proteins are expressed by human platelets (figures 13 and 15), the 
terminal stage of MK differentiation, which suggests that the NMDAR subunit protein 
expression alters during differentiation. NR2A subunit proteins are potentially expressed 
by PMA-differentiated MEG-01 cells. 
The expression of NMDAR subunit mRNA has previously been investigated in 
undifferentiated MEG-01 cells which have been shown to express the NR1, NR2C, NR2D 
and NR3 subunits (Genever et al, 1999; Hitchcock, 2003). This has been repeated in bone-
marrow derived MKs which express the NR1, NR2A and NR2D subunit mRNA 
(Hitchcock et al, 2003). In this study, the expression of mRNA for NR1, NR2A-C and 
NR3A was investigated and it was demonstrated that none of these subunits appear to be 
expressed in undifferentiated MEG-01 cells (figure 50). The contradicts the mRNA 
evidence in the literature and demonstrates a discrepancy with the protein expression data 
which illustrates that the NR1 subunit protein is expressed in undifferentiated MEG-01 
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cells (figure 46; Genever et al, 1999). One factor to take into account is that the NR1 
subunit has 8 different splice variants, and whether the antibodies and primers used in both 
studies detect different splice variants. However, the same anti-NR1 antibody was used in 
both my study and that carried out by Genever (1999) and is targeted to the extracellular 
region between the transmembrane M3 and M4 domains, which is conserved between 
splice variants (Smothers and Woodward, 2009). Different primers were used in each 
study, and while they are targeted to different regions of the N-terminus, they are both 
conserved between the splice variants. Differences in the efficacy between the two 
different primer sets could be tested in parallel using the same undifferentiated MEG-01 
sample to ascertain if the variation in results between studies is due to primer design or 
another factor. The presence of different NR1 splice variants in transfected HEK923 cells 
have been demonstrated to have varied effects on NR1/ NR3 receptors (Smothers and 
Woodward, 2009), and another extension of this project could be to determine which splice 
variants are expressed in MEG-01s and native MKs, and therefore also in platelets, and any 
functional differences this causes. 
As such, differences in splice variant detection does not explain the apparent expression of 
NR1 protein together with the lack of mRNA expression in the undifferentiated MEG-01 
cells. It is clear from my study that two different NMDAR antagonists (MK-801 and 
D-AP5) can alter MEG-01 function strongly indicating the expression of functional 
NMDARs. Future studies should investigate the selectivity of anti-NR1 antibodies for NR1 
protein and compare binding with anti-NR1 antibodies with different epitopes on the 
protein. In addition, the half-life of all the NMDAR subunit mRNA (NR1, NR2A-D and 
NR3A and B), in MEG-01 cells should be measured and compared to that of their 
respective proteins. 
5.4.2.1. PMA­induced MEG­01 expression of NMDAR subunits 
Following PMA-treatment of MEG-01 cells in this study, the NR1 and potentially the 
NR2A subunit proteins were detected, suggesting increased NR2A expression during 
MEG-01 differentiation. RT-PCR was not carried out on differentiated MKs in this study, 
however Hitchcock (2003) has demonstrated that expression of the NR2A and NR2C 
subunit mRNA increases following PMA-treatment, while NR2D expression remains static 
and neither NR2B nor NR3 subunits are detected. This rise in NR2A mRNA expression 
illustrated by Hitchcock (2003) mirrors the possible increase in NR2A protein expression 
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demonstrated in this study (figure 53). An extension to this would be to determine whether 
these increases occur in parallel by repeating the experiment and taking paired samples for 
Western blot and RT-PCR. Changes in receptor functionality could be investigated by 
electrophysiology, and localisation of receptor subunits can be determined using 
immunostaining to compare differences between differentiated and undifferentiated 
MEG-01 cells. Obtaining new primers for the NR2D and NR3B subunit mRNAs would 
also assist in determining changes in expression before and after differentiation. 
Differences in levels of protein expression of the NR1 subunit have been demonstrated 
between not only different platelet donors, but also between platelet donors and untreated 
MEG-01 cells (figure 52). This variation may reflect the differences in the surface area to 
volume ratio between platelets and MKs. Alternatively, higher expression of NR1 in 
platelets may indicate that NR1 expression increases during MK differentiation, however 
densitometry analysis demonstrated that treatment with PMA for 3 d had no effect on NR1 
subunit protein expression (figure 55). This suggests that expression of the subunit protein 
has either peaked by the megakaryoblastic stage of differentiation, that NR1 expression 
increases at a later stage closer to platelet production or that expression increases within the 
mature platelets themselves. The higher expression in human platelet indicates that further 
mRNA and protein expression studies are required using primary MKs to evaluate the 
receptor expression profile during differentiation. 
Finally, these experiments should be extended to investigate the expression of NR2 
subunits in differentiated MEG-01 cells as well as primary human MKs. In Western blot 
studies, the expression of NR2A appears to be increased upon PMA differentiation (figure 
53) and these results correlate with previous studies reporting the up regulation of NR2A 
mRNA expression upon PMA differentiation of (Hitchcock 2003). It is important to 
understand the NR2 expression profile in the differentiated MKs due to the contribution of 
the NR2 subunits to NMDAR pharmacology. To date, evidence suggests expression of 
NR2A and/or NR2D subunits from this study and previous reports in the literature. These 
NR2 subunits convey different properties to the assembled NMDAR. For example a 
2+ 
stronger stimulus is required to remove the Mg blocking the NMDAR pore if the NR2A 
subunit protein is present, than if the NR2D is present (Qian and Johnson, 2006; Clarke and 
Johnson, 2006). Additionally, affinity of MK-801 is greater for NR1/NR2A than 
NR1/NR2D containing receptors (Laurie and Seeburg, 1994).  Electrophysiological 
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measurements of NMDA-gated ion channels and calcium imaging will provide further 
insight into the pharmacological properties of the MK NMDA receptor and may distinguish 
between the different NMDAR assemblies. 
Table 43. Temporal profile of NMDAR subunit expression during haematopoiesis. Using data 
from this study, this figure compares the expression of the NR1, NR2 and N3 subunits. Expression 
of the NR2A subunit was not determined in either immature MKs (MEG-01 cells) or in platelets. 
Blue bars indicate protein expression as demonstrated in this study, darker blue bars indicate protein 
expression determined in previous studies (Morrell et al, 2008; Sun et al, 2009). Yellow bars 
indicate mRNA expression which was determined in other studies- NR1 in Meg-01 cells, NR2A in 
native human MKs, NR2C and NR2D in MEG-01 cells and native human MKs, GluR5 and 6 in 
MEG-01 cells (Genever et al, 1999; Hitchcock et al, 2003; Hitchcock, 2003; Sun et al, 2009). 
5.4.2.2. MEG­01 adhesion, cell size and morphology 
This study has demonstrated that NMDARs are required for fibrinogen-dependent 
MEG-01 adhesion. A previous study investigated whether functional NMDARs are 
required for the adherence of 2 different MK cell lines, MEG-01 and CMK, to tissue culture 
plastic (Genever et al, 1999). Adherence was detected using a crystal violet assay, and 
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shown to be inhibited by NMDAR specific inhibitors, MK-801 and D-AP5 in the presence 
of PMA. This work has been extended to investigate the role of NMDARs in MEG-01 cell 
adherence to fibrinogen as well as tissue culture plastic. It demonstrated that in contrast to 
the study by Genever et al (1999), the addition of the inhibitors potentiated adhesion to 
tissue culture plastic, while in the presence of fibrinogen NMDAR specific inhibitors 
attenuated adhesion (figures 59 and 61). 
Cell number was also investigated in parallel with the crystal violet assays, which 
demonstrated that PMA inhibits any increase in cell density above that plated at the start of 
the experiment, after 3 d in culture, whether cultured on fibrinogen or tissue culture plastic 
(figures 59 and 61). This has previously been observed in both MEG-01 cells (Ogura et al, 
1998; Meacci et al, 1996) and another megakaryoblastic cell line, HEL (Zauli et al, 1995). 
PMA has been demonstrated to differentiate both native MKs and megakaryocytic cell lines 
(Nagata et al, 1996; Goto et al, 1992; Genever et al, 1999), where one differentiation 
marker is that MKs cease to proliferate, instead increasing in size and moving towards 
platelet production (Hitchcock et al, 2003). This was observed in both the presence and 
absence of fibrinogen (figures 59 and 61), demonstrating that PMA is sufficient to stimulate 
differentiation alone without the additional presence of other differentiation triggering 
factors. 
The presence of the inhibitors had mixed effects on cell number with D-AP5 (10 µM) 
leading to an increase in cell number in the presence of PMA but absence of fibrinogen 
(figure 59C). In comparison, the presence of fibrinogen and absence of PMA, 1 µM 
D-AP5 stimulates an increase in cell number which is then inhibited as the concentration of 
D-AP5 increases (figure 61C). MK-801 was found to have an inhibitory effect on MEG-01 
cells cultured on fibrinogen without PMA at 100 µM, whereas lower concentrations 
stimulated increases in cell numbers (figure 61D). These experiments were not carried out 
in parallel, therefore this would need to be repeated to determine whether they are 
comparable, however they suggest that the presence of NMDAR specific inhibitors only 
have an inhibitory impact on cell density at higher concentrations (100 µM) in the presence 
of fibrinogen and absence of PMA. The previous literature would suggest however that 
their presence would inhibit the effects of the PMA, therefore halting differentiation and 
stimulating proliferation (Hitchcock et al, 2003). 
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Changes were also observed in the size of MEG-01 cells between those which had been 
cultured on fibrinogen and those on tissue culture plastic (figure 58). The cells cultured on 
fibrinogen were found to be smaller than those cultured on tissue culture plastic both in the 
presence and absence of PMA. The addition of NMDAR-specific inhibitors had no effect 
on cell size in either the presence or absence of fibrinogen (figures 56 and 57). The only 
differences in cell shape were observed between MEG-01 cells treated with PMA or the 
vehicle control, DMSO. DMSO-treated cells remained spherical and mostly in suspension, 
with PMA-treated cells becoming more irregular in shape and with a larger number 
appearing to adhere to the cell culture flask. Again, the addition of the inhibitors had no 
effect on these changes in cell morphology. These findings are in contrast to both original 
papers; Genever et al (1999) demonstrates by flow cytometry that MK-801 inhibits the 
increases in both cell size and CD41 expression induced by PMA, and Hitchcock et al 
(2003) that MK-801 inhibits morphological changes induced by TPO in CD34
+ 
MKs, for 
example increasing cell size and demarcation membrane together with formation of 
proplatelets and development of a multilobed nucleus. The variation between the results 
obtained in this study and those of the original studies require further investigation. 
The crystal violet dye used in the adhesion assay binds to DNA and as the number of 
adherent cells increases, the amount of dye binding increases (Yang et al, 2001). During 
MK differentiation, the ploidy of the cells and therefore the amount of DNA within the 
cells increases, potentially leading to an increase in absorption that is not proportional to an 
increase in cell number. Other assays are therefore required to determine whether the 
effects seen are due to changes in ploidy or are in fact due to the action of the inhibitors, for 
example calcein-AM, a membrane permeable dye which becomes trapped in the cytoplasm 
of viable cells following cleavage of the AM group by non-specific esterases (Braut-
Boucher et al, 1995). This would bypass the reliance on DNA-binding, removing the 
possibility of variations in ploidy affecting the results obtained. 
Fibrinogen binding plays a role both in MK differentiation and in thrombus formation, with 
MKs binding to fibrinogen within the sinusoids such that they are able to anchor and extend 
proplatelets into the blood stream (Wang et al, 1998). The αIIbβ3 integrin requires 
activation before it is able to bind fibrinogen, and in the sinusoids this is provided by the 
binding of TPO or SDF (Majka et al, 2000). Fibrinogen also has a role in the coagulation 
cascade, where it is converted to fibrin by the action of FXa and FVa (figure 3) as well as in 
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the formation of platelet aggregates when it is released from α-granules upon platelet 
activation. It is possible that glutamate released by osteoclasts would be available to MKs 
and through binding to NMDARs, could then activate the integrin stimulating fibrinogen 
binding and anchoring of the MK in the sinusoids. A recent study has demonstrated that 
glutamate release also occurs in MKs through a SNARE (soluble NSF (N-ethylmaleimide 
sensitive factor))-dependent mechanism, which has been highly characterised in 
presynaptic neurones (Thompson et al, 2010). One difference between the two systems is 
that SNAP25 is expressed only in excitable cells, with SNAP23 present instead in 
non-excitable cells, and shown in the study by Thompson et al (2010) to be expressed in 
both MEG-01 cells and human MKs. Other proteins involved in vesicle-membrane fusion 
have also been identified in these cells including VAMP (vesicular associated membrane 
protein; also known as synaptobrevin) and syntaxin 4 (Thompson et al, 2010). These are 
all required to form the SNARE attachment protein receptors which are implicated in 
tethering of the vesicle to the cell membrane. PMA-differentiated cells were found to 
release higher levels of glutamate than undifferentiated MEG-01s or human MKs, and it is 
suggested that they release glutamate spontaneously unlike neurones which require 
depolarisation (Thompson et al, 2010). 
This study could be extended by investigating the role of extracellular matrix proteins, for 
example collagen, and whether binding by MKs is affected by NMDAR activation or 
inhibition. It has previously been suggested that pre-treatment of human platelets with 
2+ 
NMDA inhibits AA-induced Ca influx into the cells, and potentiates the inhibition 
induced by the COX inhibitors ASA and indomethacin (Franconi et al, 1998). This could 
be extended by investigating whether pre-treatment with NMDA has similar effects in 
MKs, for example comparing the results obtained from a cell line to those using primary 
MKs. 
Recent studies have shown that KARs and AMPARs are present on human platelets, and 
that activation of both receptors plays a role in platelet activation and aggregation (Morrell 
et al, 2008; Sun et al, 2009). Functional AMPARs have been shown to be expressed in 
bone marrow-isolated MKs using electrophysiology, together with functional KARs 
(Morrell et al, 2008). This suggests that these receptors may also play a role in MK 
differentiation, for example they may collaborate with NMDARs in the adhesion of MKs to 
fibrinogen, which would assist in tethering in the sinusoids, or potentially play a role in 
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maintaining MKs in the bone marrow. These possibilities require further investigation, but 
it also suggests that different iGluRs could play a combined role in MK differentiation, 
particularly given the differences in their ion permeability, with NMDARs permeable to 
both Ca
2+ 
and Na
+ 
whereas AMPA and KARs are permeable to Na
+ 
(Dingledine et al, 
1999). 
5.4.3. Overall conclusions and clinical relevance 
This study has demonstrated that the NMDAR subunit NR1 is expressed in the 
megakaryoblastic cell line MEG-01, and that treatment with PMA to stimulate 
differentiations does not appear to alter the expression of the NR1, NR2A or NR2D 
subunits. It has also shown that NMDARs are implicated in MEG-01 cell adhesion to 
fibrinogen, have a potential role in changes in cell size in the presence of fibrinogen, but 
not in changes to cell shape. This requires further investigation to determine whether 
changes in subunit expression occur during later stages of differentiation than that obtained 
by 3 d of PMA differentiation or whether it occurs within platelets themselves (figures 52 
and 54). A previous study has also indicated that the NR2A subunit is expressed at the 
mRNA level in bone-marrow derived MKs, but expression has not been determined of the 
NR2A protein or mRNA in MEG-01 cells. Further investigations are required to determine 
differences between expression of the NMDA subunit proteins in the MEG-01 cell line and 
in native MKs as well as the presence of mRNA. Variation has been seen in subunit 
expression in different human donors (figures 13 and 15) indicating that studies would have 
to be carried out on MKs obtained from several different donors to take this variation into 
account. 
This work could be further extended by investigating the functional expression of 
NMDARs in platelets from patients with disorders in platelet production, for example 
8 -1 
thrombocytopenia where the platelet count is significantly reduced (below 1 x 10 ml ; 
Kaushansky et al, 1995) and sufferers experience spontaneous, prolonged bleeding for 
example, from the nose or gums (Bussel et al, 2009). NMDARs have been demonstrated in 
a previous study to play a role in MK differentiation through inhibition of proplatelet 
formation and increases in cell size indicative of MK differentiation in the presence of an 
NMDAR inhibitor, MK-801 (Hitchcock et al, 2003). It would therefore be interesting to 
determine whether the expression of NMDARs in these disorders is functionally 
compromised, expression reduced, or whether polymorphisms of the receptors are 
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expressed whose functionality is detrimentally affected. Variation in expression of the 
NR1 and NR2D subunit proteins was illustrated in this study (figure 13 and 15), showing 
that expression is not uniform between donors. Donors could also be separated into 
responders and non-responders, adding another facet to the variability (figures 17 and 33). 
Therefore a number of both patients and control donors would be required to take into 
account donor variation. This study could also be extended using animal models in which 
platelet production is compromised for example through deletions of Ets-1 or Fli-1 found in 
Paris-Trousseau syndrome (Raslova et al, 2004), to investigate changes in NMDAR 
expression in both the platelets and in the MKs.  NMDAR expression has been 
demonstrated to be maintained in the absence of c-mpl expression in mice (Hitchcock et al, 
2003), illustrating that a reduction in the ability to bind TPO, the primary regulator of MK 
differentiation, does not affect NR1 expression, however it was not determined whether 
functional receptors were formed. Therefore, NMDARs are implicated not only in the 
differentiation of MKs, platelet production and platelet activation, but also potentially in 
diseases characterised by reduced platelet numbers. 
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In this study the NR1 subunit protein has been shown to be expressed in MEG-01 cells, 
with human platelets found to express the NR1, NR2D and NR3 subunit proteins. There is 
evidence that at least 1 other NMDAR subunit protein is expressed in MEG-01 cells, as 
when they are cultured on fibrinogen for 3 d with MK-801, the cells are significantly 
smaller in size than the control cells, and the presence of MK-801 has been found to inhibit 
MEG-01 cells adhesion (figures 57 and 61). Functional NMDARs can not be formed 
solely of NR1 subunits, therefore NR2 and/ or NR3 subunits proteins must also be 
expressed. The observation that this effect only occurs when MEG-01 cells are cultured on 
fibrinogen suggests that these results are indicative of a functional role for NMDARs in the 
end stages of MK differentiation. Fibrinogen lines the blood sinusoids to which MKs 
migrate towards the latter stages of differentiation, which in this study is mimicked by the 
fibrinogen coating of tissue culture vessels. The inhibitory effect of MK-801 on MEG-01 
cell size is suggestive that NMDARs also have a role in slightly earlier stages of MK 
differentiation, as MKs cease to proliferate and increase in size as a preliminary step to 
platelet production. This was also suggested by Hitchcock et al (2003) where treatment 
with MK-801 inhibits increases in cell size together with the formation of proplatelets, α-
granules and a polyploidy nucleus. 
6.1. Receptor expression 
RT-PCR has demonstrated in earlier studies that undifferentiated MEG-01 cells express the 
NR1, NR2C and D and NR2 subunit mRNA (Genever et al, 1999; Hitchcock, 2003). In 
this investigation, primers were successfully designed for NR1 and NR2A-C subunits; a set 
for the NR3A subunit had previously been obtained. Two separate undifferentiated reverse 
transcribed MEG-01 samples were used to determine that at the time the samples were 
taken, the cells did not appear to express mRNA for any of the subunits tested (figure 50). 
Matched samples were not taken for both Western blotting and RT-PCR; implementing this 
would determine whether mRNA is expressed at the same time as the proteins of each 
subunit. This could be extended to investigate the NMDAR mRNA and proteins expressed 
by MEG-01 cells differentiated with PMA. There is evidence that NR2A mRNA 
expression increases following 3 d of PMA treatment (Hitchcock, 2003), and a possible 
increase in expression of the NR2A protein observed in this study (figure 53). Again, 
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matched samples would determine similarities and differences in timing of mRNA and 
protein expression. This would be assisted by the development of selective antibodies able 
to distinguish between the 2 NR3 subtypes, A and B, as well as obtaining another, cleaner 
anti-NR2A antibody and using a positive control in the Western blots, for example whole 
rat brain. 
6.2. NMDAR localisation 
The actions of NMDAR antagonists are restricted to the PMA differentiated MEG-01 cells. 
This maybe due to an increased expression of NR subunits, as described in the previous 
section, or an altered trafficking of NR subunits. NMDARs are known to be trafficked 
within cells, however most of the data has been obtained from work in neural cells, and 
would need to be repeated in MKs. NMDARs have been demonstrated to be highly mobile 
during in immature synapses, becoming less so once they mature (Lavezzari et al, 2004; 
Roche et al, 2001). Targeting of the subunits varies, with the NR2A subunit protein 
preferentially endocytosed via the early to the late endosomes, whereas the NR2 B subunit 
protein in more commonly recycled via the early endosomes back to the plasma membrane 
(Lavezzari et al, 2004). The activation of neuronal PKC has been demonstrated to induce 
rapid exocytosis of NMDARs to the plasma membrane (Carroll and Zukin, 2002), and the 
effect of PMA treatment on the localisation of NMDAR subunit proteins in MEG-01 cells 
could be investigated. Their movement could be tracked by labelling the different subunit 
proteins with antibodies labelled with different fluorescent tags and followed using live cell 
imaging, or alternatively following fixation at different time points after PMA treatment. 
Autoradiography using tritiated MK-801 could also be used which only binds to functional 
NMDARs, as not all clusters of NMDAR subunit proteins will form receptors (Genever et 
al, 1999). 
6.3. NMDAR expression during MK differentiation 
Native MKs are located in the bone marrow together with osteoblasts and osteoclasts which 
have been demonstrated to secrete glutamate (Morimoto et al, 2006; Rhangu et al, 2001). 
MKs have been found to take up glutamate via EAAT1 and store it in vesicles (Genever et 
al, 1999; Thompson et al, 2010), but it could also suggest that glutamate plays a role even 
earlier in differentiation than megakaryoblastic MEG-01 cells. It would therefore be 
informative to follow the expression of both the mRNA and protein for each NMDAR 
subunit from an earlier stage in development for example back to the progenitor cells, 
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HSCs, by setting up further differentiation experiments to determine when each subunit is 
expressed and therefore from which stage potentially functionally NMDARs could be 
present. This would require native MK cells or an early stage MK cell line so that changes 
in expression and cell morphology can be tracked through to the mature MK stage or even 
to platelet production. MK-801, D-AP5 and D-serine could also be used to determine the 
effects of NMDAR inhibition on MK differentiation. The part that NMDARs play in 
adhesion requires further work using a method which does not rely on a dye binding to 
nuclear material, for example calcein-AM, a cell permeable dye which remains within the 
cytoplasm making it a more accurate indicator of increases in adhesion than the dye used in 
this study, crystal violet, which binds to DNA. The DNA content of MKs increases during 
differentiation, potentially up to 128 N (Italiano et al, 1999), suggesting that the number of 
cells adhering is greater than it actually is; a cytoplasmic dye would negate this problem. 
6.4. Functional expression of NMDARs in human platelets 
The NMDARs expressed in human platelets have been demonstrated to be functional; 
activated by glutamate, glycine and NMDA; and inhibited by the receptor-specific 
inhibitors MK-801 and D-AP5, or the NR1/ NR3 inhibitor, D-serine. The data is not 
comparable between the fluo-4 and the luciferase assays, as different methods were used to 
isolate the platelets from the plasma for each assay. In future studies, the method used for 
the fluo-4 assay (section 2.7.) which has previously been published (Mackenzie et al, 1996) 
should be used for both assays. The experiments could be further improved by taking 
samples for Western blotting from the same platelet donation as that used for the assays so 
the functional results can be directly compared with the subunit proteins expressed at that 
time. If possible the assays should be carried out in parallel, as platelets taken from the 
same donor vary between each donation, which take place at least 28 d apart, and would 
increase the validity of the comparison. Previous studies have suggested that NMDARs 
play an anti-aggregatory role in human platelets (Franconi et al, 1996, 1998), however data 
obtained in this study demonstrated that the activation of NMDARs in potentially 
pro-aggregatory. Further study is required to investigate this, particularly experiments into 
the effect of treatment with NMDA prior to the addition of known pro-aggregatory agonists 
such as collagen and AA, which Franconi demonstrated had an inhibitory effect. 
Functional assays could be used alongside aggregation experiments to extend this 
investigation and examine more fully the role of NMDARs in platelet activation and 
aggregation. Glutamate release could be measured, for example using a fluorescence 
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detection assay (Sim et al, 2006) or an enzymatic probe (Morrell et al, 2008), and ATP 
release has previously been measured simultaneously with aggregation using a combined 
aggregometer and luminometer (Charo et al, 1977). In vivo work could investigate the 
effects of specific subunit knockouts or treatment of animal models with antagonists, to test 
the effects of NMDARs on bleeding time and thrombosis formation using induced injuries 
for example with ferric chloride (Morrell et al, 2008). A conditional knockout would be 
required for the NR1 subunit, as its absence during development is neonatally lethal (Li et 
al, 1994; Forrest et al, 1994). It would be informative to use similar conditional knockout 
models for the other NMDAR subunits to further determine their roles in adult systems. 
Treating human platelets with strychnine would determine whether inhibitory glycine 
receptors are also expressed and if so, whether they play a regulatory role in platelet 
activation. An NR2D antagonist has recently been developed, the use of which would also 
assist in determining the role of different subunits in platelet activation. 
6.5. S­nitrosylation of NMDARs 
NMDAR activity is known to be inhibited by S-nitrosylation through the binding of NO to 
specific cys residues in the extracellular regions of the NR1 and NR2A subunit proteins 
(Choi et al, 2000). Nitrosylation of the subunits has been detected in the brain using the 
biotin switch method (Jaffrey and Snyder, 2001). However, this is prone to producing false 
positives and can not be used in live cells (Jaffrey et al, 2001). A novel S-nitrosylation 
detection agent SNOB, has been developed at the University of Bath which can be used to 
detect nitrosylation of proteins in live cells and is a single step process (Appendix II). 
Initial optimisation was carried out using BSA which has only 1 free cys residue and 
demonstrated that SNOB could be used successfully at 37 
o
C at which only a 5 min 
incubation was required for binding to be detectable by Western blotting (figure 67). 
Human platelets were used to extend this optimisation as they are exposed to NO in the 
blood stream which is constitutively produced by eNOS located in the endothelium lining 
of the blood vessels (Dimmler et al, 1999), and proteins expressed on the surface of 
platelets are already known to be nitrosylated, for example αIIbβ3 (Walsh e al, 2007). It was 
therefore hypothesised that NMDARs on human platelet could be modulated by NO in the 
bloodstream. The data produced demonstrates that treatment with SNOB increases 
neutravidin-HRP binding, which can be increased further by treatment with NONOate, an 
NO donor, or reduced following treatment with DTT, a reducing reagent. The data 
obtained to date gives an overall view of nitrosylated proteins expressed on human platelets 
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which bind SNOB, however bands of approximately 120 kDa can be observed in figures 68 
and 70, suggesting that the NR1 subunit protein may be nitrosylated by treatment with 
NONOate. Identification of the nitrosylated proteins required further investigation, for 
example using immunoprecipitation. Determination of whether the NR1, and possibly the 
NR2A, subunit proteins are S-nitrosylated will then enable functional assays to be carried 
out, such as the fluo-4 assay to determine the action of NO on platelet activation. Platelets 
could be pre-treated with NONOate or DTT before the addition of glutamate or NMDA 
together with glycine to determine whether the responses are altered. The addition of DTT 
increases the number of free thiols and mimics the reduced oxygen levels within the body 
(hypoxia) in comparison to that of air in the laboratory (normoxia). This should increase 
the sensitivity of NMDARS to NO as all 5 extracellular cys residues will be exposed as free 
thiols as opposed to 1 under normoxic conditions. This effect could also be achieved by 
carrying out the assays in a hypoxic chamber, where NONOate could be added to simulate 
a localised increase in NO. 
6.6. Clinical relevance and overall conclusions 
There are extensive clinical applications for this further understanding of platelet and MK 
NMDARs. Their use as neuronal models would enable testing of new agonists or 
antagonists to determine their effects on native human cells without having to source 
human brain tissue, and availability would be much higher as would the range of donors 
from which samples could be taken. Platelet can not be transfected, however MKs can, 
enabling the production of platelets containing new proteins in vitro that can then be 
analysed. The identification of the NR3 subunit protein extends the similarity of platelets 
to the brain, enabling further investigation into the strychnine-insensitive, excitatory 
glycine receptor, which demonstrates an alternative signalling role for glycine in 
comparison to its other, more understood roles (Curtis et al, 1967). Further work is 
required to fully understand the complete role of NMDARs in MK differentiation and 
platelet activation, however this study provides a good initial step. 
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APPENDIX I

THROMBIN DOSE RESPONSE

Thrombin responses were detected in all donors, both those which responded to the agonist 
tested and those which did not. It was observed that responses to all of the agonists used in 
the fluo-4 assay desensitised over the duration of the experiments, therefore thrombin dose 
response data was also separated by time to determine whether this effect also occurred. 
Figure 62. Thrombin evokes an intracellular calcium response in human platelet which 
decreases over the duration of each experiment. *P< 0.05; **P< 001 in comparison to 0 �M 
thrombin using a one-way ANOVA with a Dunnetts post-hoc test. 
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The data is split into that obtained within the first 2 h of each experiment (A) and that 
obtained over 2 h from the start of the experiments (B). The figure demonstrated that 
-1 
responses to thrombin decrease for 0.3, 1 and 10 U ml over the course of each experiment, 
-1 
with a small increase in that elicited with 3 U ml (86.74 ± 6.27 rising to 
92.21 ± 14.49 % MR). It was decided that thrombin would be used as a positive control at 
-1 
3 Uml for the rest of the study. 
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APPENDIX II

NITROSYLATION

AII.1. Summary 
In this appendix, it has been demonstrated that S-nitrosylation binding (SNOB) reagents 
bind to platelet proteins where: 
- SNOB reactivity is time and temperature dependent 
- SNOB binding is increased by incubation of platelets with NO donors 
- SNOB binding is decreased by incubation of platelets with DTT, which is predicted 
to reduce S-nitrosylation. 
AII.2. Introduction 
AII.2.1. NMDAR S­nitrosylation 
NMDAR subunits NR1 and NR2A contain cysteine (cys) residues within their extracellular 
regions- cys744 and 798 in the M3-M4 extracellular loop of NR1 and cys78, 320 and 399 
in the N-terminus of NR2A (Choi et al, 2000). All 5 sites can be modulated by 
S-nitrosylation, with NR2A cys399 identified as the primary modulation site and located in 
the linker region between the ligand binding and the regulatory domains of the N-terminus 
(Choi et al, 2000). NO binds to free thiol groups (-SH) forming an S-nitrosothiol group 
(-SNO) (equation 1). 
R-SH + NO R-SNO + H 
Equation 1. R= any amino acid 
The other extracellular cysteine residues have been shown to form disulphide bonds 
(-S-S-), cys744 and cys798 (NR1) and cys78 and 320 (NR2A), and therefore can not bind 
NO. However under low oxygen, or hypoxic, conditions, for example in the brain, these 
have been demonstrated to preferentially exist as separate free thiols (Takahashi et al, 
2007). It has been suggested that the free NR1 cysteine residues form a ‘molecular oxygen 
sensor’ which enhances the extent of down-regulation of NMDAR activity by 
S-nitrosylation, under hypoxic conditions (Takahashi et al, 2007). It is then hypothesised 
that the S-nitrosylation of these residues exerts an allosteric influence on the S-nitrosylation 
of other thiols in the receptor for example cys399 of the NR2A subunit. 
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It has been shown that NMDARs can be modulated by both endogenous and exogenous NO 
(Choi et al, 2000; Monzoni and Bockaert, 1993). Exogenous NO is provided by NO donors 
such as SNOC or NONOate, with endogenous NO produced by NO synthase (NOS), for 
example neuronal NOS (nNOS) in the brain (Choi et al, 2000). NMDAR NR1 subunits 
have been found to be coupled to nNOS via postsynaptic density 95 (PSD95) in some 
neurones, and it has been shown that activation of NMDAR leads in turn to the production 
of NO (Choi et al, 2000). This inhibits further activation of NMDARs, and desensitises 
already activated receptors, preventing overstimulation which can occur for example during 
an ischemic event. Localised levels of glutamate increase rapidly, stimulating large 
2+ 
increases in Ca influx into the cells triggering not only NO production but also 
mitochondrial dysfunction and activation of caspases-3 and -9, which can trigger apoptosis 
(Rameau et al, 2003; Hardingham et al, 2002; Arundine and Tymianski, 2004). Reducing 
their activation can halt the damage which is done to not only the immediate area of the 
insult, but also the surrounding area, limiting the damage caused (Choi et al, 2000). 
Reducing agents such as DTT, which reduce –SNO groups and disulphide bonds to free 
thiols (-SH) mimic the effects of hypoxia, and leads to the removal of the S-nitrosylation 
induced inhibition of NMDARs (Kim et al, 1999; Takahashi et al, 2007). 
2R-SNO + DTT (2H) 2R-SH + 2NO + oxDTT 
R-SS-R + DTT (2H) 2R-SH + oxDTT 
Equation 2. R= any amino acid 
AII.2.2. Detection of S­nitrosylation 
Previously, the biotin switch method (Jaffrey and Snyder, 2001) has been used to detect 
nitrosylation of proteins, however a new single step process has been developed using an 
S-nitrosylation binding protein (SNOB) (Watts et al, in submission). SNOB is a long chain 
molecule with a formula of C25H43N5O4S and molecular weight of 509.71 g mol
(figure 63), that contains a terminal alkene group which can react with the unique –SNO 
bond and directly functionalise the group with biotin. It binds to S-nitrosylated cysteine 
residues within proteins through the mechanism detailed in figure 59 catalysed by light or 
221 
-1 
C.M. HOBBS

APPENDIX II: NITROSYLATION

heat. The biotin switch is an indirect approach to detect S-nitrosylation, where thiols are 
blocked by methyl methanethiosulfonate (MMTS) and the protein denatured by SDS, 
excess MMTS is then removed, after which nitrosothiols are reduced to thiols by acetone 
before the addition of biotin-(N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide 
(biotin-HPDP) which labels the exposed thiols with biotin (figure 64) (Jaffrey et al, 2001). 
In contrast, SNOB binds directly to S-nitrosylated cysteines without the need for protein 
denaturation, which suggests that SNOB could be used to detect S-nitrosylation of surface 
proteins expressed in live cells. The biotin switch is prone to false positive results as it 
works on the premise that MMTS blocks all exposed thiol groups and that acetone only 
reduces the S-nitrosylated cysteine residues. It is however feasible for exposed disulphide 
bonds to also be reduced by the acetone, increasing the number of free thiols together with 
those not blocked by MMTS, which can then be bound by the biotin-HPDP molecule 
(Jaffrey et al 2001). It is also possible that if the protein is not sufficiently reduced, thiols 
may not be blocked by MMTS, but still be accessible to biotin-HPDP, again increasing the 
amount of biotin binding and suggesting a greater level of S-nitrosylation than is actually 
present. The single step SNOB method does not use reducing agents, and is therefore free 
from this potential problem. The mechanism by which SNOB functions is described in 
figure 65 with the final step occurring under acidic aqueous conditions such as those used 
for the preparation of samples for mass spectroscopy analysis. The presence of the bound 
biotin either through biotin switch or SNOB methods can be detected by different methods 
for example running samples on SDS PAGE and detecting changes in protein biotinylation 
using Neutravidin-HRP which utilises the strong avidin-biotin bond (Giltin et al, 1987). 
Alternatively, samples can be digested, for example with trypsin, so that the fragments can 
be analysed by mass spectrometry to identify where the SNOB is bound to the protein 
(figure 64). SNOB reagent binding to S-nitrosylated cysteines has been characterised using 
recombinant bovine serum albumin (BSA) and human platelet membrane proteins. 
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Figure 63. Structure of SNOB. S-nitrosylation binding protein 6 (SNOB6) has a chemical 
-1 
formula of C25H43N5O4S and a molecular weight of 509.71 g mol . A biotin group is located at the 
N-terminus which can be detected through SNOB binding (Watts et al, in submission). 
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Figure 64. Comparison of the biotin switch and SNOB methods of detecting 
S­nitrosylated proteins. The biotin switch method is an indirect assay which can not be used on 
live cells, whereas the SNOB method is a single step process which does not require denaturation of 
the protein being labelled, and can therefore be used on live cells. In the biotin switch assay, 
proteins are denatured with sodium dodecyl sulphate (SDS) and the free thiols (-SH) 
methylthiolated with methyl methanethiosulfonate (MMTS) to render them unreactive. The excess 
MMTS is then removed and the proteins treated with acetone to denitrosylate the –SNO groups to 
free thiols. Finally the protein is reacted with a thiol-modifying reagent biotin-HPDP (N-[6-
(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide) which labels the thiols with biotin. In 
comparison, the SNOB reagent requires only an increase in temperature (Δt) or the presence of light 
(hv) to react making it a single step process; detailed mechanism shown in figure 60. With both 
methods, once the proteins have been labelled, the biotin can be detected through a range of 
methods, including Western blot using avidin-containing reagents e.g. Neutravidin-HRP, flow 
cytometry or immunolocalisation with fluorescently tagged avidin. The proteins can also be 
digested with enzymatically, for example with trypsin and the fragments found which are labelled 
and the sites of S-nitrosylation identified through LC MS/MS. 
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Figure 65. Proposed mechanism for the reaction of SNOB reagents with S­nitrosylated 
cysteines. This illustrates the proposed mechanism of activity for SNOB reagents. The SNOB 
reagent is shown as the left-hand molecule with the green biotin tag, with the protein of interest 
shown on the right in blue. The movement of electrons in the -SNO group cause denitrosylation, 
which leads to binding of the SNOB reagent to the exposed cysteine residue of the protein. 
Unpaired electrons in the NO group and at the link between the protein and SNOB form a double 
bond, adding an –N-OH group to the complex. This is then converted to a ketone by the loss of the 
–OH group under aqueous acidic conditions (Watts et al, in submission). 
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AII.3. Methods 
AII3.1.  Reagent –S­nitrosocysteine (SNOC) 
Table 44. SNOC 
REAGENT CONCENTRATION (M) 
L-cysteine 0.2 
Sodium nitrite 0.2 
HCl 10 
Equal volumes of 200 mM L-cysteine and 200 mM sodium nitrite, both made in nominally 
2+
Ca -free salt solution (saline), were combined to produce 100 mM SNOC, a clear 
colourless solution. The addition of 10 M HCl to a final concentration of 0.5 M activates 
SNOC, which becomes clear red in colour. Once activated, SNOC must be kept on wet ice 
and used within 2 h (Graves et al, 1998; Lei et al, 1992). 
AII.3.2. Detection of S­nitrosylation 
PRP was separated into the number of 2 ml aliquots required and centrifuged at 350 xg for 
2+
20 min. Each platelet pellet was washed and resuspended in 500 �l nominally Ca -free 
salt solution warmed to 37 
o
C. From this point the platelets were kept at 37 
o
C in the dark as 
both DEA NONOate (NONOate) and SNOB are light-sensitive. NONOate (5 mM) or 
SNOC (100 �M; section 2.1.1) were added to platelet suspensions as required and 
incubated for 20 min. These are both exogenous sources of NO, which generate and release 
NO into solution (Jaffrey et al, 2001; Lei et al, 1992). The cells were centrifuged (20 min, 
2+
350 xg) and resuspended in warmed nominally Ca -free salt solution. DTT (20 mM) was 
also added for 20 min either to previously untreated platelets or following NONOate 
incubation. DTT is a reducing agent, which can maintain thiol (-SH) groups and reduce 
disulphide bridges; it was used to determine whether baseline or induced nitrosylation of 
platelet membrane proteins by NONOate or SNOC can be reduced (Choi and Lipton, 
2000). Finally the SNOB (450 µM) was added for 5 min, after which the platelet 
suspension was centrifuged for 20 min at 350 xg, washed and the pellet resuspended in 
50 �l lysis buffer B. The resuspended platelets were then rocked gently for 1 h at 4 
o
C and 
centrifuged at 19000 xg for 10 min at 4 
o
C. 
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The supernatant was then removed and either run immediately on a Western blot (section 
2.4.3) or stored at -80 
o
C. Coomassie gels were run alongside the gels for immunoblotting 
to ensure that the samples were equally loaded. Once the protein was transferred, the 
membrane was blocked overnight in 5 % BSA-TTBS at 4 
o
C on a rocker (5-10 rpm). The 
-1 
membrane was then washed briefly in TTBS and incubated in 0.5 µg ml neutravidin-HRP 
in BSA-TTBS for 30 min at RT, rocking gently. Following this the membrane was washed 
six times for 5 min in TTBS. Biotinylated proteins and markers were visualised using the 
ECL chemiluminescent detection agent. 
AII.4. Results 
AII.4.1. SNOB and BSA 
BSA was chosen as a model protein as it is known to contain 35 cysteine residues of which 
24 form 12 disulphide bridges with 1 free surface cysteine residue, cys58 (Oblak et al, 
2004). Mass spectrometry data has demonstrated that SNOB binds to the QQCP sequence 
in BSA which includes the exposed cys58 residue corresponding to the peak at 998.29 amu 
(figure 66). 
-1
BSA (1 mg ml ) was nitrosylated with 1 mM NONOate in light limited conditions at pH 7, 
with a control sample that was not NONOate treated. Samples were treated with 450 �M 
SNOB for 0, 5, 10, 15, 30 and 60 min at 4, 10 or 37 
o
C and run on Western blots. Biotin 
was detected by probing with Neutravidin-HRP (figure 67). At 4 
o
C, binding of SNOB was 
detected after 30 min of SNOB treatment. This was decreased to 15 min treatment at 
10 
o
C, and reduced further to 5 min at 37 
o
C. Further investigations used 5 min treatment 
with 450 �M SNOB at 37 
o
C. 
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Figure 66. Mass spectrometry data for BSA bound SNOB. Liquid chromatography mass 
spectrometry (LC MS/MS) spectrum of SNOB bound to BSA. The BSA is subjected to peptic 
digestion (pH 3, 4 hours) prior to running on the mass spectrometer, separating the BSA into small 
fragments. This spectrum illustrates the binding of the SNOB to the peptide fragment QQCP 
58
(998.29 amu peak) which contains the exposed cysteine residue (Cys ) (Watts et al, in submission). 
Figure 67. Effects of time and temperature on SNOB binding to BSA. Nitrosylated BSA 
(1 mg ml
-1
) was treated with 450 �M SNOB at 4, 10 and 37 
o
C with samples treated for 0, 5, 10, 15, 
30 and 60 min. Samples were run on SDS PAGE and developed on Western blot using 
Neutravidin-HRP which binds the biotin present in the SNOB reagent. This demonstrates that the 
level of SNOB binding to the BSA is distinguishable above baseline from 30 min at 4 
o
C, 15 min at 
10 
o
C and from 5 min at 37 
o
C. The control lane demonstrates the baseline biotin levels in the 
absence of both DEA NONOate and SNOB (Data from Jodie Gibson, 2008). 
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AII.4.2. Treating live cells with SNOB 
Other methods of detecting S-nitrosylation such as biotin switch or SNOSID (SNO-site 
identification) (Jaffrey and Snyder, 2001; Hao et al, 2006) are not suitable for use on live 
cells, and it was hypothesised from the data obtained with BSA that as the SNOB reagent 
can be used under physiological conditions (pH 7, 37 
o
C), it could be used to detect 
S-nitrosylation of proteins on the surface of living cells. To investigate this, freshly isolated 
human platelets were used as they express proteins on their surface for example NMDARs 
which are known to be modulated by S-nitrosylation (Jaffrey and Snyder, 2001). 
AII.4.2.1. Temperature 
Figure 63 compares the binding of SNOB at either room temperature (RT; 20-22 
o
C) or at 
37 
o
C under different conditions. The background controls indicate that there are no 
observable differences in the level of biotin detected in live platelets when treated at either 
temperature. The addition of 450 �M SNOB increases the level of protein-bound biotin at 
RT, which is enhanced further following incubation at 37 
o
C, indicating a greater increase 
in S-nitrosylation. DTT is a reducing agent, which has been shown to reverse 
S-nitrosylation (Kim et al, 1999). It was added to live platelets prior to SNOB treatment to 
determine whether any changes were observed in biotin binding, which is indicative of 
changes in S-nitrosylation. This was shown to occur at both temperatures, with the levels 
of biotinylation decreasing to nearly that of the control samples. Overall this indicates that 
levels of biotinylation are higher at 37 
o
C than at RT, therefore all further experiments were 
carried out at 37 
o
C. 
AII.4.2.2. SNOB concentration 
Different concentrations of SNOB were tested to determine which to use for further 
experiments (figure 69). These were assessed in combination with DTT as previously 
described (section 6.3.3.1), together with the addition of DEA NONOate (NONOate), an 
NO donor. NONOate was added to determine whether the levels of biotinylation linked to 
changes in nitrosylation, could be raised by the presence of increased NO. DTT was added 
to determine whether both the baseline levels and levels of biotinylation enhanced by 
previous NONOate treatment, could be decreased. 
The presence of 300 �M SNOB elicited a small increase in biotinylation above the no 
SNOB control, which was increased further by the addition of NONOate prior to SNOB 
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treatment. Treating platelets with DTT following incubation with NONOate reduced the 
level of biotinylation, but not to the same level as the no treatment control. Increasing the 
concentration of SNOB to 450 µM, increased the levels of biotinylation above that with 
300 �M SNOB. As with 300 �M SNOB, the addition of DTT before SNOB treatment 
(450 �M) reduced the levels of biotinylation. The addition of NONOate increased 
biotinylation above that detected by SNOB alone, particularly in bands at approximately 
90 kDa. Detection of background biotinylation is decreased by treatment with DTT 
suggestive of decreases in S-nitrosylation, however levels do not return to those of the 
SNOB only control. From this, 450 �M SNOB will be used for further experiments. 
AII.4.2.3. SNOC 
S-nitrosocysteine (SNOC) (table 44) is another NO donor, which was tested to determine 
whether it could raise levels of biotinylation linked to increased nitrosylation comparatively 
to NONOate. SNOC is shown to increase the levels of biotinylation above that detected 
with SNOB alone, with a larger increase induced by a 10 min SNOC incubation (figure 70). 
These increases can then be reduced by the addition with DTT to similar levels to the 
baseline in the absence of SNOB. However this demonstrates that the increase in 
nitrosylation-linked biotinylation with SNOC is not as great as that in the presence of 
NONOate. 
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Figure 68. Nitrosylation of human platelet membrane proteins is increased with temperature. 
Western blot demonstrating SNOB binding to membrane proteins of human platelets at room 
temperature (RT; 20-22 
o
C) and at 37 
o
C. The table indicates the application of 450 �M SNOB and 
20 mM DTT. At both temperatures the signal increases in strength with the addition of 450 �M 
SNOB, which is reduced to almost baseline amounts with the addition of DTT, a reducing agent. 
The increase in signal with SNOB alone above baseline is higher at 37 
o
C than RT indicating a 
greater level of binding. The gel below was run alongside the upper gel using the same samples to 
demonstrate equal loading and stained with coomassie blue dye (n=1). Approximately 15 µg of 
protein was loaded per sample. 
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Figure 69. Increasing SNOB concentration leads to greater detection of nitrosylated human 
platelet membrane proteins. Western blot demonstrates the effect of increasing the concentration 
of SNOB used to detect nitrosylated proteins on human platelet membrane surface. With both 
concentrations of SNOB, the level of nitrosylation detected decreases when platelets are incubated 
with 20 mM DTT and increases above baseline with the addition of 5 mM NONOate (NO donor) to 
the platelet suspension. Treatment of platelets with NONOate, then DTT and finally SNOB 
reduced the level of protein biotinylation compared to platelets treated with the NO donor. In all 
cases 450 �M SNOB gives a greater signal than the corresponding sample with 300 �M. The table 
indicates the application of SNOB, DTT and NONOate. This is a representative blot from 3 repeats 
from 3 different human donors. The gel below was run alongside the upper gel using the same 
samples to demonstrate equal loading and stained with coomassie blue dye (n=3). Approximately 
15 µg protein was loaded per sample. 
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Figure 70. S­nitrosocysteine increases nitrosylation of human platelet membrane proteins. 
This illustrates that another NO donor, S-nitrosocysteine, (SNOC; 100 �M) can increase 
nitrosylation of human platelet membrane proteins above the baseline that can be detected using 
SNOB reagents. The SNOC-mediated S-nitrosylation detected by SNOB reagents can be reduced 
in turn by the addition of DTT to the platelet suspension. This increase can be reduced in turn by 
the addition of DTT. However the increases with SNOC are not as great as that achieved with the 
addition of NONOate. The table indicates the application of 450 �M SNOB, 20 mM DTT, 5 mM 
NONOate and 100 �M SNOC. Representative blot from 3 separate experiments using platelets 
from 3 different donors. The gel below was run alongside the upper gel using the same samples to 
demonstrate equal loading and stained with coomassie blue dye (n=3). Approximately 15 µg 
protein was loaded per sample. 
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AII.5. Discussion 
AII.5.1. NMDAR S­nitrosylation in the CNS 
NMDARs have been highly characterised in the CNS, where they are activated by 
extracellular glutamate and glycine (Matsui et al, 1995). Glutamate levels are tightly 
controlled within the CNS, increasing briefly when glutamate is released in a controlled 
manner from a presynaptic terminal to stimulate post-synaptic receptors. Sustained 
exposure of neuronal cells to high levels of glutamate has been shown to cause cell death 
(Lucas and Newhouse, 1957), in a process named excitotoxicity found to be a common 
action of high concentrations of excitatory amino acids in the CNS (Olney and Sharpe, 
1969; Olney et al, 1971). Regulation of receptors is therefore important, and one 
mechanism by which this occurs is S-nitrosylation of extracellular cysteine residues. 
NMDARs have 5 extracellular cysteine residues, of which 4 (2 in the NR1 subunit protein 
and 2 in the NR2A subunit) form disulphide bonds, while the final residue, cys399 on 
NR2A subunit, is the primary regulator of S-nitrosylation (Choi et al, 2000). Under 
reducing or hypoxic conditions, the disulphide bonds of the other cysteine residues are 
reduced, increasing the number of free thiol groups for S-nitrosylation. Previous studies 
have shown that S-nitrosylation of NMDARs inhibits NMDA-evoked currents, and that 
generation of endogenous NO also stimulates this effect (Choi et al, 2000). NMDAR NR1 
subunits are located in close proximity to nNOS via the scaffolding protein PSD95, and 
2+
activation of NMDARs has been shown to activate nNOS through increasing [Ca ]i. This 
leads to further production of NO which acts as a regulatory feedback mechanism to 
minimise further NMDAR activation (Cui et al, 2007). 
AII.5.2. Role of S­nitrosylation in platelet activation 
S-nitrosylation also plays an inhibitory role in platelet activation and aggregation. NO is 
produced in the endothelium by constitutive eNOS, and production is stimulated by fluid 
shear stress generated by the flow of blood over the endothelial cell surface (Dimmeler et 
al, 1999). This leads to activation of PI3K and Akt which phosphorylates eNOS 
stimulating production of NO which can then diffuse into the blood stream, inhibiting 
platelet aggregation (Dimmeler et al, 1999; Fulton et al, 1999). There is also evidence that 
NO is produced in platelets following the identification of eNOS expression, however this 
remains a contentious issue (Sase and Michel, 1995; Tymvios et al, 2009). Endogenous 
NO plays an inhibitory role in platelet aggregation through a combination of cyclic 
guanosine monophosphate (cGMP)-dependent and –independent pathways. The binding of 
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NO to soluble guanylyl cyclase (sGC) leads to an increase in cGMP (Mellion et al, 1983), 
activating protein kinase G (PKG) or cGMP-dependent protein kinase, which has been 
2+ 
found to inhibit a range of functions within platelets including release of Ca from 
intracellular stores (Cavellini et al, 1996), granule secretion (Michelson et al, 1996), and 
cytoskeleton re-organisation (Butt et al, 2001), as well as αIIbβ3 and P-selectin expression 
on the surface of cells (Michelson et al, 1996). The cGMP-independent pathways include 
the inhibition of αIIbβ3 phosphorylation (Oberprieler et al, 2007), P2Y12 activation (Kokkola 
et al, 2005) and thromboxane A2 synthesis (Tsikas et al, 1999). Together, these pathways 
lead to a reduction in the initiation and continuation of aggregate formation which leads to 
increased bleeding times (Michelson et al, 1996). 
AII.5.2.1. NMDARs and human platelets 
The NMDAR subunit proteins, NR1 and NR2A have been shown in this study to be 
expressed in human platelets, and there is evidence of nitrosylation of both the receptor and 
other platelet surface proteins in the literature (Jaffrey and Snyder, 2001; Walsh et al, 2007; 
Mellion et al, 1983). It was therefore hypothesised that nitrosylation of NMDARs could 
act as a regulatory step in platelet activation. This would help to limit activation during an 
ischemic event where localised concentrations of both glutamate and NO increase, with the 
activation of NMDARs inducing further NO production (Choi et al, 2000). Nitrosylation 
of other platelet proteins would also prevent the cell from aggregating within the site of 
injury, decreasing the potential for further injury. S-nitrosylation of proteins has previously 
been detected using the biotin switch method, for example NR1 and NR2A in the brain 
(Jaffrey and Snyder, 2001; Jaffrey et al, 2001). This method is however susceptible to false 
positives, and can not be used on live cells. A novel compound, SNOB, has been 
developed in collaboration with Dr Andrew Watts (University of Bath, UK) to detect cell 
surface S-nitrosylation in live cells, and specifically in human platelets. The eventual aim 
was to evaluate the S-nitrosylation of NMDARs expressed on human platelets and their 
potential regulation by NO. This appendix presents the data evaluating the compound 
using recombinant proteins, which has been extended to investigate the S-nitrosylation of 
membrane proteins in live platelets. 
Initial work demonstrated that S-nitrosylated cysteines could be detected in BSA following 
a 5 min incubation with SNOB at 37 
o
C, pH 7, which was repeated with live human 
platelets, demonstrating that SNOB reacted under physiological conditions (figures 66 and 
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68). Low levels of biotin binding were detected in the absence of SNOB in human 
platelets, suggesting that they contain endogenously biotinylated proteins, although further 
investigation is required to identify these. 
Initial studies investigated variations in biotinylation indicative of changes in SNOB 
binding, demonstrating that increases in exogenous NO using an NO donor enhances 
biotinylation, indicative of augmented S-nitrosylation of platelet proteins. Treatment of 
human platelets with a reducing agent demonstrated that SNOB binding can be reduced, 
however the intensity of some bands, for example at approximately 40 and 70 kDa, remain 
unaltered (figure 68). This suggests that these bands contain endogenously biotinylated 
proteins which are present within the platelets, and are inaccessible to the action of the 
reducing agent, but are exposed upon lysis of the platelets in preparation of gel 
electrophoresis. The action of reducing agents mimics the effects of hypoxia, the oxygen 
conditions under which platelets circulate within the body (Takahashi et al, 2007). Using a 
combined approach, the reduction of platelet membrane proteins followed by the addition 
of exogenous NO, produces a physiological insight into the reactions of platelet membrane 
proteins within the body, with increased SNOB binding above that observed with no SNOB 
treatment and a variation in expression to that with SNOB treatment (figures 69 and 70). 
AII.5.3. Overall conclusions and further studies 
Previous evidence demonstrates that S-nitrosylation of NR1 and NR2A subunit proteins 
within the brain can be detected by biotin switch (Jaffrey et al, 2001), therefore it follows 
that they could be detected using the SNOB reagent. This study has however demonstrated 
that the NR1 and not the NR2A subunit proteins are detectable in human platelets (figures 
12 and 13), and it is therefore possible that while the NR2A subunit protein is expressed in 
human platelets, it is to a lesser extent than the NR1 subunit protein; greater study is 
required to investigate this further. A previous study has shown that S-nitrosylation of just 
the NR1 N-terminal cysteine residues under hypoxic conditions has a only small inhibitory 
effect on NMDA-evoked currents (Choi et al, 2000); under normoxic conditions these form 
a disulphide bond and are therefore not accessible for S-nitrosylation. While this effect is 
small, it is possible that it is sufficient to mediate a partial inhibitory response in NMDAR 
activation and requires additional study. The Western blots in theis study identified several 
bands of different sizeds, one of which at approximately 120 kDa could potentially contain 
the biotinylated NR1 subunit protein (figures 68 and 70). Further work is needed to verify 
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the nitrosylation of NMDAR subunit proteins for example immunoprecipitation (IP) 
experiments and MS. This could be extended further using SNOB to identify the 
S-nitrosylated cys residues in NMDAR subunit proteins, detecting the biotinylation using 
LC-MS/MS with IPs to investigate regulation of S-nitrosylation under different conditions. 
Once this has been determined, the effect of S-nitrosylation and denitrosylation on 
NMDAR function can be measured using electrophysiology and calcium imaging for 
example. 
The SNOB reagent can be used to determine which other proteins expressed by platelets are 
regulated by S-nitrosylation and their role in platelet activation and thrombus formation. 
Other platelet proteins are known to be S-nitrosylated for example αIIbβ3, which could be 
inhibited by generation of NO by eNOS into the bloodstream (Dimmler et al, 1999). Given 
the differences in oxygen concentration between normoxia and hypoxia, and the potential 
disparities in effects on protein activation through exposure of different numbers of free 
thiols, additional study is required under hypoxic conditions to determine more accurately 
roles of proteins such as NMDARs, under physiological conditions. 
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